Strategies for partner notification for sexually transmitted infections, including HIV by Ferreira, A. et al.
Strategies for partner notification for sexually transmitted
infections, including HIV (Review)
Ferreira A, Young T, Mathews C, Zunza M, Low N
This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library
2013, Issue 10
http://www.thecochranelibrary.com
Strategies for partner notification for sexually transmitted infections, including HIV (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
s
o
u
r
c
e
:
 
ht
tp
s:
//
do
i.
or
g/
10
.7
89
2/
bo
ri
s.
41
85
9 
| 
do
wn
lo
ad
ed
: 
13
.3
.2
01
7
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
13RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Figure 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
Figure 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
Figure 9. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
Figure 10. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Figure 11. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
29ADDITIONAL SUMMARY OF FINDINGS . . . . . . . . . . . . . . . . . . . . . . . . . .
34DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
36AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
37ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
37REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
41CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
91DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 1 Re-infection in index
patient. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96
Analysis 1.2. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 2 Number of partners
elicited. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
Analysis 1.3. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 3 Number of partners
notified. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
Analysis 1.4. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 4 Number of partners
presenting for care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
Analysis 1.5. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 5 Number of partners testing
positive. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Analysis 1.6. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 6 Number of partners
treated. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
Analysis 2.1. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 1 Partners
elicited. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Analysis 2.2. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 2 Number of
partners presenting for care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
Analysis 2.3. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 3 Number of
partners treated. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
Analysis 3.1. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 1 Re-infection in
index patients. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Analysis 3.2. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 2 Number of partners
elicited. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
Analysis 3.3. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 3 Number of partners
notified. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
iStrategies for partner notification for sexually transmitted infections, including HIV (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.4. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 4 Number of partners
presenting for care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Analysis 3.5. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 5 Number of partners
treated. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Analysis 3.6. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 6 Number of harmful
events reported. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
Analysis 4.1. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 1 EPT vs.
enhanced patient referral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 109
Analysis 4.2. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 2 EPT vs.
enhanced patient referral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Analysis 4.3. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 3 Enhanced
patient referral plus EPT vs. simple patient referral. . . . . . . . . . . . . . . . . . . . . . 111
Analysis 5.1. Comparison 5 Contract referral versus simple patient referral, Outcome 1 Number of partners elicited. 111
Analysis 5.2. Comparison 5 Contract referral versus simple patient referral, Outcome 2 Number of partners notified. 112
Analysis 5.3. Comparison 5 Contract referral versus simple patient referral, Outcome 3 Number of partners presenting for
care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
Analysis 5.4. Comparison 5 Contract referral versus simple patient referral, Outcome 4 Number of partners testing
positive. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Analysis 5.5. Comparison 5 Contract referral versus simple patient referral, Outcome 5 Number of partners treated. . 114
Analysis 5.6. Comparison 5 Contract referral versus simple patient referral, Outcome 6 Number of harmful events
reported. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
Analysis 6.1. Comparison 6 Contract referral versus enhanced patient referral, Outcome 1 Number of partners elicited. 115
Analysis 6.2. Comparison 6 Contract referral versus enhanced patient referral, Outcome 2 Partners presenting for care. 116
Analysis 6.3. Comparison 6 Contract referral versus enhanced patient referral, Outcome 3 Partners testing positive. . 116
Analysis 7.1. Comparison 7 Contract referral versus expedited partner therapy (EPT), Outcome 1 Re-infection in index
patient. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
Analysis 8.1. Comparison 8 Provider referral versus simple patient referral, Outcome 1 Provider referral vs. simple patient
referral. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
Analysis 8.2. Comparison 8 Provider referral versus simple patient referral, Outcome 2 Choice between provider or simple
patient referral vs. simple patient referral. . . . . . . . . . . . . . . . . . . . . . . . . 119
Analysis 9.1. Comparison 9 Provider referral versus enhanced patient referral (disease intervention specialist), Outcome 1
Number of partners elicited. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Analysis 9.2. Comparison 9 Provider referral versus enhanced patient referral (disease intervention specialist), Outcome 2
Number of partners testing positive. . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Analysis 9.3. Comparison 9 Provider referral versus enhanced patient referral (disease intervention specialist), Outcome 3
Number of partners treated. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 120
Analysis 10.1. Comparison 10 Provider referral versus contract referral, Outcome 1 Number of partners elicited. . . 121
Analysis 10.2. Comparison 10 Provider referral versus contract referral, Outcome 2 Number of partners presenting for
care. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
Analysis 10.3. Comparison 10 Provider referral versus contract referral, Outcome 3 Number of partners located. . . 122
Analysis 10.4. Comparison 10 Provider referral versus contract referral, Outcome 4 Number of partners tested. . . 122
Analysis 10.5. Comparison 10 Provider referral versus contract referral, Outcome 5 Partners testing positive. . . . 123
Analysis 10.6. Comparison 10 Provider referral versus contract referral, Outcome 6 Number of partners treated. . . 123
Analysis 10.7. Comparison 10 Provider referral versus contract referral, Outcome 7 Number of harmful events reported. 124
124ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
130APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
135WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
135CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
135DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
136SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
136DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
136INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iiStrategies for partner notification for sexually transmitted infections, including HIV (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Strategies for partner notification for sexually transmitted
infections, including HIV
Adel Ferreira1, Taryn Young2 ,3, Catherine Mathews4, Moleen Zunza5, Nicola Low6
1Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 2Centre for Evidence-based Health Care,
Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 3South African Cochrane Centre, South
African Medical Research Council, Cape Town, South Africa. 4School of Public Health and Family Medicine, University of Cape
Town, Cape Town, South Africa. 5Department of Paediatrics and Child Health , Faculty ofMedicine and Health Sciences, Stellenbosch
University, Tygerberg, South Africa. 6Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland
Contact address: Nicola Low, Institute of Social and Preventive Medicine (ISPM), University of Bern, Finkenhubelweg 11, Bern, CH-
3012, Switzerland. low@ispm.unibe.ch.
Editorial group: Cochrane Sexually Transmitted Infections Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 10, 2013.
Review content assessed as up-to-date: 11 September 2012.
Citation: Ferreira A, Young T, Mathews C, Zunza M, Low N. Strategies for partner notification for sexually trans-
mitted infections, including HIV. Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD002843. DOI:
10.1002/14651858.CD002843.pub2.
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Partner notification (PN) is the process whereby sexual partners of an index patient are informed of their exposure to a sexually
transmitted infection (STI) and the need to obtain treatment. For the person (index patient) with a curable STI, PN aims to eradicate
infection and prevent re-infection. For sexual partners, PN aims to identify and treat undiagnosed STIs. At the level of sexual networks
and populations, the aim of PN is to interrupt chains of STI transmission. For people with viral STI, PN aims to identify undiagnosed
infections, which can facilitate access for their sexual partners to treatment and help prevent transmission.
Objectives
To assess the effects of different PN strategies in people with STI, including human immunodeficiency virus (HIV) infection.
Search methods
We searched electronic databases (theCochrane Central Register of ControlledTrials (CENTRAL),MEDLINE and EMBASE) without
language restrictions. We scanned reference lists of potential studies and previous reviews and contacted experts in the field.We searched
three trial registries. We conducted the most recent search on 31 August 2012.
Selection criteria
Published or unpublished randomised controlled trials (RCTs) or quasi-RCTs comparing two or more PN strategies. Four main PN
strategies were included: patient referral, expedited partner therapy, provider referral and contract referral. Patient referral means that
the patient notifies their sexual partners, either with (enhanced patient referral) or without (simple patient referral) additional verbal
or written support. In expedited partner therapy, the patient delivers medication or a prescription for medication to their partner(s)
without the need for a medical examination of the partner. In provider referral, health service personnel notify the partners. In contract
referral, the index patient is encouraged to notify partner, with the understanding that the partners will be contacted if they do not
visit the health service by a certain date.
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Data collection and analysis
We analysed data according to paired partner referral strategies. We organised the comparisons first according to four main PN strategies
(1. enhanced patient referral, 2. expedited partner therapy, 3. contract referral, 4. provider referral). We compared each main strategy
with simple patient referral and then with each other, if trials were available. For continuous outcome measures, we calculated the
mean difference (MD) with 95% confidence intervals (CI). For dichotomous variables, we calculated the risk ratio (RR) with 95% CI.
We performed meta-analyses where appropriate. We performed a sensitivity analysis for the primary outcome re-infection rate of the
index patient by excluding studies with attrition of greater than 20%. Two review authors independently assessed the risk of bias and
extracted data. We contacted study authors for additional information.
Main results
We included 26 trials (17,578 participants, 9015 women and 8563 men). Five trials were conducted in developing countries. Only
two trials were conducted among HIV-positive patients. There was potential for selection bias, owing to the methods of allocation
used and of performance bias, owing to the lack of blinding in most included studies. Seven trials had attrition of greater than 20%,
increasing the risk of bias.
The review found moderate-quality evidence that expedited partner therapy is better than simple patient referral for preventing re-
infection of index patients when combining trials of STIs that caused urethritis or cervicitis (6 trials; RR 0.71, 95% CI 0.56 to 0.89,
I2 = 39%). When studies with attrition greater than 20% were excluded, the effect of expedited partner therapy was attenuated (2
trials; RR 0.8, 95% CI 0.62 to 1.04, I2 = 0%). In trials restricted to index patients with chlamydia, the effect was attenuated (2 trials;
RR 0.90, 95% CI 0.60 to 1.35, I2 = 22%). Expedited partner therapy also increased the number of partners treated per index patient
(three trials) when compared with simple patient referral in people with chlamydia or gonorrhoea (MD 0.43, 95% CI 0.28 to 0.58) or
trichomonas (MD 0.51, 95% CI 0.35 to 0.67), and people with any STI syndrome (MD 0.5, 95% CI 0.34 to 0.67). Expedited partner
therapy was not superior to enhanced patient referral in preventing re-infection (3 trials; RR 0.96, 95% CI 0.60 to 1.53, I2 = 33%, low-
quality evidence). Home sampling kits for partners (four trials) did not result in lower rates of re-infection in the index case (measured
in one trial), or higher numbers of partners elicited (three trials), notified (two trials) or treated (one trial) when compared with simple
patient referral. There was no consistent evidence for the relative effects of provider, contract or other patient referral methods. In one
trial among men with non-gonococcal urethritis, more partners were treated with provider referral than with simple patient referral
(MD 0.5, 95% CI 0.37 to 0.63). In one study among people with syphilis, contract referral elicited treatment of more partners than
provider referral (MD 2.2, 95% CI 1.95 to 2.45), but the number of partners receiving treatment was the same in both groups. Where
measured, there was no statistical evidence of differences in the incidence of adverse effects between PN strategies.
Authors’ conclusions
The evidence assessed in this review does not identify a single optimal strategy for PN for any particular STI. When combining
trials of STI causing urethritis or cervicitis, expedited partner therapy was more successful than simple patient referral for preventing
re-infection of the index patient but was not superior to enhanced patient referral. Expedited partner therapy interventions should
include all components that were part of the trial intervention package. There was insufficient evidence to determine the most effective
components of an enhanced patient referral strategy. There are too few trials to allow consistent conclusions about the relative effects of
provider, contract or other patient referral methods for different STIs. More high-quality RCTs of PN strategies for HIV and syphilis,
using biological outcomes, are needed.
P L A I N L A N G U A G E S U M M A R Y
Strategies for partner notification for sexually transmitted infections, including HIV.
Sexually transmitted infections (STI) are a major global cause of acute illness, infertility and death. Every year there are an estimated 499
million new cases of the most common curable STIs (trichomoniasis, chlamydia, syphilis and gonorrhoea), and between two and three
million new cases of HIV. The presence of several STIs, including syphilis and herpes can increase the risk of acquiring or transmitting
HIV.
Partner notification (PN) is a process whereby sexual partners of patients given a diagnosis of STI are informed of their exposure
to infection and the need to receive treatment. PN for curable STI may prevent re-infection of the patient and reduce the risk of
complications and further spread.
2Strategies for partner notification for sexually transmitted infections, including HIV (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A review update of the research of the strategies of partner notification in people with STI, including human immunodeficiency virus
(HIV) infection was conducted by researchers in the Cochrane Collaboration. After searching for all relevant studies, they found 26
studies. This review covers four main PN strategies: 1) Patient referral means that the patient tells their sexual partners that they need
to be treated, either with (enhanced) or without (simple) additional support to enhance outcomes. 2) Expedited partner therapy means
that the patient delivers medication or a prescription for medication to their partner(s) without the need for a medical examination of
the partner. 3) Provider referral means that health service personnel notify the partners. 4) Contract referral means that the patient is
encouraged to notify partners but health service personnel will contact them if they do not visit the health service by a certain date.
The 26 trials in this review included 17,578 participants. Five trials were conducted in developing countries and only two trials were
performed among HIV-positive patients. Expedited partner therapy was more successful than simple patient referral in reducing repeat
infection in patients with gonorrhoea, chlamydia or non-gonococcal urethritis (six trials). Expedited partner therapy and enhanced
patient referral resulted in similar levels of repeat infection (three trials). Evidence about the effects of home sampling, where patients
with chlamydia received a sample kit for the partner, was inconsistent (three trials). There were too few trials to allow consistent
conclusions about the relative effects of provider, contract or other patient referral methods for different STIs. More studies need to be
performed on HIV and syphilis and harms need to be measured and reported.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Enhanced patient referral compared with simple patient referral for partner notification for STIs, including HIV
Health problem: partner notification for STIs, including HIV
Settings: people in rural and urban areas, given a diagnosis of STI (clinically or by a laboratory) in health services
Intervention: enhanced patient referral
Comparison: simple patient referral
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Simple patient referral Enhanced patient refer-
ral
Re-infection in index pa-
tient - home sampling vs.
simple patient referral
Follow-up: 12 months
Study population RR 2.14
(0.91 to 5.05)
220
(1 study)
⊕⊕©©
low1,2
64 per 1000 136 per 1000
(58 to 321)
Moderate
64 per 1000 137 per 1000
(58 to 323)
Re-infection in index pa-
tient - information book-
let vs. simple patient re-
ferral
Follow-up: 8 weeks
Study population RR 0.55
(0.22 to 1.33)
942
(2 studies)
⊕⊕©©
low3,4
180 per 1000 99 per 1000
(40 to 239)
Moderate
156 per 1000 86 per 1000
(34 to 207)
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Re-infection in index pa-
tient - patient referral
(DIS/health advisor) vs.
patient referral (nurse)
Follow-up: 6 weeks
Study population RR 0.35
(0.01 to 8.51)
140
(1 study)
⊕⊕©©
low5
14 per 1000 5 per 1000
(0 to 118)
Moderate
14 per 1000 5 per 1000
(0 to 119)
Re-infection in index pa-
tient - disease-specific
website vs. simple refer-
ral
Follow-up: 1 weeks
Study population RR 3.12
(0.17 to 58.73)
105
(1 study)
⊕⊕©©
low6
0 per 1000 0 per 1000
(0 to 0)
Moderate
0 per 1000 0 per 1000
(0 to 0)
Re-infection in index pa-
tient - additional coun-
selling vs. simple patient
referral
Follow-up: 6 months
Study population RR 0.49
(0.27 to 0.89)
600
(1 study)
⊕⊕⊕©
moderate7
101 per 1000 50 per 1000
(27 to 90)
Moderate
101 per 1000 49 per 1000
(27 to 90)
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; DIS: disease intervention specialist; RR: risk ratio; STI: sexually transmitted infection.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
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Very low quality: We are very uncertain about the estimate.
1 Method of allocation concealment was not reported. 70% completed follow-up, some were lost to follow-up and some withdrew from
the study, reasons for withdrawal were not reported. Study was not blinded.
2 Assuming alpha of 0.05 and beta of 0.2. For relative risk reduction of 20% with best estimate of control event rate of 0.2 approximately
3000 participants were required. The total sample size was 220 and did not meet the optimal information size.
3 High attrition rate and no information given on method of allocation concealment in one of the studies. Different methods were used for
outcome assessment
4 I2 = 76% (P value = 0.06) and minimal overlap of CIs.
5 Sample size less than 400, there were very few events and CIs around both relative and absolute estimates include both appreciable
benefit and appreciable harm.
6 Sample size was very small and optimal information size was not met. There were very few events and CIs overlapped, therefore, no
effect both for absolute and relative estimates.
7 Risk for selective reporting and unclear method of allocation concealment.
6
S
tra
te
g
ie
s
fo
r
p
a
rtn
e
r
n
o
tifi
c
a
tio
n
fo
r
se
x
u
a
lly
tra
n
sm
itte
d
in
fe
c
tio
n
s,
in
c
lu
d
in
g
H
IV
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
3
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Description of the condition
Sexually transmitted infections (STI) have a negative impact on
the social, health and economic well-being of a country. Every
year an estimated 499 million new cases of the four most common
curable STI, trichomoniasis, chlamydia, syphilis and gonorrhoea,
are acquired (WHO 2012). Furthermore, two to three million
new cases of human immunodeficiency virus (HIV) occur per
year (UNAIDS 2010). Up to 4000 infants become blind annually
due to eye infections attributable to underlying gonococcal and
chlamydial infections in the mother (WHO 2007).
The term STI includes both infections that remain latent or
asymptomatic and those that progress to a clinical manifestation
(disease). In this update, we used the term STI instead of sexually
transmitted diseases (STD), which was used in the original re-
view. STI are more prevalent in countries and communities where
socio-economic conditions are poor (Glasier 2006; Low 2006a).
Curable STIs are often overshadowed by the burden of HIV, but
are important causes of morbidity in their own right (Table 1).
Clinical symptoms of STIs can be non-specific and, where possi-
ble, the diagnosis needs to be confirmed by laboratory testing. In
lower-income countries, laboratory testing is not always available
and women and men reporting symptoms suggestive of an STI are
often treated according to algorithms without confirmatory tests.
For male urethritis and genital ulcers, this approach is effective
but with vaginal discharge the risk of misdiagnosis is high. Syn-
dromic management of STI can therefore lead to over-treatment
and adverse social consequences such as stigma and intimate part-
ner violence (Trollope-Kumar 2006).Women are more likely than
men to suffer from reproductive tract complications of STIs such
as chlamydia and gonorrhoea if the infection ascends to the upper
genital tract; pelvic inflammatory disease (PID), ectopic pregnan-
cies and infertility are the most commonly documented compli-
cations (Gerbase 1998). STIs are, however, often asymptomatic in
both women andmen (WHO2007). As a result, disclosing a diag-
nosis of an STI to sexual partners and partner treatment play a crit-
ical part in the comprehensive management of STI. Willingness
to disclose varies according to the STI and gender (Alam 2010). In
one study among people with a diagnosis of HIV, 85% of people
living with HIV were sexually active, but only 58% revealed their
HIV status to recent sexual partners (Simbayi 2007). In a study in
Connecticut, US, 25% of females with chlamydia intended not
to notify their partners (Niccolai 2007) as most (46%) thought it
unimportant and 43% were not willing to discuss the condition.
In a study in India, the patient characteristics most likely to in-
crease the odds of referring a partner were having a diagnosis of
genital ulcer disease (odds ratio (OR) 2.78, 95% confidence inter-
val (CI) 1.08 to 7.13, P value = 0.033) and having the intention
to inform the regular partners (OR 16.9, 95% CI 3.29 to 86.70,
P value = 0.001) (Sahasrabuddhe 2002).
Description of the intervention
“Partner notification is a process that includes informing sexual
partners of infected people of their exposure, administering pre-
sumptive treatment, and providing advice about the prevention
of future infection” (UNAIDS 1999). Partner notification (PN) is
also known as contact tracing, partner management or partner in-
formation. A person with a newly diagnosed STI is often referred
to as an ’index case’ or ’index patient’. The index patient has one
or more sexual partners. The sexual partners of the index patient
might have been the source of the infection in the index patient
or they might have acquired the infection from the index patient.
A variety of approaches has been used to notify sexual partners
and to ensure that they receive treatment. In principle, manag-
ing infection in people with more than one current sexual part-
ner should have the greatest impact on the spread of STI (Fenton
1997). The use of different approaches depends partly on the STI
for which theywere originally intended. There are other influences
at the country level, including cultural factors, the structure and
financing of health systems, and clinical consensus. At the indi-
vidual level, factors such as patient choice influence choice of PN
strategies. Traditionally, three main approaches have been defined:
patient referral, provider referral and contract (or conditional) re-
ferral. Definitions and explanations of these PNmethods are given
below.
Patient referral (patient-led referral) refers to an approach in
which health service personnel encourage index patients to notify
their own partners. In this review, we used the term simple patient
referral to refer to spoken advice from health service personnel
about the need for sexual partners to receive treatment. This can
be seen as a minimum standard for a PN intervention. There is,
however, no agreement about the content of a consultation for
simple patient referral. Patient referral was developed in the 1970s
when rates of gonorrhoea in the US were very high and the capac-
ity of specialist PN personnel was exceeded. Patient referral has
since become the preferredmethod of PN for gonorrhoea and sub-
sequently chlamydia in many countries. There has been great in-
terest in developing methods to support index patients so that the
outcomes of patient referral can be improved or enhanced (Trelle
2007). Patient referral can, therefore, be split into two categories
(simple and enhanced), according to the level of support given to
the patient. Expedited partner therapy (EPT) has developed in the
US since the late 1990s as a new patient-led strategy to help index
patients to get their partners treated more quickly.
Enhanced patient referral refers to a group of strategies that sup-
plement the spoken advice with the aim of improving patient re-
ferral success, including educationalmaterial such as videos viewed
in waiting rooms, written disease-specific information for index
patients to give to their partners, home sampling kits for partners,
disease-specific websites, theory-based counselling and reminders
by telephone or other means (Trelle 2007).
EPT is a group of strategies to enhance the success of patient refer-
ral by increasing the numbers of partners treated and speeding up
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the time to treatment (CDC 2006). The EPT strategies include:
patient-delivered partner medication (PDPM) or patient-deliv-
ered partner therapy (PDPT), where the index patient receives
antibiotics (often in a package with condoms and written infor-
mation) to give to their partner without the need for a medical
examination of the partner (Golden 2005); or additional prescrip-
tions given to index patients for their partner(s). EPT can reduce
loss to follow-up of index cases (Young 2007), and reduce the risk
of repeated infection in the index case (Golden 2005). There are,
however, disadvantages, including the risk of adverse drug reac-
tions, other underlying disease remaining undetected and amissed
opportunity for counselling and testing for other STIs including
HIV (Golden 2005). In some countries, such as the UK, EPT is
not legal unless the partner is assessed before receiving antibiotic
treatment (ECDC 2013).
Provider referral (provider-led referral) uses third parties (usually
specialist health service personnel) to notify partners. The name of
these health professionals differs between countries, for example;
’disease intervention specialists’ (DIS) in the US; ’health advisers’
in the UK and ’Kurators’ in Sweden. Provider referral originated
in Scandinavia and the UK as a method to trace and refer the
sexual partners of people with syphilis when treatment first became
available. More recently, it has been used for other clinically severe
STIs such as HIV infection and hepatitis B. It can also be used
for other STIs such as gonorrhoea and chlamydia when the index
patient is unable to notify partners by themselves. Provider referral
should only be done with the explicit consent of the index patient.
In some countries, for example France, provider referral does not
occur because it is seen as an invasion of privacy (ECDC 2013).
Contract referral (conditional referral) refers to an approach in
which there is an agreement (contract) between the patient and the
health professional. Health service personnel encourage index pa-
tients to notify their partners, with the understanding that health
service personnel will notify those partners who do not visit the
health service by an agreed date. Contract referral is, in practice,
difficult to define as a separate PN approach. It can be difficult
to distinguish from provider referral if the time window for pa-
tient referral is very short (two or three days) (Peterman 1997). In
contrast, contract referral is often used as an extension to simple
patient referral, rather than a separate strategy, if the index patient
has not been able to inform their partner(s) when they are followed
up.
How the intervention might work
There are different aims of PN, depending on the level at which
it is targeted and the infection (Low 2006a). At the level of the
index patient with a curable STI the aim is to provide concurrent
antibiotic treatment to the sexual partner(s) so that infection can
be eradicated in both people and re-infection prevented in the
index patient, which is a clinical goal. For the sexual partner(s)
the aim is to identify and treat infection that might have been
the source of infection in the index patient, or might have been
acquired from the index patient. At the level of sexual networks
and populations, the aim is to interrupt chains of transmission
and reduce the spread of STIs, which is a public health goal. For
viral STIs, the aim is to identify previously undiagnosed infections,
which can provide early access for sexual partners to treatment and
prevent onward transmission through behavioural change by the
infected person.
To succeed, PN strategies need to first elicit from the index patient
details of all sexual partners fromwhom he/she may have acquired
the infection, or whom he/she might have subsequently infected.
Identifying partners in the latent period of infection (usually three
months for primary syphilis and one month for acute urethritis)
(Toomey 1996), should identify those from whom infection was
acquired, while identifying partners after the onset of symptoms
will identify those who were likely to have been infected by the
index case. The time period for identifyingpartners differs between
countries for different STIs.
Formost PN strategies, eliciting partner information from infected
people is a prerequisite to notifying sexual partners. For example,
when health service personnel notify partners, they rely on the
index patient to count, name and provide details to enable all his/
her partners to be traced. Once partners have been elicited, PN
strategies need to provide either the index patient or the health
service personnel with the necessary knowledge, skills or resources
to enable them to locate, notify, medically evaluate and test or
treat these partners.
Communication between partners, during which the index pa-
tient encourages them to consider screening or treatment, has
been identified as a critical point in effective PN strategies (Young
2007). The communication usually requires the index patient to
disclose their STI diagnosis. Disclosure can lead to benefits other
than successful partner treatment, such as emotional support and
protecting the health of others. Disclosure can also lead to stigma,
rejection, physical abuse and discrimination (Arnold 2008).
Why it is important to do this review
PN has been practised as a measure to control STIs since the early
1900s (ECDC 2013), but there is limited evidence of its pub-
lic health impact. Many evaluations have not been conducted as
randomised controlled trials (RCTs) and many were conducted in
developed countries before the HIV/acquired immunodeficiency
syndrome (AIDS) pandemic. It is not known whether interven-
tions developed for high-income countries are applicable to re-
source-limited settings.
There are several published systematic reviews of PN. The first
included only studies conducted in developed countries (Oxman
1994). Another included only published studies conducted in the
US after 1980 (Macke 1999). The original Cochrane Review by
Mathews et al. was assessed as up to date in July 2001 (Mathews
2001). Trelle et al. systematically reviewed studies of enhanced
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methods of patient referral, including EPT, to improve the effec-
tiveness of simple patient referral (Trelle 2007). The latest sys-
tematic review only studied curable STIs in developing countries
(Alam 2010). Considering the ongoing developments in this field,
the Cochrane Review was updated in line with recommendations
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
O B J E C T I V E S
To assess the effects of alternative PN strategies.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs that compared at least two PN strategies.
Types of participants
People in rural and urban areas, given a diagnosis of STI (clini-
cally or by a laboratory) in health services with any of the follow-
ing STI: gonorrhoea (Neisseria gonorrhoeae), chlamydia (Chlamy-
dia trachomatis), trichomoniasis (Trichomonas vaginalis), syphilis
(Treponema pallidum), chancroid (Haemophilus ducreyi), genital
herpes, hepatitis B and HIV. We also included diagnoses of the
following STI syndromes: genital ulcer syndrome - non-vesicular
or vesicular, urethral discharge syndrome, vaginal discharge syn-
drome and lower abdominal pain in women. Studies conducted
in any type of health service were included.
Types of interventions
Strategies directed at patients (patient-led) or health workers
(provider-led) were included. The following types of strategies
were included:
• strategies to enhance the effectiveness of patient referral
through, for example, health education and counselling, health
education materials (such as pamphlets, posters, video and audio
productions), patient assistance strategies directed at facilitating
patient referral (such as referral cards, incentives, reminders,
video and audio productions). EPT was included as a specific
type of enhanced patient referral;
• contract referral strategies;
• provider referral strategies;
• combinations of the above.
Types of outcome measures
Primary outcomes
Number of index patients with curable STIs given a clinical or lab-
oratory diagnosis of re-infection. Re-infection implies re-infection
of the index patient with the same STI from an untreated sexual
partner. In practice, the outcome measured is repeated detection
of the STI at some time interval after the index case has been
treated. Repeated detection of an STI could also result from a new
infection in the index case acquired from a new sexual partner,
or treatment failure due to antibiotic resistance or subtherapeutic
dosing. These causes cannot be reliably distinguished and the term
re-infection is used to include repeated detection from any cause.
Secondary outcomes
Numbers of partners elicited (sexual partners that the health pro-
fessional obtains from the index patient for the recall period in
question), located (sexual partners that the index patient was able
to find; this number is likely to be a subset of partners elicited),
notified (sexual partners that the index patient informed of their
possible exposure to an STI; this number is likely to be a subset
of partners located), presenting for care, testing positive or treated
per index case; delay in partners presenting for care; incidence of
STIs; changes in the index patient’s or partner’s behaviour with
regard to condom use, abstinence in the presence of symptomatic
infections, the number of partners, the number of concurrent part-
ners; emotional impact on the index patient or partner in their
relationship; harm to the patient or partners, such as domestic vi-
olence, abuse or suicide; ethical outcomes (patient autonomy vs.
beneficence).
Search methods for identification of studies
Electronic searches
Search method for original review (Mathews 2001)
The original review authors searchedMEDLINE (1966 to 24 July
2001), EMBASE (1974 to 24 July 2001), Psychological Abstracts
(1967 to 24 July 2001) and Sociological Abstracts (1963 to 24
July 2001). The Cochrane Controlled Trials register was searched
with the text words ’sexual partners’, ’partner notification’, ’con-
tact-tracing’ and ’contact tracing’. The Effective Practice and Or-
ganisation of Care (EPOC) register of studies was searched, as was
the register of the HIV and AIDS Cochrane Review Group.
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Search method for the review update
We searched three electronic databases, MEDLINE, EMBASE
and CENTRAL, from 5 January 2001 to 31 August 2012. Search
strategies are shown in Appendix 1, Appendix 2 and Appendix 3.
Searching other resources
Original Cochrane review (Mathews 2001)
The original review authors handsearched the Proceedings of the
International AIDS Conferences (1996 to 24 July 2001) and
the International Society for STD Research meetings (ISSTDR)
(1991 to 24 July 2001). Bibliographies of studies and previous
reviews were examined for references to other trials. Experts in the
field were contacted.
Review update
We searched all reference lists of potential studies and previous
reviews for relevant RCTs and contacted experts in the field. We
searched the International Clinical Trials Registry Platform (IC-
TRP) from 18 March 2011 to 31 August 2012 to identify on-
going studies (www.who.int/ictrp/en/). We searched the ICTRP
for the protocols of the 16 new studies. Trial registries were not
searched for the protocols of the original included studies because
these were all published before 1998.
Data collection and analysis
Selection of studies
Two review authors (CathyMathews, CM and Riabatu Abdullah,
RA (original review); and Adel Ferreira, AF and Taryn Young, TY
or CM or Moleen Zunza, MLZ (update)) independently screened
titles and abstracts of the electronic search results. We obtained
all the eligible abstracts of comparative studies in full-text format,
and two review authors (CM and RA original review and AF and
TY or CM update) independently reviewed them for inclusion
using prespecified eligibility criteria. We included all studies that
reported random allocation. We assessed the risk of bias in the
methods of sequence generation and allocation, as described in
the section ’Assessment of risk of bias in included studies’ and
considered risk of bias interpreting the strength of evidence for
each intervention.
Data extraction and management
Two review authors (CM and Nicol Coetzee, NC or Merrick
Zwarenstein, MZ (original review) and AF and TY or CM or
MLZ (update)) independently abstracted study characteristics and
outcomes including information on: social context (developing
(World Bank classification: countries with low or middle levels of
gross national product (GNP) per capita as well as five high-in-
come developing economies - Hong Kong (China), Israel, Kuwait,
Singapore and the United Arab Emirates. These five economies
are classified as developing despite their high per-capita income
because of their economic structure or the official opinion of
their governments. Several countries with transition economies are
sometimes grouped with developing countries based on their low
or middle levels of per-capita income, and sometimes with devel-
oped countries based on their high industrialisation (World Bank
2012)) or developed country); access to health services; legisla-
tive context (permissive or proscriptive public health legislation);
methodological quality of study; type of health facility; type of
provider (for example, nurse, physician, DIS); participants; type
of interventions; outcome measure; results and correspondence
required using a data extraction form.
We resolved disagreements by discussion. We summarised data
from included studies in the Characteristics of included studies
table and data from excluded studies in the Characteristics of
excluded studies table. We summarised studies with insufficient
information in theCharacteristics of studies awaiting classification
table. Where there were missing data, we attempted to contact
study authors by email.
Assessment of risk of bias in included studies
Two review authors (AF and CM or MLZ) independently eval-
uated the risk of bias using The Cochrane Collaboration’s tool
(Higgins 2011a). We made judgements about the presence of bias
by selecting one of three categories of risk of bias: low risk, high
risk and unclear risk of bias. We resolved disagreements by discus-
sion. If we could not reach consensus, we involved a third inde-
pendent review author (TY). We contacted trial authors if there
were any unclear issues and, if we received no response, we made
a judgement of ’unclear risk of bias’.
We assessed and summarised the following main items in the ’Risk
of bias’ table: sequence generation, allocation concealment, blind-
ing of participant and personnel, blinding of outcome assessment,
whether incomplete outcome data were adequately addressed, se-
lective reporting and any other bias. We searched the ICTRP for
protocols of the 16 additional studies to assess selective reporting
bias. Figure 1 and Figure 2 show the ’Risk of bias’ graphs, which
illustrate the proportions of studies with low, high and unclear
risk of bias. In the 10 studies of the original review, the ICTRP
was not searched; instead, the methods and result sections were
compared to evaluate if the same outcomes were reported in these
two sections. If the protocol was not available, the methods and
results sections were compared to assess selective reporting bias.
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Figure 1. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Measures of treatment effect
The review authors prepared tables summarising the results of each
study for each comparison.
We defined re-infection rate in index patients as the percentage of
index patients with a repeated diagnosis of the same STI divided
by the number of index patients retested.
Partners elicited, notified, presenting for care, tested, treated or
harmed: we assumed that the number of units of each outcome per
index patient was a random variable following a Poisson distribu-
tion. We assumed that the index patients from the groups within
a study had similar distributions for exposure time to partners,
for time to notify their partners, and that the same assumption
held for partners with respect to the time taken to present to the
health service. The value of the mean and the variance of a Poisson
distribution are the same.
To calculate a CI for the difference in relevant outcomes, we used
the normal approximation to the Poisson distribution since only
summarised data from the included RCTs were available.
The approximate 95% CI for the rate difference is given by:
(Lamda1 - Lamda2) ± 1.96
√
(lamda1/n1 + lamda2/n2),
where lamda1 and lamda2 are the rates of partners per index pa-
tient in two groups, and n1 and n2 the number of index patients.
To calculate the standard error (SE) the formula used was:
(upper limit of 95% CI - lower limit of 95% CI)/3.92.
To calculate the standard deviation (SD) the formula used was:
SE/
√
(1/Nexp+ 1/Ncont),
where Nexp is the number of index patients randomised to the
experimental group and Ncont is the number of index patients
randomised to the control group
For continuous outcomes (number of partners elicited, notified,
presenting for care, tested, treated or harmed), we recorded the
mean (in number of partners per index patient randomised), SE
and sample size. Where the exact numbers of partners were not
available, we contacted study authors. If authors did not respond
or could not provide the exact numbers, themean difference (MD)
could not be calculated and we reported the study findings de-
scriptively. In studies where the rate of partners elicited per index
patient was not reported, we used the number of contact cards
given to the index patient as a proxy indicator.
We described the delay in partners presenting for care as the mean
or median number of days after index patient enrolment.
Unit of analysis issues
We dealt with studies with multiple intervention groups as recom-
mended in the Cochrane Handbook for Systematic Intervention Re-
views (Higgins 2011b). We compared each intervention arm with
another.
Where this resulted in shared intervention groups, we did not per-
form a meta-analysis to prevent ’double-counts’ of participants. In
these studies, we described the results in narrative form (Ellison
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undated; Montesinos 1990). We did not include any cluster ran-
domised trials and, therefore, no adjustments were necessary.
Dealing with missing data
Where there were missing data, we attempted to obtain the data
by contacting study authors by email. We contacted the authors
of eight trials and authors provided requested data for five of the
eight trials.
Assessment of heterogeneity
We assessed sources of clinical and methodological heterogeneity
by looking at characteristics of studies, evaluating similarity be-
tween type of participants, intervention used and outcomes. We
calculated the Chi2 test for heterogeneity (Deeks 2011), and the I2
statistic to evaluate statistical heterogeneity. Values of the I2 statis-
tic were interpreted as follows (Deeks 2011): 0% to 40%: might
not be important; 30% to 60%: might represent moderate hetero-
geneity; 50% to 90%: might represent substantial heterogeneity;
75% to 100%: might represent considerable heterogeneity.
Assessment of reporting biases
We did not find a sufficient number of studies to produce funnel
plots to investigate publication bias for specific comparisons.
Data synthesis
We analysed data according to paired partner referral strategies
(Table 2). We organised the comparisons first according to the
four main PN strategies (1. enhanced patient referral, 2. EPT,
3. contract referral, 4. provider referral). Each main strategy was
compared with simple patient referral and then with each other, if
trials were available. We compared each enhanced patient referral
with another enhanced patient referral. This resulted in 10 com-
parisons (Table 2).
The largest group of trials (Table 2; comparison 1, enhanced pa-
tient referral versus simple patient referral) included several differ-
ent interventions to enhance the outcomes of patient referral. We
grouped these into six categories: (1) patient referral with DIS or
health adviser, (2) postal testing kit, (3) information booklet, (4)
disease-specific website, (5) additional counselling or (6) showing
a videotape.
We performed meta-analyses where appropriate using random-ef-
fects models to report the pooled MD (for continuous outcomes)
or risk ratio (RR for dichotomous outcomes) with 95%CI. When
there was a moderate or low level of heterogeneity (I2 ≤ 50%),
we pooled results. If there was more substantial evidence of het-
erogeneity (I2 > 50%), we pooled the results of individual studies
if appropriate or described in the narrative. We reported results of
tests for heterogeneity (Tau2, Chi2 test with number of degrees of
freedom (df ), P value and I2 statistic).
Subgroup analysis and investigation of heterogeneity
We used subgroup analyses to explore possible sources of hetero-
geneity. These included: age of participant, gender, specific STIs
investigated, setting (developed vs. developing country) and cate-
gory of healthcare worker.
Sensitivity analysis
We performed a sensitivity analysis on the primary outcome, re-
infection rate of index patient with curable STIs. Given the lim-
ited numbers of trials and meta-analyses, the sensitivity analysis
examined only the effect of attrition bias. We repeated meta-anal-
yses excluding trials with more than 20% attrition and compared
results with the primary analysis.
’Summary of findings’ table
We interpreted results using a ’Summary of findings’ table, which
provided key information about the quality of evidence for the
studies included in a comparison, themagnitude of effect of the in-
terventions examined and the sum of available data on the primary
outcome. We imported data from Review Manager 5 (RevMan
2011), using the GRADE profiler (GRADE 2004). We selected
the primary outcome of re-infection in the index case for the ’Sum-
mary of findings’ table.
R E S U L T S
Description of studies
Results of the search
The initial search (1966 to 24 July 2001; Mathews 2001) identi-
fied 11 RCTs, including 8041 participants. The updated search (5
January 2001 to 31August 2012) identified an additional 16RCTs
(9597 participants; 6841 women and 2756 men). One study was
listed as awaiting classification (Characteristics of studies awaiting
classification). In the original review, Levy 1998 (with 60 partici-
pants) was listed as under ’Included studies’ but, in this update, it
was placed under ’Characteristics of studies awaiting classification’
because no results were available. We found four ongoing studies
in trial registers (Characteristics of ongoing studies).
Included studies
Twenty-six RCTs (Figure 3) were included in the review including
17,578 participants (Characteristics of included studies). Most of
the trials (14) were conducted in the US, four in the UK, two
in Denmark, and one each in Australia, Malawi, South Africa,
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Uganda, Zambia and Zimbabwe. Most trials (21) were based in
public health clinics. One was conducted in a large academic med-
ical centre (Trent 2010), three in general practice (Andersen 1998;
Low 2006b; Ostergaard 2003), and one on a university campus
(Montesinos 1990).
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Figure 3. Flow diagram detailing the updated search and selection of studies.
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Participants
Trials were conducted among patients with gonorrhoea (three tri-
als, Cleveland undated; Potterat 1977; Solomon 1988); gonor-
rhoea or non-gonococcal urethritis (one trial, Montesinos 1990);
non-gonococcal urethritis only (one trial, Katz 1988); chlamydia
(six trials, Andersen 1998; Apoola 2009; Cameron 2009; Low
2006b; Ostergaard 2003; Schillinger 2003); syphilis (one trial,
Peterman 1997); HIV (two trials, Brown 2011; Landis 1992);
chlamydia or gonorrhoea, or both (four trials, Golden 2005;
Kerani 2011;Kissinger 2005;Wilson 2009); trichomonas (two tri-
als, Kissinger 2006; Schwebke 2010); PID (one trial, Trent 2010);
and chlamydia or non-gonococcal urethritis (one trial, Tomnay
2006). Four trials in developing countries where syndromic diag-
noses are made included patients with any STI syndrome (Ellison
undated; Faxelid 1996; Moyo 2002; Nuwaha 2001). In six stud-
ies, STI diagnoses were made clinically, based on symptoms or
clinic tests (Ellison undated; Faxelid 1996;Katz 1988;Moyo 2002;
Nuwaha 2001; Trent 2010). In the other 20 trials, STI diagnoses
(other than non-gonococcal urethritis) were confirmed with lab-
oratory testing. There were no RCTs among patients with labora-
tory-diagnosed hepatitis B, genital herpes or chancroid.
Six trials included male patients only, or reported over 90%
male index patients (Cleveland undated; Katz 1988; Kerani 2011;
Kissinger 2005; Potterat 1977; Solomon 1988). Seven trials in-
cluded female index patients only (Andersen 1998; Apoola 2009;
Cameron 2009; Kissinger 2006; Schillinger 2003; Schwebke
2010; Trent 2010).The remaining trials included male and female
index patients. Two trials included men who had sex with men
(Kerani 2011; Landis 1992) and one included male and female
injecting-drug users (Landis 1992).
Types of interventions
Included studies investigated the effects of various PN strategies
(Table 2; Table 3):
• Enhanced patient referral versus simple patient referral;
• Enhanced patient referral versus other enhanced patient
referral method;
• EPT versus simple patient referral;
• EPT versus enhanced patient referral;
• EPT and enhanced patient referral versus simple patient
referral;
• contract referral versus simple patient referral;
• contract referral versus enhanced patient referral;
• contract referral versus EPT;
• provider referral versus simple patient referral;
• choice between provider or simple patient referral versus
simple patient referral;
• provider referral versus enhanced patient referral;
• provider referral versus contract referral.
Outcomes
Outcomes assessed are reported in Table 3. The comprehensive
details of included studies can be seen in the Characteristics of
included studies table.
One study from the original review was classified as a study await-
ing assessment because there were no results available (Levy 1998)
(Characteristics of studies awaiting classification).
Four ongoing studies were identified from the trial register
(Characteristics of ongoing studies).
Excluded studies
We excluded 11 studies (see Characteristics of excluded studies for
details).
Risk of bias in included studies
The risk of bias for each study is presented in the ’Risk of bias’
table in the section Characteristics of included studies. Figure 1
and Figure 2 illustrate the summary of risk of bias in all the studies.
Allocation
Random sequence generation
Eleven trials reported adequate generation of the random alloca-
tion sequence (Apoola 2009; Brown 2011; Cameron 2009; Faxelid
1996; Kissinger 2005; Kissinger 2006; Low 2006b; Nuwaha
2001; Tomnay 2006; Trent 2010; Wilson 2009). Of these trials,
eight used blocked randomisation (Apoola 2009; Brown 2011;
Cameron 2009; Kissinger 2005; Kissinger 2006; Low 2006b;
Tomnay 2006; Wilson 2009), two trials used computer-gener-
ated random numbers tables (Nuwaha 2001; Trent 2010), and, in
one study, lots were drawn by index patient (Faxelid 1996). Se-
quence generation was adequate in six of nine trials reporting the
primary outcome of re-infection with a bacterial STI (Cameron
2009; Kissinger 2005; Kissinger 2006; Low 2006b; Tomnay 2006;
Wilson 2009).
In 13 trials, random sequence generation was unclear (Cleveland
undated; Ellison undated; Golden 2005; Katz 1988; Kerani 2011;
Landis 1992; Montesinos 1990; Moyo 2002; Ostergaard 2003;
Peterman 1997; Schillinger 2003; Schwebke 2010; Solomon
1988) and two trials reported methods used that can introduce
a high risk of bias (Andersen 1998; Potterat 1977). In Andersen
1998, the date of birth of index patient was used and, in Potterat
1977, assignment of index patient was performed alternately to
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specific intervention arms. Both of these trials reported secondary
outcomes only.
Allocation concealment
Five trials reported adequate allocation concealment (Apoola
2009; Brown 2011; Low 2006b; Schillinger 2003; Tomnay 2006).
Of these, four trials reported the use of sealed, opaque, sequen-
tially numbered envelopes (Apoola 2009; Brown 2011; Schillinger
2003; Tomnay 2006), and one trial reported the use of a cen-
tralised telephone service (Low 2006b). In 18 trials, the meth-
ods used for allocation concealment were not adequately de-
scribed (Andersen 1998; Cameron 2009; Cleveland undated;
Faxelid 1996; Golden 2005; Katz 1988; Kerani 2011; Kissinger
2005; Kissinger 2006; Landis 1992; Moyo 2002; Nuwaha 2001;
Ostergaard 2003; Potterat 1977; Schwebke 2010; Solomon 1988;
Trent 2010; Wilson 2009). Allocation concealment was adequate
in three of nine trials reporting the primary outcome of re-infec-
tion with a bacterial STI.
Three studies reported methods that could introduce a high risk
of bias (Ellison undated; Montesinos 1990; Peterman 1997). In
Ellison et al., the interventions were allocated in turn to each
consecutive patient according to a printed schedule, which could
have influenced enrolment or exclusion andhence the intervention
received by the index patients (Ellison undated). In Montesinos
et al., the protocol used in the intervention was colour coded and
the counsellor removed the protocol for the next index patient
from a randomly ordered set (Montesinos 1990). Peterman et al.
reported that the assignment was known to the interviewer before
contact with index patients and sequentially adapted (Peterman
1997).
Blinding
Blinding of participants and personnel (performance bias)
Twenty-five trials did not have blinding of the participants or the
personnel (Andersen 1998; Apoola 2009; Brown 2011; Cameron
2009; Cleveland undated; Ellison undated; Faxelid 1996; Golden
2005; Katz 1988; Kerani 2011; Kissinger 2005; Kissinger 2006;
Landis 1992; Low 2006b;Montesinos 1990;Moyo 2002;Nuwaha
2001; Peterman 1997; Potterat 1977; Schillinger 2003; Schwebke
2010; Solomon 1988; Tomnay 2006; Trent 2010; Wilson 2009).
In one trial, the index patient received identical specimen collec-
tion kits to be given to their partners, and was, therefore, blinded
to the intervention in which they were taking part (Ostergaard
2003).
Blinding of outcome assessment (detection bias)
Eleven trials did not report blinding of the outcome assessors (
Apoola 2009; Faxelid 1996; Katz 1988; Kerani 2011; Kissinger
2005; Kissinger 2006; Montesinos 1990; Moyo 2002; Nuwaha
2001; Peterman 1997; Potterat 1977). In five trials, the outcome
assessors were blinded (Cleveland undated; Ellison undated; Low
2006b; Solomon 1988; Wilson 2009). Cameron et al. reported
that the laboratory personnel (primary outcome) were blinded but
not the interviewers (Cameron 2009). We judged the risk of bias
as low. In six studies, the blinding of outcome assessors was unclear
(Andersen 1998; Landis 1992; Ostergaard 2003; Schwebke 2010;
Tomnay 2006; Trent 2010). In the remaining three studies, the
outcome assessor was not blinded but we judged the risk of bias as
low because the primary outcome was objectively assessed (Brown
2011; Golden 2005; Schillinger 2003).
Incomplete outcome data
Seven trials had a high (> 20%) attrition rate (Cameron
2009; Golden 2005; Kerani 2011; Kissinger 2005; Moyo 2002;
Schwebke 2010; Trent 2010), including four of nine trials report-
ing re-infection with a bacterial STI as an outcome. In Cameron
2009, 65% of index patients submitted at least one urine sam-
ple in 12 months, while in Golden 2005, 68% of index patients
completed the study. In Kerani 2011, 71% of index patients com-
pleted baseline and follow-up interviews. In Kissinger 2005, 79%
of index patients had a follow-up interview but only 37.5% were
retested, and in Moyo 2002, only 50% of index patients had a
follow-up interview. In Schwebke 2010, 40% of index patients
completed the study. In Trent 2010, 62% of index patients had a
follow-up interview.
Selective reporting
We compared the trial protocols with published trial results sec-
tions to assess reporting bias. If the trial protocol was not avail-
able, we compared the methods and results sections of the trial.
We searched three trial registries for the protocols of the 16 addi-
tional studies included in this update. Protocols were available for
five of these studies (Apoola 2009; Kissinger 2006; Low 2006b;
Schwebke 2010; Wilson 2009).
We judged 21 trials to have a low risk of reporting bias either
because the primary outcome stated in the protocol was reported
in the trial result sections (Apoola 2009; Schwebke 2010), or the
outcomes stated in the method sections were reported in the result
sections (Andersen 1998; Brown 2011; Cameron 2009; Cleveland
undated; Ellison undated; Faxelid 1996; Katz 1988; Kerani 2011;
Landis 1992; Montesinos 1990; Moyo 2002; Nuwaha 2001;
Ostergaard 2003; Peterman1997; Potterat 1977; Schillinger 2003;
Schwebke 2010; Solomon 1988; Tomnay 2006; Trent 2010).
We considered four trials to have an unclear risk of reporting
bias because the outcomes reported in the results sections differed
from those stated in the method sections (Golden 2005; Kissinger
2005), or protocols (Kissinger 2006; Low 2006b). In Kissinger
2006, the protocol had primary and secondary outcomes whereas
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in the trial report outcomes were not divided into primary and
secondary. Furthermore, additional sexual and behavioural out-
comes were reported. Low et al. reported some outcomes in the
published paper that differed from the protocol (Low 2006b).
We assessed one trial as being at high risk of reporting bias. In
Wilson 2009, the primary outcomes stated in the protocol differed
from those stated in trial report; in the protocol there were also
three intervention arms described but only two were reported in
the trial publication.
Other potential sources of bias
One study had a high potential for other bias (Peterman 1997).
The authors of the study reported contamination between the
three groups caused by overlap of partners common to index pa-
tients. In eight studies, it was unclear if there was any other po-
tential source of bias (Andersen 1998; Cleveland undated; Golden
2005; Kerani 2011; Landis 1992; Nuwaha 2001; Potterat 1977;
Solomon 1988). Of these seven studies, in five no comparisons of
baseline characteristics between study arms were given (Andersen
1998; Cleveland undated; Landis 1992; Potterat 1977; Solomon
1988). In Golden 2005, selective reporting of subgroups might
have introduced bias and in Nuwaha 2001, partners of the pa-
tient referral group could have been treated elsewhere leading to
misclassification bias. In the remainder of the studies, the risk for
potential sources of bias was low.
Effects of interventions
See: Summary of findings for the main comparison Enhanced
patient referral compared with simple patient referral for partner
notification for STIs, including HIV; Summary of findings 2
Expedited partner therapy compared with simple patient referral
for partner notification for STIs, including HIV; Summary of
findings 3 Expedited partner therapy compared with enhanced
patient referral for partner notification for STIs, including
HIV; Summary of findings 4 Contract referral compared with
expedited partner therapy for partner notification for STIs,
including HIV
Enhanced patient referral
1. Enhanced patient referral versus simple patient referral
Sixteen studies looked at different types of enhanced patient
referral compared with simple patient referral among patients
with gonorrhoea (Cleveland undated; Solomon 1988), chlamy-
dia (Andersen 1998; Apoola 2009; Cameron 2009; Low 2006b;
Ostergaard 2003), non-gonococcal urethritis (Katz 1988), gonor-
rhoea or chlamydia (Kerani 2011; Kissinger 2005; Wilson 2009),
trichomoniasis (Kissinger 2006), chlamydia or non-gonococcal
urethritis (Tomnay 2006), PID (Trent 2010), or any STI syn-
drome (Ellison undated; Moyo 2002).
There were seven different types of enhanced patient referral in-
terventions for patients or partners: 1) an additional counselling
session (Cleveland undated; Ellison undated; Moyo 2002; Wilson
2009); 2) a home testing kit for the partners to use and send back to
a laboratory (Andersen 1998; Cameron 2009; Ostergaard 2003),
or for the partners to bring back to the clinic (Apoola 2009);
3) an additional information booklet to be given to the partner
(Kissinger 2005; Kissinger 2006); 4) a videotape shown to the
index patient (Solomon 1988; Trent 2010); 5) a disease-specific
website was available to the partner (Kerani 2011; Tomnay 2006);
6) health education messages for the index case (Ellison undated);
and 7) health education plus counselling for the index patient
(Ellison undated). In addition, two studies compared patient re-
ferral performed by a contact tracer (DIS or health adviser) with
patient referral performed by a nurse (Katz 1988; Low 2006b).
Primary outcome
Six studies (2007 participants) assessed the index patient re-infec-
tion rate (Cameron 2009; Kissinger 2005; Kissinger 2006; Low
2006b; Tomnay 2006; Wilson 2009) (Figure 4). Owing to sub-
stantial heterogeneity (Tau2 = 0.38; Chi2 = 16.86, df = 5 (P value
= 0.005); I2 = 70%), the results of individual studies were not
pooled. In one comparison, the risk of re-infection in the index pa-
tients was 51% lower in the enhanced patient referral (additional
counselling) compared with the simple patient referral group (RR
0.49, 95% CI 0.27 to 0.89) (Wilson 2009). In two smaller stud-
ies, the risk of re-infection was higher in index patients receiving
the enhanced patient referral strategy but CIs included the pos-
sibility of no difference (Cameron 2009; Tomnay 2006). In the
other three studies, there was no statistical evidence of a difference
between enhanced and simple patient referral (Table 4).
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Figure 4. Forest plot: 1 Enhanced patient referral versus simple patient referral, outcome: 1.1 Re-infection
in index patient, by STI.
We judged the quality of evidence for the primary outcome, using
the GRADE approach, as low for four of the five enhanced patient
referral interventions. We judged additional counselling to pro-
vide moderate evidence of a beneficial effect when compared with
simple patient referral but there was only one trial in this group
(Wilson 2009) (Summary of findings for the main comparison).
Secondary outcomes
Twelve studies (6045 participants) used five different compar-
isons and assessed the number of partners elicited (Andersen
1998; Apoola 2009; Cameron 2009; Cleveland undated; Ellison
undated; Katz 1988; Kerani 2011; Kissinger 2005; Low 2006b;
Moyo 2002; Solomon 1988; Tomnay 2006). There was no evi-
dence of clinically relevant differences between enhanced and sim-
ple patient referral strategies (Table 5).When simple patient refer-
ral delivered by a nurse was compared with specialist contact tracer
(DIS or health adviser) (Katz 1988; Low 2006b), the number of
partners elicited was slightly higher in the simple patient referral
(nurse) group. We conducted a sensitivity analysis, removing the
trial by Andersen 1998 (high risk of bias in random sequence gen-
eration), but there was no appreciable difference in the results.
In Ellison et al. there were four intervention arms comparing three
different enhanced patient referral methods with simple patient
referral: (1) patient referral with a health education message, (2)
patient referral with counselling and (3) patient referral with health
education message and counselling (Ellison undated). Small in-
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creases in the number or partners elicited per index patient were
observed in the enhanced patient referral strategy with a health
education message (MD 0.25, 95% CI 0.10 to 0.39) and health
education message plus counselling (MD 0.6, 95% CI 0.45 to
0.76). In Solomon et al. the authors reported that there was no evi-
dence of differences between enhanced patient referral (videotape)
and simple patient referral group for number of partners elicited
(Solomon 1988).
Six studies (1885 participants) assessed number of partners no-
tified (Cameron 2009; Moyo 2002; Ostergaard 2003; Tomnay
2006; Trent 2010;Wilson 2009). InTrent 2010 andWilson 2009,
the exact number of partners notified was not reported so we could
not calculate the MD. In three studies (Table 6), there was no evi-
dence of a difference in the number of partners notified per index
patient between the groups (Cameron 2009; Ostergaard 2003;
Tomnay 2006). In Moyo et al. additional counselling resulted in
slightly more partners being notified (Moyo 2002).
Five studies (2684 participants) assessed the number of partners
who presented for care (Andersen 1998; Apoola 2009; Cameron
2009; Cleveland undated; Solomon 1988). Data were only avail-
able for four studies (Andersen 1998; Apoola 2009; Cameron
2009; Cleveland undated). There was no evidence that one group
resulted in more partners who presented for care compared with
another (MD 0.1, 95% CI -0.08 to 0.28; heterogeneity: Tau2
= 0.02; Chi2 = 12.59, df = 3 (P value = 0.006); I2 = 76%). In
Solomon 1988), the authors reported no difference in number of
partners presenting for care when a videotape was used.
Five studies (2601 participant) assessed the number of partners
who tested positive (Andersen 1998; Cameron 2009; Cleveland
undated; Katz 1988; Ostergaard 2003). There was no evidence
that there were more partners testing positive in one group than
the other (MD 0.04, 95% CI -0.01 to 0.09; heterogeneity: Tau2
= 0.00; Chi2 = 8.49, df = 4 (P value = 0.08); I2 = 53%).
Six studies (3275 participants) assessed the number of partners
treated (Table 7) (Apoola 2009; Ellison undated; Katz 1988;
Kissinger 2005; Low 2006b; Trent 2010). In Trent 2010, the ex-
act number of partners treated was not reported so we could not
calculate the MD. The enhanced group receiving the information
booklet had slightly more partners treated compared with sim-
ple patient referral (Kissinger 2005). The combination of a health
education message and counselling also resulted in slightly more
partners treated (Ellison undated) (MD 0.08, 95% CI 0.01 to
0.14). There was no evidence of a difference in partners treated
with the other enhanced patient referral strategies.
In one study (902 participants), 14.5% of partners in the simple
patient referral group and 3.3% in the enhanced group (videotape)
attended the clinic eight or more days after the index patient (
Solomon 1988).
Five studies (1138 participants) assessed the number of harmful
events reported (Kerani 2011; Moyo 2002; Tomnay 2006; Trent
2010; Wilson 2009). In two of these, no harms were reported
(Kerani 2011; Tomnay 2006). In Wilson et al., no evidence of
a difference of the amount of harm (argument, fight or physical
violence) was found in the group receiving the enhancement (ad-
ditional counselling) compared with simple patient referral group
(Wilson 2009). In the fourth trial, complications due to medicine
or symptoms worsening were equally distributed between two
groups (Trent 2010). The fifth study did not specify the number
of harms (physical and verbal abuse) reported but stated that it
was not associated with the study arm assignment (Moyo 2002).
No information was available for incidence of STI, changes in
behaviour emotional impact and ethical outcomes.
2. Enhanced patient referral versus other enhanced patient
referral method
Two studies (1351 participants) compared one enhanced patient
referral method with another enhanced patient referral method
among patients with any STI syndrome (Ellison undated) and
gonorrhoea or non-gonococcal urethritis (Montesinos 1990).
Secondary outcomes
Both studies assessed the number of partners elicited. In Ellison et
al., a health education message plus counselling elicited a slightly
higher number of partners compared with counselling alone (MD
0.48, 95% CI 0.32 to 0.64) or to a health education message
alone (MD 0.35, 95% CI 0.19 to 0.52) (Ellison undated). There
was no difference between the groups receiving health education
messages alone compared with the group receiving counselling
alone (MD -0.12, 95% CI -0.27 to 0.03). In Montesinos 1990,
there was no evidence of differences in the number of partners
elicited when counselling was compared with a combination of
counselling plus incentive plus contact cards, and with counselling
plus no incentive plus follow-up call.
One study (65 participants) assessed the number of partners who
presented for care (Montesinos 1990), and found no difference
between groups when index patients received counselling plus fol-
low-up call plus no incentive plus contact cards compared with
counselling alone or counselling plus incentive plus contact cards.
One study (1286 participants) assessed number of partners treated
(Ellison undated). There was no difference between the groups re-
ceiving counselling plus health education message compared with
health message alone (MD 0.05, 95% CI -0.01 to 0.12) or with
counselling alone (MD0.03, 95%CI -0.03 to 0.1).No evidence of
a difference between groups receiving health message alone com-
pared with counselling alone was found (MD 0.02, 95% CI -0.04
to 0.08).
No information was available for index patient re-infection rate,
partners notified, delay in partners presented for care, partners
testing positive, incidence of STI, changes in behaviour, emotional
impact, harms or ethical outcomes.
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Expedited partner therapy
3. Expedited partner therapy versus simple patient referral
Eight studies compared EPT versus simple patient referral among
patients with chlamydia (Cameron 2009; Schillinger 2003), tri-
chomoniasis (Kissinger 2006; Schwebke 2010), gonorrhoea or
chlamydia (Golden 2005; Kerani 2011; Kissinger 2005) and any
STI syndrome (Nuwaha 2001).
Primary outcome
Six studies (6018 participants) assessed the index patient re-infec-
tion rate (Cameron 2009;Golden 2005; Kissinger 2005; Kissinger
2006; Schillinger 2003; Schwebke 2010). Index patients in the
EPT group had a 29% lower risk of being re-infected compared
with index patients in simple patient referral group (RR 0.71, 95%
CI 0.56 to 0.89; heterogeneity: Tau2 = 0.03; Chi2 = 8.15, df = 5
(P value = 0.15), I2 = 39%) (Figure 5). When a sensitivity analysis
was performed and only studies with attrition less than 20% were
included (Kissinger 2006; Schillinger 2003), the effect of EPTwas
attenuated and CIs were wider (RR 0.8, 95% CI 0.62 to 1.04;
heterogeneity: Tau2 = 0.00; Chi2 = 18, df = 1 (P value = 0.67), I2
= 0%).
Figure 5. Forest plot: 3 Expedited partner therapy versus simple patient referral, outcome 3.1 Re-infection
in index patients, by STI.
The GRADE quality of the overall evidence for six studies report-
ing the primary outcome of re-infection was moderate. We down-
graded the quality of the evidence because of the serious risk of bias
resulting from attrition and from inadequately described methods
in several of the studies. When stratified according to type of STI
(two studies each), there was low-quality evidence suggesting no
difference between EPT and simple patient referral for chlamydia,
and low-quality evidence favouring EPT for trichomonas and a
combined outcome of either chlamydia or gonorrhoea (Summary
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of findings 2).
Secondary outcomes
Six studies (4339 participants) assessed the number of partners
elicited (Cameron 2009; Golden 2005; Kerani 2011; Kissinger
2005; Nuwaha 2001; Schwebke 2010). There was no evidence of
a difference between the two groups (MD -0.02, 95% -0.09 to
0.04; heterogeneity: Tau2 = 0.00; Chi2 = 1.05, df = 5 (P value =
0.96); I2 = 0% (Figure 6).
Figure 6. Forest plot: 3 Expedited partner therapy versus simple patient referral, outcome 3.2 Number of
partners elicited.
In one small study of men who have sex with men (75men, Kerani
2011), a slightly higher number of partners was elicited when the
index patient received EPT compared with simple patient referral
(MD 0.42, 95% CI 0.05 to 0.79).
Three studies (3600 participants) assessed number of partners no-
tified (Cameron 2009;Golden 2005; Kissinger 2005). These three
studies showed inconsistent results (heterogeneity: Tau2 = 0.07;
Chi2 = 29.71, df = 2 (P value < 0.001); I2 = 93%) (Figure 7). Het-
erogeneity was explored by setting, STI and gender, and it could
not be explained by subgroup analysis. In one study, slightly more
partners of index patients in the EPT group were notified (MD
0.45, 95%CI 0.28 to 0.62) (Kissinger 2005). In two studies, there
was no significant difference (Cameron 2009: MD 0.13, 95% CI
-0.06 to 0.32; Golden 2005: MD -0.05, 95% CI -0.12 to 0.01).
Figure 7. Forest plot: 3 Expedited partner therapy versus simple patient referral, outcome 3.3 Number of
partners notified.
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One study (220 participants) found no evidence of a difference in
the number of partners who presented for care between the groups
(MD 0.05, 95% CI -0.12 to 0.23) (Cameron 2009).
Four studies (4085 participants) assessed the number of partners
treated (Golden 2005; Kissinger 2005; Nuwaha 2001; Schwebke
2010). The studies showed results in the same direction but were
very heterogeneous (heterogeneity: Tau2 = 0.07; Chi2 = 59.57, df
= 3 (P value < 0.001); I2 = 95%) (Figure 8). Subgroup analysis
(setting, STI, gender) did not explain the heterogeneity. In three
of the four trials, there was a moderate difference favouring EPT
(Kissinger 2005: MD 0.43, 95% CI 0.28 to 0.58; Nuwaha 2001:
MD 0.50, 95% CI 0.34 to 0.67; Schwebke 2010: MD 0.51, 95%
CI 0.35 to 0.67). The difference between groups was very small in
the fourth trial (Golden 2005: MD 0.06, 95% CI 0.01 to 0.12).
Figure 8. Forest plot: 3. Expedited partner therapy versus simple patient referral, outcome 3.5 Number of
partners treated.
One of the studies included a measure of harm (Nuwaha 2001).
This study (383 participants) found no statistical evidence of a
difference in harm between simple patient referral and EPT (MD
0.06, 95% CI 0.0 to 0.12). The index patients in the EPT group
reported 23 incidents of quarrelling compared with 11 incidents
of quarrelling reported in simple patient referral group. Side effects
were reported by index patients in 20 partners in the EPT group
and in 10 partners in the simple patient referral group.
No informationwas available for: partners testing positive, changes
in behaviour, emotional impact, ethical outcomes, delay in part-
ners presenting for care or incidence of STI.
4. Expedited partner therapy versus enhanced patient
referral
Four studies compared EPT versus enhanced patient referral
among patients with gonorrhoea or chlamydia (Kerani 2011;
Kissinger 2005), trichomoniasis (Kissinger 2006) or chlamydia
(Cameron 2009).
Primary outcome
Three studies (1220) assessed the index patient re-infection rate
(Cameron 2009; Kissinger 2005; Kissinger 2006). There was no
evidence of a difference between the two groups (RR 0.96, 95%
CI 0.6 to 1.53; heterogeneity: Tau2 = 0.06; Chi2 = 2.99, df = 2 (P
value = 0.22); I2 = 33%) (Figure 9). Sensitivity analysis including
only studies with attrition less than 20% (Kissinger 2006) also
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found no evidence of a difference between the two groups (RR
0.73, 95% CI 0.30 to 1.76).
Figure 9. Forest plot: 4 Expedited partner therapy versus enhanced patient referral, outcome: 4.1 Re-
infection in index patients.
The GRADE assessment suggests low-quality evidence that there
was no difference between EPT and enhanced patient referral for
preventing re-infection inpatientswith curable STI (three studies).
The evidence was downgraded because of the risk of bias in the
methods and imprecision in the effect estimate (Summary of
findings 3).
Secondary outcomes
Three studies (945 participants) assessed the number of partners
elicited (Cameron 2009; Kerani 2011; Kissinger 2005). There was
no evidence of a difference between the two groups (MD 0.07,
95% CI -0.180 to 0.32; heterogeneity: Tau² = 0.02; Chi² = 3.33,
df = 2 (P = 0.19); I² = 40%) (Figure 10).
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Figure 10. Forest plot: 4 Expedited partner therapy versus enhanced patient referral: 4.2 Secondary
outcomes.
One study (220 participants) measured the number of partners
notified and found no evidence of a difference between the groups
(MD 0.11, 95% CI -0.08 to 0.3) (Cameron 2009).
One study (220 participants) measured the effect on number of
partners presenting for care. There was no evidence of a difference
between groups (MD 0.01, 95% CI -0.02 to 0.03) (Cameron
2009).
One study (692 participants) found a small increase in the number
of partners treated per index patient randomised to the EPT group
compared with the enhanced patient referral group (MD 0.22,
95% CI 0.21 to 0.23) (Kissinger 2005).
No information was available for delay in partners presenting for
care, partners testing positive, changes in behaviour, emotional
impact, harms, ethical outcomes and incidence of STI.
One study compared EPT plus enhanced patient referral or simple
patient referral amongmenwhohave sexwithmenwith chlamydia
or gonorrhoea (Kerani 2011). A website, ’inSPOT’ was used to
enhance the patient referral intervention. The primary outcome
assessed was the number of partners treated or notified. In the
comparison of EPT and inSPOT (41 participants), a moderately
higher number of partners was elicited in the combination group
compared with inSPOT alone (MD 1.15, 95% CI 0.22 to 2.08).
There was no evidence of differences in the number of partners
treated or notified for the comparisons of EPT and inSPOT versus
EPT alone (40 participants; MD 0.17, 95% CI -0.89 to 1.23); or
EPT and inSPOT versus simple patient referral (42 participants,
MD 0.58, 95% CI -0.4 to 1.57).
No information was available for index patient re-infection rate,
incidence of STI, partners notified, partners presenting for care,
number of partners tested, number of partners testing positive,
partners treated, delay in partners presented for care, changes in
behaviour, emotional impact, harms or ethical outcomes.
Contract referral
5. Contract referral versus simple patient referral
Five trials compared contract referral versus simple patient refer-
ral among patients with HIV (Brown 2011; Landis 1992), gon-
orrhoea (Cleveland undated; Potterat 1977) or trichomoniasis
(Schwebke 2010).
Primary outcome
The index patient re-infection rate was assessed in one trial
(322 participants) among women with trichomoniasis (Schwebke
2010). There was no statistical evidence of a difference in the risk
of re-infection in the women receiving contract referral or simple
patient referral at either one month (RR 1.65, 95% CI 0.74 to
3.65) or three months (RR 1.65, 95% CI 0.4 to 6.77).
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The GRADE level of evidence was very low because the findings
were from one small trial with a serious risk of bias in the methods
(Summary of findings 4).
Secondary outcomes
All five studies (2006 participants) assessed the number of partners
elicited per index patient. Slightly fewer partners were elicited in
the contract referral than the simple patient referral group (MD
-0.22, 95% CI -0.37 to -0.06; heterogeneity: Tau2 = 0.01; Chi
2 = 5.27, df = 4 (P value = 0.26); I2 = 24%) (Figure 11). We
conducted a sensitivity analysis, removing the trial by Potterat et
al. (high risk of bias in random sequence generation), but there
was no appreciable difference in the results.
Figure 11. Forest plot: 5 Contract referral versus simple patient referral, outcome: 5.1 Number of partners
elicited.
One study (74 participants) assessed the number of partners no-
tified per index patient among patients with HIV (Landis 1992).
There were more partners notified per index patient in the con-
tract referral group than those that were asked to refer partners
themselves (MD 1.71, 95% CI 1.24 to 2.19).
Three studies (1610 participants) assessed the number of partners
who presented for care (Brown 2011; Cleveland undated; Potterat
1977). Contract referral resulted in slightly more partners present-
ing for care (MD 0.25, 95% CI 0.18 to 0.32; heterogeneity: Tau
2 = 0.00; Chi2 = 0.85, df = 2 (P value = 0.65); I2 = 0%). We con-
ducted a sensitivity analysis, removing the trial by Potterat 1977
(high risk of bias in random sequence generation), but there was
no appreciable difference in the results.
Two studies (481 participants) assessed the time delay between
enrolment of the index patient and presentation of the partner
for care (Brown 2011; Schwebke 2010). In both studies, authors
reported that the partner presented sooner in the simple patient
referral than the contract referral group. In one study, the median
time between enrolment of the index patient and partner presen-
tation was 3 days (interquartile range (IQR) 2 to 7 days) in the
simple patient referral group compared with 7 days (IQR 3 to
11 days) in the contract referral group (Brown 2011), and, in the
other trial, the mean time was 5 days in the simple patient referral
group and 7.25 days in the contract referral group (P value = 0.19)
(Schwebke 2010).
Four studies (1684 participants) assessed the number of partners
who tested positive (Brown 2011; Cleveland undated; Landis
1992; Potterat 1977). Contract referral resulted in slightly more
partners who tested positive (MD 0.12, 95% CI 0.07 to 0.17;
Heterogeneity: Tau2 = 0.00; Chi2 = 2.73, df = 3 (P value = 0.44); I
2 = 0%). We conducted a sensitivity analysis, removing the trial by
Potterat 1977 (high risk of bias in random sequence generation),
but there was no appreciable difference in the results.
Two studies (509 participants) assessed the number of partners
treated (Potterat 1977; Schwebke 2010). In one study, slightly
more partners of women with trichomoniasis were treated in con-
tract referral than in the simple patient referral group (MD 0.28,
95% CI 0.14 to 0.42) (Schwebke 2010). In the trial of men with
gonorrhoea (Potterat 1977), there was no evidence of a difference
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between groups (MD 0, 95%CI -0.04 to 0.03). These two studies
were not summarised in a meta-analysis (heterogeneity: Tau2 =
0.04; Chi2 = 14.61, df = 1 (P value = 0.0001); I2 = 93%). These
two studies were both performed in the US but in different gender
groups reporting different STI.
One study (159 participants) reported on harms with one event
in each group (Brown 2011). One episode of abandonment was
reported in the simple patient referral group and the police were
contacted to placate the partner of one index patient in the contract
referral group.
No information was available for incidence of STI, changes in
behaviour and emotional impact.
6. Contract referral versus enhanced patient referral
One study (1266 participants) compared contract referral versus
enhanced patient referral (counselling) among patients with gon-
orrhoea (Cleveland undated).
Secondary outcomes
The number of partners elicited per index patient randomised was
moderately lower in contract referral group than the enhanced
patient referral (counselling) group (MD -0.40, 95% CI -0.59 to
-0.21).
The number of partners who presented for care per index patient
(MD 0.25, 95% CI 0.17 to 0.33) and the number of partners
who tested positive per index patient (MD 0.11, 95% CI 0.05 to
0.18) were slightly higher in the contract referral group than the
enhanced patient referral (counselling) group.
7. Contract referral versus expedited partner therapy
One study (324 participants) compared contract referral with EPT
among patients with trichomoniasis (Schwebke 2010).
Primary outcome
There was no statistical evidence of a difference in index patient
re-infection rate at one or threemonths after treatment comparing
EPT with contract referral (one month: RR 0.40, 95% CI 0.16
to 1.01 and three months: RR 2.0, 95% CI 0.7 to 5.72).
Secondary outcomes
There was no statistical evidence of a difference between the two
groups in the number of partners elicited per index patient (MD
0.11, 95% CI -0.11 to 0.33). The number of partners treated per
index patient was slightly higher in the EPT group compared with
the contract referral group (MD 0.23, 95% CI 0.05 to 0.41).
No information was available for incidence of STI, changes in
behaviour, emotional impact, harms, ethical outcomes, partners
notified, partners presented for care, delay in partners presented
for care or partners testing positive.
Provider referral
8. Provider referral versus simple patient referral
Two studies compared provider referral versus simple patient re-
ferral among patients with HIV (Brown 2011), and non-gonococ-
cal urethritis (Katz 1988). One study compared a choice between
simple patient or provider referral with counselling versus sim-
ple patient referral among patients with STI syndromes (Faxelid
1996). None of these studies rinvestigated the primary outcome.
Secondary outcomes
Both studies comparing provider referral with simple patient re-
ferral (Brown 2011; Katz 1988) (596 participants) assessed the
number of partners elicited per index patient. The results of these
two studies showed effects in the opposite direction (heterogene-
ity: Tau2 = 0.14; Chi2 = 7.76, df = 1 (P value = 0.005); I2 = 87%).
Subgroup analysis showed that these two studies included index
patients with different STI, different settings and participants, and
these studies were reported individually. Among women and men
with HIV infection (Brown 2011), there was no evidence of a dif-
ference in the number of partners elicited per index patient (MD
0.21, 95% CI -0.15 to 0.57). Among men with non-gonococcal
urethritis (Katz 1988), those receiving provider referral reported
fewer partners (MD -0.36, 95% CI -0.55 to -0.17).
In one study (158 participants), the time delay in partners pre-
senting for care was measured (Brown 2011). Partners presented
sooner for care in the simple patient referral group (median time
from index patient enrolment to partners presenting for care 3
days (IQR 2 to 7 days)) compared with the provider referral group
(median time 4 days (IQR 2 to 8 days)).
In both trials, there was a small increase in the number of partners
testing positive per index patient in the provider group compared
with the simple patient referral group (MD 0.06, 95% CI 0.02 to
0.11; heterogeneity: Tau2 = 0.00; Chi2 = 0.35, df = 1 (P value =
0.55); I2 = 0%).
Among men with non-gonococcal urethritis (438 participants)
there was a moderate increase in the number of partners treated
per index patient in the provider referral group compared with
the simple patient referral group (MD 0.5, 95% CI 0.37 to 0.63)
(Katz 1988).
One trial (158 participants) reported harms among patients with
HIV infection (Brown 2011). In the provider referral group, no
harms were reported and in the simple patient referral group one
episode of abandonment was reported.
No information was available for index patient re-infection rate,
partners notified, partners presenting for care, incidence of STI,
changes in behaviour, emotional impact or ethical outcomes.
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In the study that compareda choice between simple patient or
provider referral with counselling versus simple patient referral (
Faxelid 1996) (396 participants), there was evidence of a difference
between the two groups in the number of partners elicited (MD -
0.03, 95% CI -0.3 to 0.23).
The number of partners notified per index patient (MD 0.41,
95% CI 0.18 to 0.64) and the number of partners who presented
for care per index patient (MD 0.46, 95% CI 0.24 to 0.69) were
moderately higher in those given a choice than the simple patient
referral group. The number of harms reported per male index
patient randomised was slightly higher in choice option compared
with patient referral option (MD0.15, 95%CI 0.06 to 0.25). The
trial authors did not report individual data but stated that there
was no difference between the two groups in the number of harms
reported.
No information was available for delay in partners presenting for
care, partners testing positive, partners treated, changes in be-
haviour, emotional impact or ethical outcomes.
9. Provider referral versus enhanced patient referral
One study (461 participants) compared provider referral versus
enhanced patient referral (contact tracer (DIS)) among men with
non-gonococcal urethritis (Katz 1988). This study did not inves-
tigate the primary outcome.
Secondary outcomes
No evidence of a difference was found in the two groups when
comparing the number of partners elicited per index patient (MD
-0.05, 95% CI -0.21 to 0.11). The number of partners who tested
positive per index patient (MD -0.06, 95% CI -0.11 to -0.02) and
number of partners treated per index patient (MD -0.54, 95% CI
-0.66 to -0.42) were slightly lower in the provider referral group
than the enhanced patient referral (contact tracer) group.
No information was available for index patient re-infection rate,
partners notified, partners presented for care, delay in partners
presented for care, incidence of STI, changes in behaviour, emo-
tional impact, harms or ethical outcomes.
10. Provider referral versus contract referral
Two studies (1491 participants) compared provider referral ver-
sus contract referral among patients with HIV (Brown 2011), and
syphilis (Peterman 1997). Peterman et al. also compared a strategy
of enhanced provider referral (field testing) with contract referral
(1224 participants) and with provider referral alone (1380 partici-
pants). Neither of these studies investigated the primary outcome.
Secondary outcomes
Both studies that compared provider referral with contract referral
(Brown 2011; Peterman 1997) assessed the number of partners
elicited. The results were inconsistent (heterogeneity: Tau2 = 3.03;
Chi2 = 127.21, df = 1 (P value < 0.001); I2 = 100%). Subgroup
analysis (setting, STI, gender) could not explain heterogeneity.
Brown et al. (163 participants) found no evidence of a difference
between the two groups in patients with HIV infection (MD -
0.27, 95% CI -0.62 to 0.07). The other study (1328 participants)
found that the number of partners elicited per index patient with
syphilis was higher in the contract referral group than the provider
referral group (MD 2.2 95% CI 1.95 to 2.45) (Peterman 1997).
Both studies (1491 participants) assessed the number of partners
located. No evidence of a difference between the two groups was
found (MD 0.10, 95% CI -0.01 to 0.2; heterogeneity: Tau2 =
0.00; Chi2 = 0.05, df = 1 (P value = 0.82); I2 = 0%).
One of these studies (163 participants) compared the number
of partners who presented for care and found no evidence of a
difference between the two groups (MD 0.03, 95% CI -0.19 to
0.25) (Brown 2011).
Peterman et al. (1328 participants) assessed the number of partners
tested per index patient and found no evidence of a difference
between two groups (MD 0.05, 95% CI -0.05 to 0.15) (Peterman
1997).
Both studies (1491 participants) compared the number of partners
testing positive (Brown 2011; Peterman 1997). No evidence was
found of a difference between two groups (MD 0.02, 95% CI -
0.03 to 0.06; heterogeneity: Tau2 = 0.00; Chi2 = 0.07, df = 1 (P
value = 0.79); I2 = 0%).
Peterman et al. (1328 participants) compared the number of part-
ners treated per index patient and found no evidence of a differ-
ence between the two groups (MD 0.06, 95% CI -0.03 to 0.15)
(Peterman 1997).
One of these studies (163 participants) reported on harms (Brown
2011). The study reported no harms reported in the provider
referral arm and one episode of abandonment reported in the
contract referral arm (MD 0.01, 95% CI -0.01 to 0.04).
One study (163 participants) assessed the time delay in partners
presented for care after enrolment of index patient (Brown 2011).
The study found that the partners of the index patient in the
provider referral arm presented sooner for care (median time be-
tween enrolment of index patient and partner presenting 4 days
(IQR2 to 8 days) comparedwith the contract referral arm (median
time between enrolment of index patient and partner presenting
for care 7 days (IQR 3 to 11 days).
No information was available for ethical outcomes, index patient
re-infection rate, partners presenting for care, incidence of STI,
changes in behaviour or emotional impact.
InPeterman et al., the number of partners elicited per index patient
was moderately higher in the enhanced provider (field testing)
referral group compared with the contract referral group (MD
0.5, 95% CI 0.21 to 0.79) and much higher than in the group
receiving provider referral alone (MD 2.7, 95% CI 2.45 to 2.95)
(Peterman 1997).
There was no evidence of a difference between enhanced provider
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(field testing) referral group compared with contract referral or
provider referral alone in the number of partners located per in-
dex patient (contract referral: MD -0.10, 95% CI -0.22 to 0.02;
provider referral: MD 0.0, 95% CI -0.11 to 0.11), in the number
of partners who were tested (contract referral: MD -0.06, 95%
CI -0.17 to 0.05; provider referral: MD -0.01, 95% CI -0.11 to
0.09), in the number of partners testing positive (contract referral:
MD -0.02 95% CI -0.07 to 0.03; provider referral: MD 0.0; 95%
-0.05 to 0.04) or in the number of partners receiving treatment
(contract referral: MD -0.05, 95% CI -0.14 to 0.04; provider re-
ferral: MD 0.01, 95% CI -0.07 to 0.09).
No information was available for incidence of STI, partners noti-
fied, index patient re-infection rate, partners presenting for care,
delay in partners presenting for care, changes in behaviour, emo-
tional impact, harms, and ethical outcomes.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Expedited partner therapy compared with simple patient referral for partner notification for STIs, including HIV
Health problem: partner notification for STIs, including HIV
Settings: people in rural and urban areas, given a diagnosis of STI (clinically or by a laboratory) in health services
Intervention: expedited partner therapy
Comparison: simple patient referral
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Simple patient referral EPT
Re-infection in index pa-
tients
Follow-up: 2-12 months
Study population RR 0.71
(0.56 to 0.89)
6018
(6 studies)
⊕⊕⊕©
moderate1
110 per 1000 78 per 1000
(62 to 98)
Moderate
84 per 1000 60 per 1000
(47 to 75)
Re-infection in index pa-
tients - chlamydia
Follow-up: 3-12 months
Study population RR 0.9
(0.6 to 1.35)
2007
(2 studies)
⊕⊕⊕©
moderate2
114 per 1000 102 per 1000
(68 to 154)
Moderate
92 per 1000 83 per 1000
(55 to 124)
Re-infection in index pa-
tients - trichomonas
Study population RR 0.67
(0.34 to 1.28)
631
(2 studies)
⊕⊕©©
low3,43
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67 per 1000 45 per 1000
(23 to 85)
Moderate
67 per 1000 45 per 1000
(23 to 86)
Re-infection in index pa-
tients - chlamydia or
gonorrhoea
Follow-up: 4-18 weeks
Study population RR 0.61
(0.39 to 0.94)
3380
(2 studies)
⊕⊕©©
low5,6
116 per 1000 71 per 1000
(45 to 109)
Moderate
164 per 1000 100 per 1000
(64 to 154)
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 There was high attrition rate in three of the studies. Methods of sequence generation and allocation concealment not reported in two of
the studies.
2 CI includes possibility of no effect (i.e. RR of 1.0).
3 Method of sequence generation and allocation concealment not reported in one of the studies. There was high attrition rate in one of
the studies.
4 Sample size was greater than 400 but CI overlaps, therefore, no effect (i.e. RR of 1.0).
5 There were no details on method of sequence generation and allocation concealment. One of the studies had a high attrition rate.
6 I2 = 74%
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Expedited partner therapy compared with enhanced patient referral for partner notification for STIs, including HIV
Health problem: partner notification for sexually transmitted infections, including HIV
Settings: people in rural and urban areas, given a diagnosis of STI (clinically or by a laboratory) in health services
Intervention: expedited partner therapy
Comparison: enhanced patient referral
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Enhanced patient refer-
ral
EPT
EPT vs. enhanced pa-
tient referral - re-infec-
tion in index patients
Follow-up: 1-12 months
Study population RR 0.96
(0.6 to 1.53)
1220
(3 studies)
⊕⊕©©
low1,2
92 per 1000 88 per 1000
(55 to 140)
Moderate
86 per 1000 83 per 1000
(52 to 132)
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; EPT: expedited partner therapy; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 No details on method of sequence generation in one of the studies. One study had high attrition rate and one study used different
methods for outcome assessment.
2 Sample size is high but CI includes appreciable benefit and harms with both relative risk reduction and increase being greater than 25%.3
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Contract referral compared with expedited partner therapy for partner notification for STIs, including HIV
Health problem: partner notification for sexually transmitted infections, including HIV
Settings: people in rural and urban areas, given a diagnosis of STI (clinically or by a laboratory) in health services
Intervention: contract referral
Comparison: expedited partner therapy
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
EPT Contract referral
Re-infection in index pa-
tient
Follow-up: 3 months
Study population RR 2
(0.7 to 5.72)
322
(1 study)
⊕⊕©©
low1,2
99 per 1000 198 per 1000
(69 to 565)
Moderate
99 per 1000 198 per 1000
(69 to 566)
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; RR: risk ratio.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Method of sequence generation and allocation concealment not reported. The study had high attrition rate. No blinding.
2 Imprecision owing to small sample size.
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D I S C U S S I O N
Summary of main results
Twenty-sixRCTs including17,578 participants (9015women and
8563 men) conducted in 10 countries were included in this sys-
tematic review.
Summary of evidence according to type of partner
notification strategy
EPT for index patients, in trials including those with gonorrhoea,
chlamydia, gonorrhoea or chlamydia, or trichomonas (six trials)
was better than simple patient referral for the prevention of re-
infection of the index patient. EPT also increased the number of
partners treated per index patient (four trials). The re-infection
rate after EPT was similar to that with enhanced patient referral
(three trials) but EPT resulted in more partners treated (one trial).
When contract referral was compared with EPT (one trial), there
was no difference in re-infection rates among index patients but
EPT resulted in more partners being treated. There was insuffi-
cient evidence to determine the most effective components of an
enhanced patient referral intervention.
We found some evidence that more partners were treated with
provider referral (one trial of non-gonococcal urethritis) compared
with simple patient referral. In patients with syphilis (one trial),
contract referral elicited more partners than provider referral but
the number of partners presenting for care and receiving treatment
was the same in the two groups. There was no consistent evidence
for the relative effects of provider, contract or patient referral for
other STI.
The results of four trials comparing home sampling kits for part-
ners with simple patient referral found no evidence of a reduc-
tion in re-infection rates in index cases or higher numbers of part-
ners elicited, notified or treated. We found no studies evaluating
provider training. Only seven trials assessed potential harms; we
could not combine the results but there was no evidence of differ-
ences in the incidence of adverse effects in any of the individual
trials.
Summary of evidence, by infection
There were 11 different categories of STI included in the review.
Fifteen studies assessed strategies for PN in individual STI and
11 studies assessed combinations of STI or syndromic diagnoses.
There were no RCTs among patients with laboratory-diagnosed
hepatitis B, genital herpes or chancroid.
HIV
Only two studies evaluated PN strategies among patients with
HIV (314participants) (Brown 2011; Landis 1992). Both contract
referral and provider referral resulted in more partners presenting
for care and testing positive than simple patient referral.
Chlamydia
There was no evidence of a difference in index patient re-infection
rates in two trials that compared EPT with simple patient refer-
ral (2007 participants) (Cameron 2009; Schillinger 2003). Four
studies compared home sampling kits for partners with simple pa-
tient referral (1058 participants) (Andersen 1998; Apoola 2009;
Cameron 2009; Ostergaard 2003). One study found no reduction
in re-infection in index patients (Cameron 2009). There was no
difference between groups in numbers of partners elicited, notified
or treated.
Gonorrhoea
There was no evidence about index patient re-infection rates.
Three studies were performed among patients with gonorrhoea
(Cleveland undated; Potterat 1977; Solomon 1988). One study
compared simple patient referral versus contract referral (Potterat
1977), another study compared simple patient referral versus en-
hanced patient referral (videotape) (Solomon 1988), and the third
study compared simple patient referral versus contract referral ver-
sus enhanced patient referral (additional counselling) (Cleveland
undated). Simple patient referral elicited a slightly higher number
of partners if compared with contract referral (Cleveland undated;
Potterat 1977). The authors of one study using the enhanced pa-
tient referral (videotape) did not report results (Solomon 1988).
Chlamydia or gonorrhoea
In trials that included index patients with either chlamydia or
gonorrhoea, there was evidence that EPT reduced the index pa-
tient re-infection rate compared with simple patient referral (3380
participants) (Golden 2005; Kissinger 2005). There was also evi-
dence from one trial (600 participants) that index patient re-infec-
tion rates were reduced by patient referral enhanced by additional
counselling compared with simple patient referral (Wilson 2009).
In one trial among men who had sex with men, more partners
were elicited when a combination of EPT and enhanced patient
referral (inSPOT website) was used compared with enhanced pa-
tient referral (inSPOT website) alone (Kerani 2011).
Trichomonas
There was no statistical evidence that EPT resulted in a lower re-
infection rate in female index patients in comparisons of: EPT
versus patient-booklet enhanced patient referral versus simple pa-
tient referral (463 participants) (Kissinger 2006); or EPT versus
contract referral versus simple patient referral (484 participants)
(Schwebke 2010). Slightly more partners were treated when EPT
was used compared with contract referral (Schwebke 2010).
34Strategies for partner notification for sexually transmitted infections, including HIV (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Non-gonococcal urethritis
One study (678 participants) compared simple patient referral
delivered by a nurse versus enhanced patient referral delivered by a
DIS versus provider referral (Katz 1988). Provider referral resulted
in slightly more partners who tested positive and who received
treatmentwhen comparedwith simple patient referral delivered by
a nurse. Simple patient referral by a nurse was superior to enhanced
patient referral in the number of partners elicited, but there was
no evidence of a difference between groups in number of partners
who tested positive.
Non-gonococcal urethritis or gonorrhoea
There was no evidence about index patient re-infection rates. One
study (65 participants) compared patient referral enhanced by ad-
ditional counselling alone, counselling with incentives and coun-
selling with a follow-up telephone call (Montesinos 1990). There
was no evidence of superiority of any of the different method as-
sessed in eliciting partners or increasing the number of partners
who presented for care.
Non-gonococcal urethritis or chlamydia
In one study (105 participants), there was no evidence that the use
of a website reduced index patient re-infection rates, or increased
the number of partners elicited or notified (Tomnay 2006).
Syphilis
One study (1966participants)was performed amongpatients with
syphilis (Peterman 1997). This study compared contract referral
versus provider referral versus enhanced provider referral (with
field testing).Contract referral elicitedmore partners thanprovider
referral. There was no difference between the numbers of partners
who were tested, who tested positive or who received treatment
between the contract and provider referral group.
Pelvic inflammatory disease
There was no evidence about index patient re-infection rates. One
study (126 participants) was included on PID, but exact numbers
of partners notified were not available from trial authors (Trent
2010).
Any sexually transmitted infections syndrome
Four studies (2770 participants) in developing countries in Africa
were performed among patients with a syndromic diagnosis of a
STI (Ellison undated; Faxelid 1996; Moyo 2002; Nuwaha 2001).
One study (396 participants) found that index patients given a
choice between patient and provider referral, compared with sim-
ple patient referral resulted in slightly more partners notified and
presenting for treatment (Faxelid 1996). One study (383 partici-
pants) found that EPT resulted in slightly more partners treated
(Nuwaha 2001). In two studies (1991 participants), simple patient
referral was compared with enhanced patient referral with addi-
tional counselling (Ellison undated; Moyo 2002). In one study
(858 participants), a combination of giving additional counselling
and health education messages compared with simple patient re-
ferral resulted in slightlymore partners elicited and treated (Ellison
undated).
Overall completeness and applicability of
evidence
We identified 16 new trials in the update in addition to the 11
in the first Cochrane review (Mathews 2001). We found studies
on the four most common curable STIs: chlamydia (six trials),
gonorrhoea (three trials), chlamydia or gonorrhoea (four trials),
trichomoniasis (two trials) and syphilis (one trial). We included
only two trials among people with HIV and we identified no stud-
ies on chancroid, genital herpes or hepatitis B. Only five of the
26 trials were conducted in developing countries. Only one trial
included in this review enrolled men who had sex with men who
were infected with chlamydia or gonorrhoea (Kerani 2011). One
of the trials among people with HIV infection included men who
had sex with men (Landis 1992). We added EPT as a new strat-
egy to enhance the effectiveness of patient referral in this update.
In addition, we separated patient referral interventions into those
that added components such as counselling, written information,
websites and specimen testing kits (enhanced patient referral), and
those restricted to spoken advice about the need for partners to
receive treatment (simple patient referral).We found no studies on
provider training. Nine studies reported index patient re-infection
rate, the primary outcome for curable STIs. Few of the studies
assessed the proportion of partners who were infected, but both
studies of patients with HIV infection reported this outcome. In-
stead, most studies relied on surrogate outcomes such as partners
presenting for medical evaluation, or reports by index patients of
partners presenting. Secondary outcomes reported on infrequently
or not at all included delays in partners presenting for care, inci-
dence of STIs, changes in behaviour, emotional impact and ethical
outcomes.
Quality of the evidence
In every study, there were risks to the validity of the findings and
assessment of risk of bias was hampered by incomplete reporting
in more than half of the included studies. Sequence generation
was adequate in 11 studies while allocation concealment was only
adequate in five studies. Inadequate methods of allocation con-
cealment are an important source of potential bias for RCTs of
PN interventions, where those enrolling participants might pref-
erentially allocate selected patients to one particular intervention.
Blinding of investigators and patients was not feasible for the types
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of interventions studied and only six studies reported blinding of
outcome assessors. Where outcomes can be subjective, for exam-
ple judgingpatient-reported outcomes, unblinded outcome assess-
ment could introduce bias. Re-infection is an objective biological
outcome, so lack of blinding of outcome assessors would be less
important. Seven studies reported loss to follow-up of more than
20%. Most studies had a low risk of selective outcome reporting.
In addition, methods and sensitivity of tests used to diagnose STIs
varied across studies.
When the body of evidence about PN strategies was considered,
there were only four comparisons reporting the primary outcome
of re-infection of index patients with curable STI. EPT compared
with simple patient referral was the comparison with the largest
number of trials, showing moderate-quality evidence that EPT
reduces re-infection more than simple patient referral when we
pooled results from trials of all curable STIs. We downgraded the
quality of evidence because of the risk of bias resulting from at-
trition and inadequately described methods. There was also low-
quality evidence (limited by the small number of studies and at-
trition bias), that effect size might differ for different STI. There
was also low-quality evidence from three trials that the effect of
EPT was similar to that of enhanced patient referral strategies.
Comparisons of enhanced versus simple patient referral were lim-
ited to one or two trials for each strategy. There was moderate-
quality evidence that additional counselling reduced re-infection
more than simple patient referral. There was low-quality evidence
from one trial that the effect of contract referral was similar to
patient referral.
Potential biases in the review process
We conducted an extensive and comprehensive search strategy
with no language restrictions of electronic databases to identify
all published and unpublished trials. We contacted experts in the
field and searched trial registries to identify ongoing studies. We
contacted trial authors, where necessary, to obtain missing data.
To minimise bias in the review process, two review authors in-
dependently performed all study selection, eligibility assessment,
data extraction and assessment of risk of bias. If consensus could
not be reached, we consulted a third review author. We used stan-
dardised eligibility and data extraction forms.
Agreements and disagreements with other
studies or reviews
Our findings were consistent with the findings of the two most
recently published systematic reviews (Alam 2010; Trelle 2007).
The first found that counselling increased partner referral and was
reasonable for developing countries where it was well received by
index patient, easily integrated and cost effective (Alam 2010).
It also found that EPT resulted in more partners treated com-
pared with simple patient referral alone. Barriers to partner refer-
ral were mainly cultural and psychosocial (fear of rejection and
abuse). The second review also found that EPT resulted in fewer
re-infections of the index patient and more partners treated than
simple patient referral and that the outcomes of EPT were similar
to those with enhanced patient referral (Trelle 2007). Consistent
with this update, both Trelle 2007 and Alam 2010 reported the
inappropriateness of summarising the evidence in a meta-analysis
due to the differences in PN methods used and the way outcomes
were reported. Two observational studies reported on adverse ef-
fects, 9% of index patients reported physical violence (Kissinger
2003), and 44% reported negative emotional reactions by part-
ners (Rosenthal 1995). In Trelle et al., the authors suggested that
labour-intensive methods, such as provider and contract referral,
could be considered for more serious conditions, such as HIV and
syphilis, even though evidence for their superiority was inconsis-
tent (Trelle 2007).
Furthermore, Trelle et al. argued for more studies on the use of
EPT in chlamydia and gonorrhoea, as well as large RCTs on PN
and HIV and syphilis, and that adverse effects need to be reported
specifically (Trelle 2007).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence assessed in this systematic review does not identify a
single optimal strategy for partner notification (PN) for any par-
ticular sexually transmitted infection (STI). Few studies evaluated
syphilis and human immunodeficiency virus (HIV), most were
conducted in developed countries for STIs acquired heterosexu-
ally and few studies assessed adverse events.
It is important that expedited partner therapy (EPT) interventions
include all the components that were part of the EPT package in
trials to achieve the outcomes expected. The EPT interventions
in the trials in this review included condoms, details of STI clin-
ics, and written information for patients and partners in addition
to treatment with antibiotics. In practice, many physicians report
giving additional courses of antibiotics or prescriptions to index
patients, but it is not clear whether they also give additional sup-
port (CDC 2006). EPT is more successful than simple patient re-
ferral in preventing re-infection of the index patient and resulted in
more partners treated when compared with simple patient referral
and contract referral. The effect of EPT was attenuated when we
excluded studies with high attrition (> 20%) from the analysis. In
addition, in many countries, EPT is not legal and, therefore, not
an available option at present. Provider referral and contract refer-
ral identified slightly more new infections in partners of patients
with HIV compared with simple patient referral. These strategies
are more labour and cost intensive than simple patient referral but
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are considered worthwhile for serious conditions such as HIV and
syphilis (Trelle 2007).
When considering the use of enhanced patient referral in chlamy-
dia, gonorrhoea or trichomonas infections or non-gonococcal ure-
thritis, most methods were only investigated in one trial and there
was no strong evidence of differences in specific outcomes when
compared with simple patient referral. The most effective compo-
nents in the enhanced patient referral strategy could not be iden-
tified.
Implications for research
There is a need for more evaluations of interventions combining
provider training and patient education, and for evaluations con-
ducted in developing countries. The use of syndromic diagnosis
in trials needs to be discouraged especially where vaginal discharge
is the concern. Self sampling and self testing need to be evaluated
in low-income communities relying heavily on syndromic man-
agement. Evaluations of interventions to improve the training in
delivering PN for healthcare providers and interventions combin-
ing both training and patient education would be valuable.
Large randomised controlled trials (RCTs) for PN in syphilis and
HIV are needed and could compare the outcomes of provider re-
ferral with methods of enhanced patient referral. Trials conducted
in the future should strongly consider using biological outcomes,
such as re-infection of the index patient for curable STI and num-
bers of infected partners identified for HIV. The effect of PN
strategies on changes in the behaviour of index patients or partners
should also be assessed, particularly for HIV patients. Further-
more, they need to consider measuring to what extent strategies
are successful at reaching partners who have a high potential for
onward transmission of STI as opposed to monogamous partners.
The acceptability of various PN strategies to index patients and
partners needs to be assessed, and the costs and potential harms
of PN need to be measured and compared. A proposed question
for primary research is: “In patients given a diagnosis of HIV in
developing countries, will provider referral when compared with
enhanced patient referral increase the number of infected partners
identified?”
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Andersen 1998
Methods Setting: general practices in Aarhus, Denmark
Enrolment: women who tested positive for Chlamydia trachomatis were randomised - no
specific date given
Follow-up: no follow-up was recorded
Participants 96 women with C. trachomatis were randomised
Inclusion criteria
• Women
• C. trachomatis positive
Exclusion criteria
• Not specified
Interventions Patient referral with home sampling (n = 45)
Index patients were given a questionnaire about numbers of sexual partners. Index pa-
tients were given an envelope with a urine sample home test kit for each partner. The
sample was to be sent by the partner to the study laboratory in the provided prepaid
envelope
Patient referral with office sampling (n = 51)
Not stated if index patients completed questionnaire. Index patients were given an en-
velope containing a contact slip and a request to partner to visit his doctor to request
sampling by urethral swab. The doctor was to send a sample in a prepaid envelope to
the study laboratory
Outcomes • Partners contacted (partners receiving a urine sample test kit or contact slip
delivered by index patient)
• Partners tested (review of laboratory records)
• Partners testing positive for chlamydia (review of laboratory records)
• Time until testing (clinical records
Notes It is not known how many of the partners who tested positive were treated
Ethical approval was obtained but no details given
Unclear whether consent was obtained
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Used date of birth “Ninety six women
with C trachomatis infection seen in gen-
eral practices in Aarhus County, Denmark,
were randomly divided according to their
date of birth into an intervention group (45
patients) and a control group (51 patients)
”
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Andersen 1998 (Continued)
Allocation concealment (selection bias) Unclear risk Envelopes used for both groups but not
stated if they appeared identical. Envelopes
for the intervention group contained a 10
mL container that may be palpable
Incomplete outcome data (attrition bias)
All outcomes
Low risk Test outcome for each partner of every in-
dex patient who was randomised was avail-
able
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section. Trial reg-
istries were not searched
Other bias Unclear risk No comparison of baseline characteristics
between study arms
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel were not
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Samples were sent to the laboratory in pro-
vided envelopes. It is not stated whether
the laboratory personnel knew which pro-
cedure was allocated to which group. For
urine sample a PCRwas performed, for ure-
thral swab enzyme immune assay and if in-
conclusive a PCR to confirm
Apoola 2009
Methods Setting: STI clinic at a single study site in Derbyshire, UK
Enrolment: participants recruited by health adviser - recruitment period not given
Follow-up: no follow-up of index patient
Participants 200 index patients with a diagnosis of genital chlamydia were randomised
Inclusion criteria
• Diagnosis of genital chlamydia
• Female
Exclusion criteria
• Not specified
Interventions Patient referral with swab testing (clinic) (n = 100)
Index patients were seen by a health adviser and details of contacts recorded. Contact
slips coded with the diagnosis were given to the index patient to give to themale partners,
who were to bring this to the clinic for testing by urethral swab and treatment
Patient referral with home sampling urine kit (n = 100)
Index patients were seen by health advisers and details of contacts recorded. Contact slips
coded with the diagnosis and a urine sampling kit, for the partner, with instructions, on
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collecting a first pass urine sample at home, were given to the index patient. Sampling
kits included directions to clinic where the samples would be tested and partners would
be treated if they tested positive
Outcomes Primary outcome:
• Number of partners treated per index case (clinic records)
Secondary outcomes:
• Number of partners identified per index (recorded by health adviser)
• Number of traceable partners (contact slips)
• Number of partners treated within 28 days (clinic records)
• Number of index patients with at least 1 partner treated within 28 days per index
case (%, clinic records)
Notes Ethical approval was obtained from the Derbyshire Research Ethics Committee
When the study was originally designed, the PN rate at the study site was 0.3 contacts per
index case of chlamydia and the study was powered to detect a difference of 0.2 contacts
per index case. However, during the study period, the PN rates improved significantly
making it more difficult to detect 0.2 contacts per case difference
Authorswere contacted regardingblinding, consent and exact numbers reported. Authors
reported that investigators were not blinded, oral consent was obtained and they gave
the number of partners elicited
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Blocked randomisation based on random
numbers
Allocation concealment (selection bias) Low risk Allocated group concealed in sealed opaque
numbered envelopes opened sequentially
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome for each partner of every index
patient who was randomised was available
Selective reporting (reporting bias) Low risk Protocol was available from trial registry.
Only primary outcome was stated in pro-
tocol, no secondary outcomes were stated.
Primary outcome in protocol same as in
trial. Outcomes in method section of trial
are the same outcomes reported
Other bias Low risk No other bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participants or personnel
(health adviser)
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Apoola 2009 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Investigators were not blinded. Nucleic
acid amplification tests with high speci-
ficity and sensitivity were used on urine
specimens. Test used for urethral swab not
specified. Details on blinding not given but
obtained from authors directly who advised
that investigators were not blinded
Brown 2011
Methods Setting: 2 hospitals in Malawi, outpatient STI clinics
Enrolment: participants enrolled from 2 October 2008 to 2 September 2009
Follow up: 2 weeks after initial diagnosis follow-up was scheduled but authors did not
report number of index patients returning for follow-up
Participants 240newly diagnosedHIV-positivemen (n= 100) andwomen (n = 140) from2Malawian
hospitals were randomised
Inclusion criteria
• From Lilongwe
• HIV-positive test result for first time
• 18 years or older
• Sexually active in the last 90 days
• Willing and able to provide locator information for sexual partners
• Agreed to be randomised to method of PN and eligible
Exclusion criteria
• Previously diagnosed with HIV
Interventions All index patients were provided with referral cards, all counselled on importance of safe
sex behaviour, staged according to WHO, blood drawn for CD4 count
Simple patient referral (n = 77)
Index patients notify partners themselves
Contract referral (n = 82)
Index patients were given 7 days to notify their partners after which a healthcare provider
contacted partners, who had not reported to the clinic, for counselling and testing
Provider referral (n = 81)
Notification of partners within 48 hours by community outreach workers who were
trained HIV testing counsellors or nurses
Outcomes Primary outcome
• Partner visit to the clinic during the 30 days after index enrolment (identified as
partners if they presented a partner referral card or their name was on the log of named
partners)
Secondary outcomes
• Harms - abandonment (reported by index patient (2 weeks after enrolment) and
partners (at clinic visit))
• Partners testing positive (clinic records)
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Notes Authors did not report the number of index patients who came for 2-week follow-up.
Authors were contacted but data from Malawi on 2-week follow-up were not available
Ethics approval from Institutional Review Board at the University of North Carolina,
Chapel Hill and the National Health Sciences Research Committee in Malawi
Power was set at 85% to detect an absolute difference of 25% between passive referral
and the 2 active referral study arms - therefore need 80 index patients in each arm -
respective arms had 77, 82, 81 therefore sufficient
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised using a permuted block de-
sign with randomly allocated block sizes of
6, 9 and 12 stratified by sex and study site
Allocation concealment (selection bias) Low risk Was concealed in a sealed envelope until
the end of the enrolment visit (after all part-
ner data and locator information had been
collected)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Clinic visit and test outcome data were
available for each partner of every index pa-
tient who was randomised
Harms - number of index patients return-
ing for 2-week follow-up was not given,
therefore, loss to follow-up cannot be cal-
culated
Selective reporting (reporting bias) Low risk Outcome for each partner of every index
patient who was randomised was available.
Protocol not available in 3 trial registries
Other bias Low risk No other bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding of participants not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Personnel not blinded to which group in-
dex patient or partner belonged - partner
identified if presented with a patient refer-
ral card or if their name was found on the
log. Index patient returned 2 weeks after
enrolment and were asked if partners were
notified, how they were notified and what
their behaviour was like (harms). HIV an-
tibody-negative or antibody-indeterminate
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specimens were tested for the presence of
HIV RNA using the ultrasensitive Roche
Amplicor Monitor HIV RNA assay. Pri-
mary outcome low risk
Cameron 2009
Methods Setting: city centre FPC, GUM or a hospital termination of pregnancy in Edinburgh,
UK
Enrolment: participants enrolled from May 2004 to December 2006
Follow-up: index patients agreed to submit a urine sample at 3-monthly intervals over
12 months
Participants 330 index patients who tested positive for Chlamydia trachomatis were randomised in
Edinburgh
Inclusion criteria
• Positive for Chlamydia trachomatis (uncomplicated)
• Woman
• 16-45 years old
• Index patient who have at least 1 sexual partner not been treated and able to be
contacted
• Planning to be resident in Lothian (Edinburgh and surrounding area) for 12
months after recruitment
• Able to give written consent
Exclusion criteria
• Women with partners who had known or suspected allergies to azithromycin
• Women with partners with significant illnesses (to address concern about safety of
administering azithromycin)
Interventions All index patients received written and verbal information about chlamydia and the
importance of partner treatment
Simple patient referral (n = 110)
Index patients provided details of partners of past 6 months. Index patients contacted
partners themselves and were given standard contact slips to be given to partners. Index
patients also received information leaflet about chlamydia with details of GUMs. After
4 weeks, index patient was contacted by study personnel to check if partners were suc-
cessfully contacted
Patient referral with postal testing urine kit (n = 110)
Index patient provided details of partners of past 6 months. Index patient received 1
postal testing kit to deliver to each partner to collect a urine sample in. Postal testing kit
consisted of a universal container for the urine sample, laboratory form with preferred
contact method, an instruction leaflet and a postage paid pre-addressed envelope to send
sample to laboratory. The kit also included a leaflet about chlamydia, information about
the study and contact details of study nurse if further information required
EPT (n = 110)
Index patient provided details of partners of past 6 months. Index patient was given 1
treatment pack to give to each partner. The treatment pack contained azithromycin 1 g,
an information leaflet about the study with contact details for study nurse, information
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Cameron 2009 (Continued)
about chlamydia, drug safety leaflet and details of GUMs they could attend for testing/
treatment if they preferred. The study information leaflet contained a ’tear-off ’ slip that
the partner was asked to complete and return (in a pre-addressed postage paid envelope)
to confirm that they had taken the medication. There was also an ’objection’ slip that
could be completed and returned, if the partner objected to treatment in this way
Outcomes Primary outcome
Re-infection in index patient (all index patients received a postal testing kit for themselves,
and were asked to post a urine sample to laboratory for re-testing at 3 months’ post-
treatment, further postal testing kits were sent to index patient at 6, 9 and 12 months
for repeat testing)
Secondary outcomes
Partner testing/treatment rates (laboratory and clinic databases were checked)
Notes Ethical approval obtained from the Lothian Research Ethics Committee. Approval was
also obtained from both the Research and Developmental Department and the Chief
Pharmacist of the Responsible Health Care Trust
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation num-
bers in blocks, stratified for each recruit-
ment site
Allocation concealment (selection bias) Unclear risk Sealed opaque envelopes, not clear if se-
quentially numbered
Incomplete outcome data (attrition bias)
All outcomes
High risk Primary outcome: 215/303 participants
submitted at least 1 urine sample in the
12-month follow-up (70%) period - 13
woman informed the study personnel that
they did not want to take part anymore
(reasons not given), other 75 loss to follow-
up no details given. No details given on
ITT
For secondary outcomes the partners of ev-
ery index patient who was randomised had
an outcome
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section. Protocol
not available in 3 trial registries
Other bias Low risk No other bias detected
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk There was no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The research nurse and doctor were not
blinded. They were involved in the base-
line interview and did the 6-month follow-
up call to record whether partners were no-
tified - to validate treatment and testing
rates the laboratory, FPC and GUM clinic
databases were checked
Primary outcome assessment was blinded.
The postal testing kit samples of the par-
ticipating woman were labelled with non-
identifying subject study codes so the labo-
ratory staff who reported the results did not
know towhich intervention the woman be-
longed
The COBAS Amplicor CT test was used
on urine samples
Partner treatment/test rates: outcome as-
sessment not blinded but validated by
records
Cleveland undated
Methods Setting: Dade County Department of Public Health, Georgia, US
Enrolment: once the study criteria were met, participants were enrolled - details not
given
Follow-up: a test of cure was performed 3-5 days after treatment. A re-screening interview
was performed 28 days after treatment
Participants 1898 index patients with gonorrhoea were randomised, 1786 men and 112 women
Inclusion criteria
• Gonorrhoea positive by routine screening
• Diagnosis confirmed by positive smear (males only) or culture
• Treated according to US Public Health Service recommendations
Exclusion criteria
• Identified as a contact
• Identified as a transient person
• Concomitant syphilis infection
• Infected with gonorrhoea during the previous 6 weeks
Interventions Patient referral with pamphlet and health worker interview (n = 634)
Index patient received an informational pamphlet. A health worker used the pamphlet
to explain asymptomatic partners, re-infection and complications. The patient was also
encouraged to ask questions. Index patient was advised to refer his partners of the previous
30 days to the clinic. Index patient was offered 4 referral cards to be given to partners
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Cleveland undated (Continued)
and where asked if he/she needed more or less. The number of cards taken was recorded
Contract referral with interview from health worker (n = 632)
Index patient received a standard interview to offer medical information, allow rapport
building and to elicit contact details of partners. Index patient was advised to refer his
partners of the previous 30 days to the clinic and was told that if partners did not present
at the health service after 3 days, then the health worker would contact them
Simple patient referral standard message (n = 632)
Index patient only received a message to say that he/she had been diagnosed with gon-
orrhoea, that it was contracted sexually and that sexual partners of the previous 3-4
weeks needed examination and treatment. Index patient was offered 4 referral cards to be
given to partners and where asked if he/she needed more. No contact details of partners
recorded
Outcomes • Partners presented to health service (clinic records, contact cards returned)
• Partners testing positive (laboratory records)
• Cost effectiveness (clinic records)
Notes No details on ethics approval or consent from participants
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were assigned through random se-
lection to an intervention - no specific de-
tails given
Allocation concealment (selection bias) Unclear risk No details given
Incomplete outcome data (attrition bias)
All outcomes
Low risk Test outcome available for all partners of
every index patient who was randomised
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section. Trial reg-
istries not searched
Other bias Unclear risk Baseline comparability not reported
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Clinic worker showed partner a referral
card and asked them whether they have
seen one of these, it was coded to what
mode of interview was used originally
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Ellison undated
Methods Setting: Alexandra Health Centre and University Clinic, a community health clinic and
principle provider of health care to the township of Alexandra, South Africa
Enrolment: participants enrolled from 23 June to 12 September 1997
Follow-up: no follow-up of index patient scheduled
Participants 1719 index patients, 811 men and 908 females, with any STI syndromically diagnosed
were enrolled
Inclusion criteria
• Any outpatient aged 19-60 years
• Diagnosed with STI
• Not accompanied by partner
• Not enrolled in the study previously
Exclusion criteria
• Not specified
Interventions Simple patient referral (n = 433)
Index patient received a standard clinical consultation given by a nurse and received a
contact card to be given to partner
Patient referral and health education message (n = 431)
Index patient received a standard clinical consultation, contact card and standardised
verbal health education message given by nurse
Patient referral and counselling (n = 430)
Index patient received a standard clinical consultation, contact card and patient-centred
counselling in a private room, conducted by trained lay-counsellors of same gender
Patient referral with health education message and counselling (n = 425)
Index patient received a standard clinical consultation, contact card and both interven-
tions (health education by the nurse and counselling by lay-counsellors)
Outcomes • Partners presented for care with a notification slip at the health centre (clinical
records)
• The time taken for notified partner to seek treatment at the health centre (clinical
records)
• Contact cards issued and returned (recorded by nurse or lay-counsellor)
Notes Ethical approval from Committee for Research on Human Subjects of the University of
the Witwatersrand in Johannesburg
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Each consecutive patient received an
anonymous consecutive number - no spe-
cific details on how these numbers were de-
livered
Allocation concealment (selection bias) High risk Research nurse allocated alternate patients
to 1 of 4 groups. Research nurse allocated
alternate interventions to each consecu-
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tive patient according to a printed sched-
ule (drawn up by project co-ordinator).
Authors acknowledge that research nurse
could unwittingly or deliberately influence
which patient received each intervention
Incomplete outcome data (attrition bias)
All outcomes
Low risk Low risk for main outcome, partner treated
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section
Other bias Low risk No other risk of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Personnel and participant not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The research personnel at the pharmacy
and casualty unit who collected the PN
slipsweremasked towhich intervention the
participant received
Masked bivariate analysis, unmasked mul-
tivariate statistical analysis took place
Faxelid 1996
Methods Setting: urban health centre, Lusaka, Zambia
Enrolment: participants were enrolled from October 1992 to March 1993
Follow up: interview and follow-up 2 weeks after enrolment of index patient
Participants 396 index patients (94 women, 302 men) with clinically or laboratory diagnosed STI
were randomised
Inclusion criteria
• Clinically or laboratory diagnosed STI
Exclusion
• More than 1 diagnosis
Interventions Simple patient referral (n = 200)
Index patient received standard care, no contact cards were given
Choice between patient and provider referral with counselling (n = 196)
Index patient received individual counselling (10-20 minutes) from same-gender nurse
(female) or clinical officer (male). Index patient was given health education, information
on importance of completing treatment, advise on abstinence and how to informpartners
of previous 3 months of their exposure. Index patients received contact cards with the
index patient’s file number on to be given to partners. Names and address of partners
taken. Provider referral offered if patient did not want to talk to partner
52Strategies for partner notification for sexually transmitted infections, including HIV (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Faxelid 1996 (Continued)
Outcomes • Partners elicited (names and addresses of the partners were recorded during initial
interview)
• Partners notified (self report by index patient and contact cards filed at clinic)
• Partners treated (self report by index patient and contact cards filed at clinic)
• Harms - quarrels and partner refusal to go for treatment (self report by index
patient)
Notes The policy at this health service was not to treat an index patient unless they bring a
partner. This may affect the generalisability of the study to other settings
No details on ethical approval given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Authors state that patients were ran-
domised. Patients drew lots - in each box 4
cards with “intervention” and 4 cards with
“non-intervention”
Allocation concealment (selection bias) Unclear risk No details given
Incomplete outcome data (attrition bias)
All outcomes
Low risk 188/196 (96%) index patients in interven-
tion group and 189/200 (94.5%) index pa-
tients in control group returned for follow-
up
Selective reporting (reporting bias) Low risk Same outcomes inmethods as in results sec-
tion. Trial registries were not searched
Other bias Low risk No other bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participant and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding. Outcomes are subjective and
therefore risk of detection bias
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Methods Setting: participants were interviewed at the Public Health-Seattle and King County
(PHSKC) STI clinic and one other PHSKC clinic in King County, Washington, US
Enrolment: patients who received a diagnosis of gonorrhoea or genital chlamydial in-
fection between 29 September 1998 and 7 March 2003 were identified through labo-
ratory reporting, case reports from healthcare providers and onsite case ascertainment
were identified. Clinicians who made diagnosis were contacted to seek permission and
potential participants were contacted for an interview
Follow-up: interview of index patient 10-18 weeks after treatment
Participants 2751 index patients, 646 men and 2105 women, with either gonorrhoea or chlamydia
or both infections were randomised
Inclusion criteria
• Women
• Heterosexual men
• Diagnosis of gonorrhoea or chlamydia
Exclusion criteria
• Patients who could not be contacted 14 days after treatment
• Patients with partners already treated
• Men who had sex with men
• Non-English speaking people
• Previously enrolled in the study
• Homeless or institutionalised
• Diagnosed in context of sexual assault
• Less than 14 years of age
• Unable to give informed consent
• Patients with partners who were jailed or institutionalised
• Patients with incomplete case reports
• Patients enrolled in another PN study
Interventions Before randomisation, study personnel offered to contact partners who index patients
were unable or unwilling to contact themselves
Simple patient referral (n = 1376)
Index patients were advised to tell their partners to seek care and that care was available
at no cost at the STI clinic
EPT (n = 1375)
Index patients were offered medication to give to up to 3 partners, study staff members
offered medication to partners they contacted themselves. Partner packages were dis-
tributed to patients or their partners through commercial pharmacies, the PHSKC STI
Clinic or direct mailing. Packets also contained condoms, information on medication,
warning for adverse effects, telephone contact for study staff and brochure. Pharmacies
were contacted 1 week after medication prescribed to determine whether it was picked
up - if not picked up within 1 week patient received a telephone call reminder
Outcomes Primary outcome
• Persistent or recurrent gonorrhoea or chlamydial infection in index patient (urine
testing at 10- to 18-week follow-up interview)
Secondary outcome
• Behavioural outcomes - PN, sexual interaction with untreated partner (self report
by index patient)
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Notes Ethical approval obtained from the institutional review board of the University of Wash-
ington and Group Health Cooperative
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk At enrolment, 2751 patients reported hav-
ing untreated partners they could contact
and underwent randomisation. No details
given
Allocation concealment (selection bias) Unclear risk No details given
Incomplete outcome data (attrition bias)
All outcomes
High risk Of 1375 assigned to the expedited treat-
ment arm, 929 (68%) completed study. Of
1376 assigned to partner referral arm, 931
(68%) completed study. Only participants
completing the study were included in the
analysis
Selective reporting (reporting bias) Unclear risk Persistent or recurrent gonorrhoea or
chlamydia were the primary outcome
stated in the methods section. Behavioural
outcomes were reported in the outcome
section. Adverse events were not reported
and unclear whether no adverse events were
reported orwhether authors failed to record
them. Protocol was not available from 3
trial registries
Other bias Unclear risk Selective reporting of subgroups, thismight
have been a potential bias but there is in-
sufficient information to assess whether an
important risk of bias exist
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participant and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk No blinding. Urine test use LCx (Abbott)
ligase chain reaction used for primary out-
come - objective. Self report on behavioural
outcome - subjective
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Methods Setting: public STI clinic, Indianapolis, Indiana, US
Enrolment: male participants with NGU enrolled between July and December 1985
Follow-up: no follow-up stated for index patients
Participants 678 index patients with NGU were randomised to 1 of 3 interventions
Inclusion criteria
• Heterosexual male
• Microscopically confirmed NGU
Exclusion criteria
• No exclusion criteria specified
Interventions Simple patient referral with nurse (n = 217)
Nurse providing health education and referral letters. No contact details of partners were
requested
Patient referral with contact tracer (DIS) (n = 240)
Counselling with contact tracer, partners names recorded but no referral letters given
and no partner contact details elicited
Provider referral by contact tracer (n = 221)
Interview with contact tracer, contact details of partners taken, attempt to contact by
phone calls, letters or visits
Outcomes • Cost-effectiveness (clinic records)
• Partners located (contact tracer telephoned partner, send letter via post or field
visit)
• Partners treated (partners were matched to index patient by referral letter or by
computerised database)
Notes Ethical approval details not mentioned
The effectiveness of interventions 1 and 2 underestimated due to bias in outcome as-
sessment: partners choosing to be treated at other health services were not counted for
these groups
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Patients were randomised - no details given
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data for all partners of index pa-
tients randomised available
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section. Trial reg-
istries not searched
Other bias Low risk No other bias identified
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participant and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding. Partners were matched to the
index patient by the referral letter or the
clinic’s computerised database in group 1
and 2. In group 3, the contact details were
taken and partners were contacted by the
provider
Kerani 2011
Methods Setting: Public Health-Seattle & King County (PHSKC), Washington State, US
Enrolment: men who had sex with men who were given a diagnosis of gonorrhoea or
chlamydia or both were enrolled at the time they were contacted to provide them with
partner services between 1 July 2007 and 31 March 2009
Follow-up: index patients completed a follow-up interview approximately 2 weeks after
enrolment
Participants 75 men with gonorrhoea or chlamydia or both were randomised
Inclusion criteria
• Men who had sex with men
• Diagnosis of chlamydia or gonorrhoea or both
Exclusion criteria
• Less than 18 years of age
• Not able to speak English
• If reported that all partners treated
• Not sexually active with another man in the 60 days prior to diagnosis
• If case report was received more than 2 weeks after patient’s treatment
• If patient was diagnosed with HIV or syphilis in the 90 days before diagnosis with
gonorrhoea or chlamydia
Interventions Simple patient referral (n = 18)
Index patients notify partners themselves
Enhanced patient referral (n = 17)
Index patient used inSPOT (inspot.org), an Internet-based PN service. Index patients
received a printed card with the site’s Internet address or telephonic instructions if not
present in STI clinic
EPT (n = 16)
Index patient received prepackaged medicine to give to 3 different partners. The package
also included information on STI, importance of HIV testing, allergy warning to medi-
cation, condoms and a free visit to STI clinic. If not present in STI clinic, index patient
was telephoned and informed to pick up similar packages at several local pharmacies
Combination of EPT and enhanced patient referral (n = 24)
Index patient received EPT and inSPOT
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Outcomes Primary outcome
• Number of partners notified (data recorded by contract tracer from index patient
or clinical records)
• Number of partners treated (data recorded by contract tracer from index patient
or clinical records)
Secondary outcome
• Method (telephone or in person) of PN used (self report index patient)
• Partner tested for HIV/syphilis (self report index patient)
• Adverse events (passive surveillance)
Notes Ethical approval was received fromUniversity ofWashington Institutional ReviewBoard.
Authors were contacted to clarify type of allocation concealment and whether protocol
was available. Exact numbers of partners treated and notified per intervention arm were
also requested and the type of adverse events. Authors failed to provide any of the above
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk A computer was used to randomly assign
participants - no details given how this was
performed
Allocation concealment (selection bias) Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 53/75 (70.6%) participants com-
pleted the study. Only participants com-
pleting the study were included in the anal-
ysis
Selective reporting (reporting bias) Low risk Primary outcomes reported inmethods sec-
tion were reported in results section. The
protocol was not available from 3 trial reg-
istries
Other bias Unclear risk Baseline imbalances (race, type of STI) ev-
ident but insufficient to assess whether an
important risk of bias existed. Early stop-
ping due to low recruitment rate are not
more likely to show extreme results and not
considered to be prone to bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and personnel not blinded
Blinding of outcome assessment (detection
bias)
High risk Participants and personnel not blinded,
outcomes subjective
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All outcomes
Kissinger 2005
Methods Setting: public STI clinic in New Orleans, US
Enrolment: participants enrolled from December 2001 to March 2004
Follow-up: index patients were asked to return 4 weeks after the initial clinic visit (with
a window of 2-8 weeks) for a follow-up interview and a urine specimen
Participants 977 index patients with diagnosis of urethritis were randomised
Inclusion criteria
• Male
• Diagnosis of urethritis
• Test positive for Chlamydia trachomatis or Neisseria gonorrhoeae
• 16-44 years old
• At least 1 female sexual partner who did not accompany them to clinic
Exclusion criteria
• No criteria specified
Interventions Simple patient referral (n = 285)
Index patients were instructed to tell their partners that they needed to go to either the
public STI clinic or the clinic of their choice for STI evaluation and treatment
Patient referral booklet enhanced (n = 348)
Index patients were given a wallet-sized booklet that contained 4 tear-out cards with
information for the partner and treatment guidelines for professionals. If they had more
than 4 partners they were given additional booklets
EPT (n = 344)
Index patients were given packages containing medication, written instructions about
how to take medication, warning about adverse effects, 24-h nurse’s pager number to
call if any enquiries and asked to give package to each of their partners
Outcomes Primary outcome
• Proportion of partners who received antibiotic treatment (self report by index
patient)
Secondary outcome
• Recurrence of C. trachomatis and N. gonorrhoeae in index patient (urine sample or
urethral swab collected at follow-up interview)
• Behavioural outcome - partners treated (self report)
• Sexual outcome - unprotected sex before partner treatment, re-initiated sex with
baseline partner, unprotected sex with any partner (self report)
Notes Institutional review board approval was obtained from all participating institutions
Authors were contacted for statistical analysis (sample size calculations, power) details
and exact numbers, authors replied that sample size calculations were performed, but
could not provide exact details
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomised by month in which they at-
tended the clinic to 1 of 3 study arms. Ran-
domisation of months was conducted us-
ing a blocked scheme of 3 to 6 units using
Microsoft Excel software
Allocation concealment (selection bias) Unclear risk No information given
Incomplete outcome data (attrition bias)
All outcomes
High risk 770/977 (79%) participants returned for
follow-up interview but only 37.5% were
retested. At follow-up interview, index pa-
tients were asked outcome questions for
each partner. Outcome of interest was the
response to the question: “Did baseline
partner tell you that he or she took the
medicine?”
Selective reporting (reporting bias) Unclear risk Same outcomes in the methods section
(re-infection index patient and partners
treated) were reported in the results sec-
tion.With additional sexual outcomes (un-
protected sex before partner treatment, re-
initiated sex with baseline partner, unpro-
tected sex with any partner) not stated in
themethods section. Protocol not available
from 3 trial registries
Other bias Low risk No other bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participant and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The 1-month interview was performed ei-
ther by computer-assisted self interview or
study staff
The outcomes were assessed by an inter-
view either computer-assisted self inter-
view (24.3%), telephonic (35.4%) or face-
to-face (40.2%). The interviewer was not
blinded. An in-person interviewhas the po-
tential for information bias
No details given whether laboratory per-
sonnel were blinded but outcome measure
was objective
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Kissinger 2006
Methods Setting: the Orleans Women’s Health Clinic in New Orleans, US
Enrolment: participants enrolled from December 2001 to August 2004
Follow-up: participants were asked to return 4 weeks after the initial visit (with a window
of 2-8 weeks)
Participants 463 index patients with a culture-confirmed diagnosis of Trichomonas vaginalis were
randomised
Inclusion criteria
• Women
• Culture-confirmed Trichomonas vaginalis diagnoses
• Not in first trimester of pregnancy
• No medical contraindication to take metronidazole or bringing metronidazole to
partner
• At least 1 male sexual partner in the last 60 days
Exclusion criteria
• No criteria specified
Interventions Study staff counselled women in all study arms about T. vaginalis and the importance of
partner treatment before randomisation
Simple patient referral (n = 155)
Index patients were instructed to tell their partners that they need to go to a clinic for
STI evaluation and treatment
Booklet enhanced partner referral (n = 154)
Index patients were given a wallet-sized booklet containing tear-out cards with informa-
tion for the partner and treatment guidelines for providers
EPT (n = 154)
Index patients were given packages for their partners, containing medicine, written
instructions on how to take medicine, warnings about side effects and nurse’s pager
number for enquiries
Outcomes • Re-infection rate of index patient (T. vaginalis culture)
• PN (self report index patient - interview)
• Partner treatment (self report index patient)
• Having unprotected sex before partner took medication (self report index patient)
• Re-initiated sex with baseline partner (self report index patient)
• Unprotected sex with any partner (self report index patient)
• Cost effectiveness
Notes Ethical approval from Institutional review board fromTulane University Health Sciences
Center, CDC and the Louisiana Office of Public Health
Author was contacted and provided details on consent (oral) and exact numbers of how
many women returned for follow-up and testing. Details to what intervention arm the
woman with re-infection belonged to was also provided
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk Blocked scheme of 3 or 6 units using Mi-
crosoft Excel
Allocation concealment (selection bias) Unclear risk Previously prepared envelopes. Not speci-
fied if these were sealed or identical
Incomplete outcome data (attrition bias)
All outcomes
Low risk 412/463 (89%) index patients were re-in-
terviewed (some interviews done by tele-
phone, and, therefore, no sample sub-
mitted) but only 376/463 (81%) index
patients were retested and re-interviewed
(data from author directly)
Selective reporting (reporting bias) Unclear risk Protocol available from trial registries
Outcomes stated in the protocol:
Primary - Index patient report of partner
taking medicine at 6-8 weeks
Secondary - Index patient re-infection at 6-
8 weeks, cost-effectiveness outcomes
Outcome reported in actual study:
Outcomes were not reported as primary
and secondary. Additional sexual and be-
havioural outcomes reported Re-interview
scheduled for 4 weeks after treatment (win-
dow of 2-8 weeks)
Outcome inmethod section same as results
section but differs from protocol
Other bias Low risk No other bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participant and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding
Although some outcomes were subjective,
the outcome of interest in the telephone
interview was the response to this ques-
tion: “Did partner tell you that he took the
medicine?” Different methods were used
for outcome assessment (i.e. telephone or
computer-assisted self interview) that may
have introduced detection bias, outcomes
assessors were unlikely blinded
Assessment ofT. vaginalis culture result was
not blinded but is an objective outcome
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Landis 1992
Methods Setting: 3 large county health departments in North Carolina, US
Enrolment: participants enrolled from 16 November 1988 to 30 June 1990
Follow up: no follow-up of index patient reported
Participants 74 HIV-infected men (51) and women (23) were randomised
Inclusion criteria
• Patients returning for their positive HIV result
• Patients with sex or needle-sharing partners whose name they knew
Exclusion criteria
• Previously tested positive for HIV and had no new sexual or needle-sharing
partners
• Only had partners that they did not know name
• Had no needle-sharing or sexual partners during the last year
• Lived outside jurisdictions of the 3 county health departments or whose partners
did
Interventions Public health counsellor revealed diagnosis, provided standard counselling and explained
study before randomisation. After consent partner information was obtained
Simple patient referral (n = 35)
Index patient had interview with counsellor, discussing the process of notification. Index
patient received coloured cards with identification codes to be given to their partner.
After 1 month, the counsellor attempt to contact any partner not yet contacted
Contract referral (n = 39)
Index patient could choose to notify some or all of their partners themselves. Index
patient received coloured cards with identification codes to be given to their partner. The
remaining partners, as well as those not presenting at the health service after 2 weeks
were contacted by the counsellors
Outcomes • PN (through location of partners by counsellors or partners arriving at the health
department)
• Partner tested (clinic records)
• Partner tested positive (clinic records)
Notes Ethical approval from the Ethics Committee on the protection of the rights of human
subjects of the University of North Carolina School of Medicine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly assigned no specifications
Allocation concealment (selection bias) Unclear risk No details given
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome for each partner of every index
patient who was randomised was available
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Landis 1992 (Continued)
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section. Trial reg-
istries were not searched
Other bias Unclear risk Baseline comparability unclear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participant and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Coded cards were used but it is unclear
if it was obvious to personnel whether
they belonged to intervention or control
group. Unclear who collected the cards and
whether person had involvement in study
findings
Low 2006b
Methods Setting: 27 general practices in Bristol and Birmingham, UK
Enrolment: participants enrolled from March 2001 to October 2002
Follow-up: 6 weeks after randomisation there was telephone follow-up of index patient
Participants 140 index patients (92woman and48men)withChlamydia trachomatiswere randomised
Inclusion criteria
• Positive chlamydia test result received at their general practise
Exclusion criteria
• No criteria specified
Interventions All participants received antibiotic treatment before randomisation
Simple patient referral with counselling from practice nurse (n = 72)
Nurses received 1 day of training about sexual history taking, management of chlamydia
and PN. The index patient had a PN interview with the trained nurse. This interview
involved taking of sexual history of the previous 6 months, patient referral using contact
slips, abstinence and information about being screened for other STIs. Contact slips
included details of the study GUM clinics and requested the treatment centre to return
the slip to the study centre. Practise nurses did not follow-up the index patient
Referral to GUM clinic for partner referral from specialist health advisor (n = 68)
At randomisation, index patients were referred to GUM clinic. If clinic had not been
contacted by telephone within 1 week by index patient, the health adviser made 2
attempts to contact them. PN was performed according to standardised protocols and
contact slips were issued. The index patient was also offered a consultation for screening
for other STIs. Follow-up was by telephone
Outcomes Primary outcome
• Proportion of index patient with at least 1 sexual partner treated (self report
during telephone interview with index patient, or a contact slip returned to the study
centre or the partners was confirmed to have attended a local GUM clinic after the
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index patient received intervention)
• Number of partners treated per index patient 6 weeks after randomisation (clinic
records)
Secondary outcomes
• Number of partners elicited (self report by index patient in sexual history)
• Proportion of index patients with a positive chlamydia test result 6 weeks after
randomisation (urine or vulval swab specimen available)
• Proportion of index patients with all sexual partners treated (clinic records)
Notes Ethical approval South West multicentre research ethics committee
Only 72 in nurse arm and 47 in clinic arm
Study author was contacted to clarify clustering and replied. The author replied that the
trial was individually randomised. However, there was often more than 1 participant
from a single general practice (i.e. clustering), and it means that there are likely to be
similarities between patients within the same practice
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers,
permuted blocks, stratified by practice
Allocation concealment (selection bias) Low risk Central computerised telephone system
Incomplete outcome data (attrition bias)
All outcomes
Low risk The PR (nurse) group had PN interview on
same day. In PR (GUM) 21/68 (31%) did
not attend PN interview. Authors used ITT
analysis and assumed those lost to follow-
up were not treated
Selective reporting (reporting bias) Unclear risk Protocol available from trial registries. In
protocol, adherence to advice to abstain
from sexual intercourse until both partners
completed treatment was stated as a sec-
ondary outcome but not reported in trial.
Outcome “Cases with all partners treated”
was not prespecified in study protocol but
reported
Other bias Low risk No other bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participant and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk A researcher not involved in the partici-
pant’s PN did the follow-up
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Montesinos 1990
Methods Setting: the health service of the Southern Illinois University, a large mid-western uni-
versity, Illinois, US
Enrolment: participants were enrolled from July 1984 to June 1985
Follow-up: no follow-up recorded of index patients
Participants 65 index patients (48 men and 17 females) with gonorrhoea or NGU were randomised
Inclusion criteria
• Diagnosis of gonorrhoea or NGU
• University students
• Participant’s partners were university students
• At least 1 sexual partner in the previous 6 weeks
Exclusion criteria
• No criteria specified
Interventions Patient referral with counselling (nurse of physician) (n = 27)
Index patient received counselling from a physician (in his office) or a nurse (designated
private area) following a written protocol. Counsellor ascertained the reason for seeking
treatment, gave information on STI, obtained names of sexual partners in previous 6
weeks, advise index patient to notify partner and assured index patient of confidentiality
Patient referral with counselling, incentive and cards (n = 19)
Index patient received counselling from a physician (in his office) or a nurse (designated
private area) following a written protocol. Counsellor ascertained the reason for seeking
treatment, gave information on STI, obtained names of sexual partners in previous 6
weeks, advised index patient to notify partner and assured index patient of confidentiality.
In addition, counsellor advised index patient that USD 3 charge, for index patient and
partner, will be waived if partner successfully referred. A card with naming specific STI
and advise to seek treatment given to index patient to give to partner
Patient referral with counselling, cards, follow-up call after 5 days, no incentive (n
= 19)
Index patient received counselling from a physician (in his office) or a nurse (designated
private area) following a written protocol. Counsellor ascertained the reason for seeking
treatment, gave information on STI, obtained names of sexual partners in previous 6
weeks, advised index patient to notify partner and assured index patient of confidentiality.
A card naming specific STI and advise to seek treatment given to index patient to give
to partner. Index patient did not receive any financial incentive. Counsellor told index
patient that if partner failed to arrive at health service within 5 working days the index
patient would be contacted by telephone
Outcomes • Partners elicited (self report by index patient)
• Partners presenting at health service (a list of partners identified in counselling
session was kept at health service)
• Mean cost per partner traced (clinic records)
Notes Ethical approval from Southern Illinois University - Committee for Research involving
Human Subjects
17 females vs. 48 males. 2 different time periods. Group 1 was interviewed from July
to December 1984 and groups 2 and 3 received intervention in January to June 1985 -
possibility that holidays can play a role on who is available during that time
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) High risk The protocol was colour coded. The coun-
sellor removed the next protocol for the
next patient from a randomly ordered set
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data for all partners of index pa-
tients available
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section. Trial reg-
istries not searched
Other bias Low risk No other bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participant and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding. Names of partners were
recorded on the counselling protocols. A
list for these identified partners were main-
tained for up to 1month after index patient
was seen to see if partners returned
Moyo 2002
Methods Setting: 2 large public STI clinics in Harare, Zimbabwe
Enrolment: index patients were consecutively recruited from July to September 2000
Follow-up: index patient was interviewed for 15 minutes at the routine 1-week clinic
follow-up visit
Participants 272 index patients (135 men and 137 women) with a syndromically diagnosed bacterial
STI were randomised
Inclusion criteria
• Over the age of 18 years
• Syndromically diagnosed bacterial STI seen on their first visit for treatment
Exclusion criteria
• No criteria specified
Interventions All index patients completed a standard STI treatment and counselling consultation, a
clinic nurse or doctor explained the objectives andprocedure. The same gender counsellor
explained the basic procedure to all, then conducted the 30-minute baseline interview
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with each patient. All participants were given reminder cards to visit the study counsellor
for a 15-minute follow-up interview when returning for routine 1-week clinic follow-up
visit
Patient referral with additional counselling session (n = 131)
Counsellor conducted an additional individualised session with the index patient lasting
approximately 30 minutes. Session included identification of likely sources and spread
of STI, approaches to notification, role playing, motivating factors, barriers and domes-
tic violence. Session also include health education. Index patients were also allocated
coupons to give to partners for free treatment at the study clinic
Simple patient referral (n = 141)
Counsellor did a 30-minute baseline interview with index patient. No coupons were
given for partners free treatment
Outcomes Primary outcome
• Notification and referral of partners for treatment (as reported by index patient at
follow-up interview 1 week after treatment)
Secondary outcome
• Adverse events - physical and verbal abuse (as reported by index patient at follow-
up interview 1 week after treatment)
Notes Ethics approved by the Committee on Human Research at the University of California,
San Francisco, and by the Medical Research Council of Zimbabwe
Authors were contacted without success regarding discrepancies in numbers reported
and distribution of harms in intervention arms
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation process not described
Allocation concealment (selection bias) Unclear risk The nurse or doctor selected a sealed,
opaque envelope from a box that randomly
assigned the patient to intervention or con-
trol. Envelopes were constructed prior to
any recruitment. An equal number of the
allocation slips with the words ’interven-
tion’ or ’control’ were placed in the box and
manually mixed. All participants brought
the envelope to the study counsellor, where-
upon it was opened in the presence of
both study counsellor and patient. Unclear
whether these envelopes were sequentially
numbered
Incomplete outcome data (attrition bias)
All outcomes
High risk Self reported notification and referral of
partners to treatment were assessed at fol-
low-up interview. 137/272 (50%) partic-
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ipants completed the follow-up interview.
ITT analyses were performed. However,
the high loss to follow-up is potentially a
source of bias
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section. No proto-
col available from trial registries
Other bias Low risk No other bias identified
The randomisation scheme produced ap-
proximately equivalent numbers in the in-
tervention and control groups for men and
women. Of note, people randomly allo-
cated to the intervention arm were slightly
older, more likely to be working in the for-
mal economy, and more likely to be cur-
rently married or co-habiting. These find-
ings may indicate a problemwith randomi-
sation
It may also be due to the small sample
size that baseline differences occurred by
chance
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not possible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No blinding. Index patient reports about
PN can introduce bias
The same study counsellor who did the
counselling session did the 1-week follow-
up interview - this might have introduced
detection bias
Nuwaha 2001
Methods Setting: Mulago Hospital STI clinic in Kampala, Uganda treats patients free of charge.
Clinic is the main STI reference centre, mainly serves as a walk-in primary care STI
treatment centre
Enrolment: consecutive patients with STI symptoms enrolled between November 1999
and January 2000
Follow-up: index patients were asked to return to the clinic within 2 weeks
Participants 383 index patients (196 men, 187 women) with STI symptoms were randomised
Inclusion criteria:
• STI symptoms presented for the first time
• Sexual intercourse in previous 3 months or for the period with STI symptoms
• Female patients with vaginal discharge were included, if on examination with
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speculum cervical discharge was present, or if they had vaginal discharge associated
with genital ulcer or with Trichomonas vaginalis
Exclusion criteria
• Partners already had treatment
• Partners lived too far to be reached within 1 month
• Female patients were diagnosed with only candida infections or bacterial vaginosis
Interventions All index patients were given information, education and communication for 5-10 min-
utes. Trained research assistants performed interviews using a pre-tested questionnaire
Simple patient referral (n = 191)
Index patients were given contact slips to take to sexual partners. Index patient asked to
return 2 weeks later
EPT (n = 192)
Index patients were given medications to take to sexual partners. Index patient were
asked to return after 2 weeks. Index patients were request to return medication if their
partners refused them or if they could not trace the partner
Outcomes • Partners (regular and casual) treated (contact slips returned, all patients attending
the clinic were asked if they were referred, index patients records were reviewed to link
partners to index patients, at 2-week follow-up index patient was asked if partners were
treated)
• Partners (regular and casual) elicited (self report by index patient)
• Index patient 2-week post-treatment return (clinic records)
• Adverse reactions such as quarrelling, fighting and refusal of sexual intercourse
(index patient report at 2-week interview)
• Side effects of drugs (index patient report at 2-week interview)
Notes Ethics approval by Mbarara University, the Faculty of Medicine Research Committee,
the Uganda AIDS Committee, the Uganda National Council for Science and Technol-
ogy, and the Ethics Research Committee at Karolinska Institute (Stockholm, Sweden).
Permission to conduct the study was obtained from theMulago Hospital administration
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random number be-
tween 0 and 999; even numbers to EPT
group, and odd numbers were assigned to
the patient-based partner referral group.
Stratified randomisation according to the
sex of the index patient was used
Allocation concealment (selection bias) Unclear risk No detail of allocation concealment given
Incomplete outcome data (attrition bias)
All outcomes
Low risk ITT analysis was used. In EPT, 187/192
(97%) index patients returned after 2weeks
and in simple patient referral 117/191
(61%) returned.On return, participants re-
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ported onpartner treatment andpartner re-
action. Attrition bias in the simple patient
referral arm
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section. Protocol
not available from 3 trial registries
Other bias Unclear risk Partners of participants in simple patient
referral group could have been treated else-
where leading to misclassification bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not possible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Partners in simple patient referral group re-
turned coded slips. Clinic workers checked
clinic records for all patients who said they
had been referred by a partner to attempt to
link them to an index patient. In addition,
they collected reports from index patients
on partner referral (not analysed in this re-
view)
In the EPT participants, the outcome was
index patient reports whether partner took
medication. This can introduce detection
bias
Ostergaard 2003
Methods Setting: 4 counties in Denmark
Enrolment: participants enrolled between February 1999 to March 2000
Follow up: no follow-up of index patient reported
Participants 562 index patients ( 414 women and 148 men) with a positive chlamydia swab were
randomised
Inclusion criteria
• Positive chlamydia swab
• Completed questionnaire
Exclusion criteria
• No criteria specified
Interventions Specimen collection package was posted to the index patient’s home address. There were
5 specimen collection kits in this package. The index patient was instructed to give
collection kits to his/her sexual partners of the previous 12 months. The collection kits
were identical. For male partners the kit contained 10 mL tube to collect first void urine
sample. The female partners received a vaginal pipette containing 5 mL sterile normal
saline to be inserted into the vagina, flushed and aspirated
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Patient referral with home sampling (n = 304)
Samples collected by the partners at home had to be posted directly to the diagnostic
laboratory in postage paid and pre-addressed envelopes
Patient referral with office sampling (n = 258)
Partners had to bring specimen collection kit into the office of a healthcare provider to
obtain sample. Partners also brought a letter with them, explaining the study and the
importance that the healthcare provider used the provided specimen collection kit to
collect sample. The healthcare provider posted the sample to the laboratory
Outcomes Primary outcome
• Proportion of index patients with at least 1 partner tested for Chlamydia
trachomatis (laboratory results)
Secondary outcomes
• Proportion of index patients with at least 1 partner positive for C. trachomatis
(laboratory results)
Notes Ethical approval by Danish ethics committee system
Implied consent
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk The index patient was randomised based
on a positive swab sample - no details given
Allocation concealment (selection bias) Unclear risk No details on allocation concealment given
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data for all partners of index pa-
tients available
Selective reporting (reporting bias) Low risk Outcomes in method same as in results.
Protocol not available from 3 trial registries
Other bias Low risk No other bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Specimen collection kits for the 2 study
groups were identical and the index patient
was blinded to content of the specimen col-
lection kit. However there is no guaran-
tee that the index patient did not open the
package before forwarding to partner
The healthcare provider, who did the office
sampling, was not part of the study. They
only collected the samples and posted it to
the study centre
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It is notmentionedwhether laboratory per-
sonnel were blinded. However, the chlamy-
dia test is an objective outcome measure
Peterman 1997
Methods Setting: public health services in Broward County, Florida; Tampa, Florida; Patterson,
New Jersey, US
Enrolment: participants were enrolled from December 1990 to March 1993
Follow up: no follow-up recorded of index patients
Participants 1966 index patients with syphilis were randomised, 1042 male and 924 female
Inclusion criteria
• Primary, secondary or early latent syphilis infection
Exclusion criteria
• Criteria not specified
Interventions After syphilis diagnosis all index patients were interviewed by DIS to identify sexual
partners
Contract referral (n = 586)
Index patient to notify partners within 2 days, or a DIS would notify them on the third
day
Provider referral (n = 742)
Partner notified immediately by DIS and referral of partner for testing
Provider referral and field test (n = 638)
Partner notified immediately by DIS who could draw blood for testing in the field, if it
seemed unlikely for partner to come in for testing
Outcomes • Numbers of partners coming for syphilis testing, treatment or prevention (name
and locating information of all partners were recorded in interview before
randomisation, record searching)
• Cost per partner treated (clinic records)
Notes Details on ethical approval not given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Individual index patients were randomly
assigned. Every day the study co-ordinator
at each site generated a list of assignments
by using a random number table. The to-
tal number of patients in each arm differed
significantly from 742, 638 and 586, this
raises suspicion about whether randomisa-
tion was performed appropriately
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Allocation concealment (selection bias) High risk The assignment was known to the inter-
viewer before contact with the patient and
themethodwas sequentially adapted by the
interviewer
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data were available for all part-
ners of index patients
Selective reporting (reporting bias) Low risk Same outcomes in methods section com-
pared to results section. Trial registries not
searched
Other bias High risk Deviation from protocol was reported by
authors
Some contamination was reported by the
authors and this would have reduced the
difference between the 3 groups
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not possible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The DIS was not blinded, DIS did the in-
terview before randomisation and also the
intervention. No blinding of data entry
personnel or data analyst
No control in place to ensure 2-day waiting
period
Potterat 1977
Methods Setting: El Paso, City-county health department, Colorado, US
Enrolment: participants were enrolled from February to September 1975
Follow up: index patient in patient referral group was re-interviewed 7-10 days after
enrolment
Participants 187 index patients with gonorrhoea were randomised
Inclusion criteria
• Heterosexual males with gonorrhoea
Exclusion criteria
• Not specified
Interventions Simple patient referral (n = 93)
Study personnel had a short interview (3-5 minutes) with index patient where the disease
and importance of PN were discussed. Index patient received contact cards to be given
to partners. Study personnel did not elicit any partner details
Contract referral (n = 94)
Study personnel had a longer interview (15-20 minutes) with index patient and partner
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contact details were elicited. Index patient was informed that health services personnel
would contact partners if they did not present at the health service within 7-10 days
Outcomes • Partners testing positive for gonorrhoea (contact cards and self report by partner)
• Cost (clinic records)
Notes Ethical approval details not given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Alternately assigned “During the period
February-September 1975, we assigned all
heterosexual male patients with gonor-
rhea diagnosed at the El Paso City-County
Health Department (Colorado) alternately
to a Study or Control group”
Allocation concealment (selection bias) Unclear risk No information given
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data for partners of all index pa-
tients available. In simple patient referral
group, a second interview was performed
to record contact details (91/93 index pa-
tients re-interviewed). These details were
used to contact partners to find out their
subsequent clinical course and fate of con-
tact slips
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section. Trial reg-
istries were not searched
Other bias Unclear risk Baseline comparability unclear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding not possible
Blinding of outcome assessment (detection
bias)
All outcomes
High risk The personnel knew towhat group the par-
ticipant belonged and, due to longer time
spent with control group, this could have
introduced detection bias. No specifics on
test used. 9 contacts in the study groupwere
also identified through field effort although
field effort was not part of the original in-
tervention in the study group - detection
bias
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Schillinger 2003
Methods Setting: FPCs (Southern California (SC), Seattle (S) and New Orleans (NO)), ado-
lescent clinics (Birmingham (B), Indianapolis (I), Northern California (NC) and S),
primary care clinics (I) and STD clinics (B, I, NO, SC, NC, S) or emergency and
other hospital departments (B), US
Enrolment: participants enrolled between September 1996 and June 2000
Follow-up: index patients returned for a follow-up at 1 and 3 months after enrolment
for an interview and urine test
Participants 1889 index patients with laboratory confirmed Chlamydia trachomatis were randomised
Inclusion criteria
• Women
• Aged 14-34 years
• Laboratory-confirmed uncomplicated urogenital chlamydial infection
Exclusion criteria
• Already been treated
• No intercourse in 60 days before enrolment
• Male partners already been treated for chlamydia
• Pregnant
• HIV infected
• Co-infected with Neisseria gonorrhoeae, Treponema pallidum or Trichomonas
vaginalis
• History of adverse reaction to macrolide antibiotics
Interventions At enrolment all women were treated for chlamydia infection and were advised to abstain
from intercourse until 7 days after partner’s treatment
Simple patient referral (n = 943)
Index patients were instructed to tell their partners that they had been exposed to chlamy-
dial infection and to recommend that they seek treatment. They were given an informa-
tion sheet for each partner and list of clinics where the partner could obtain free care
EPT (n = 946)
Index patients were provided with up to 4 doses of medication for their partners, in-
structed to tell their partners of their exposure, and to give a package with the medica-
tion, instructions, warnings, fact sheet on chlamydia and telephone number to contact
if partners had any questions. Index patients were advised to abstain from intercourse
until 7 days after each partner’s treatment
Outcomes • Re-infection with C. trachomatis in index patient measured by DNA in urine
collected 21 days or more after treatment for initial infection (laboratory results)
Notes Ethical approval by investigational review boards at each of participating institutions and
the CDC
Limited power as only 1454 participants completed study to 1 follow-up. With 0.05
significance, this study only had 62% power to detect a 30% reduction in infection. For
a 20% difference in infection rate (as was observed in this study), there was only 37%
power to detect a significant difference between 2 interventions. In order to have 80%
power, need 2035 women in each arm
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Study allocations were made with use of
“randomly sized blocks”
Allocation concealment (selection bias) Low risk Study arm assignments were printed on
cards and placed in sequentially numbered,
opaque envelopes and sealed at the study
co-ordination centre
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1454/1787 (81%) participants came for at
least 1 follow-up visit and gave a urine sam-
ple for the outcome measure. There was a
similar proportion in each study arm. ITT
was not followed because index patients
who did not return for follow-up or for
whom no urine test result existed were ex-
cluded
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section. Protocol
not available from 3 trial registries
Other bias Low risk No other bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk 1 month after treatment, women were in-
terviewed again and urine tested with LCx/
PCR. Assessor knew assignment but out-
come measure was objective
Schwebke 2010
Methods Setting: Jefferson County Department of Health in Birmingham, AL, US
Enrolment: participants were enrolled between February 2003 and June 2008
Follow-up: index patientswere asked to return to clinic 5-9 days after enrolment for a “test
of cure”. Follow-up visits to detect repeat infections were performed at the clinic, 1 and
3 months after “test-of-cure”. At these visits an examination was performed, including
culture for Trichomonas vaginalis and a follow-up questionnaire completed
Participants 484 index patients with Trichomonas vaginalis were randomised
Inclusion criteria
• Women
• Aged 19 years and older
• Culture or wet prep positive for trichomonas
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Exclusion criteria
• Infection with other STI pathogens
• Pregnancy
• Currently breast feeding
• Recent (8 hours) ingestion of alcoholic beverages or intention to do so in next 24
hours
• Allergy to metronidazole
• Presence of sexual partner in the clinic during enrolment
• History of referral by a partner already treated for trichomoniasis
• Report of more than 4 sexual partners in the preceding 30 days
Interventions Simple patient referral (n = 160)
Simple patient referral: usual care - index patient were given a standard message on the
importance of PN and asked to tell partners to come for treatment. If the partner did
present to the clinic they were offered participation in the male substudy
Contract referral (n = 162)
Index patients were interviewed by a DIS who took the details of partners of previous
60 days, then entered in to a verbal contract with DIS to refer their partners to the clinic
for treatment, partners were telephoned within 1-2 days of index patient’s enrolment.
The partners were informed that they will be eligible for remuneration if participate in
male study. If treatment of partner could not be verified within 2 working days the DIS
attempted to notify partner by telephone or field visits
EPT (n = 162)
Index patients were given medication for up to 4 partners. The index patients were also
given a list of contraindications of the medication and a 24-hour phone number for
partners if they had any questions regarding medication, indications for therapy and
further evaluation of symptoms
Outcomes • Re-infection rates 1 and 3 months post-treatment (In clinic follow-up visit where
examination and culture were performed)
Notes Ethical approval by the Institutional Review Boards of the University of Alabama and
the Jefferson County Department of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details given
Allocation concealment (selection bias) Unclear risk No details given
Incomplete outcome data (attrition bias)
All outcomes
High risk There were data available on 296/484
(61%) index patients at 1-month follow-
up and 194/484 (40%) participants com-
pleted the study
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Selective reporting (reporting bias) Low risk Protocol available from trial registries. In
the protocol, the only outcome was the re-
currence of trichomonas in index patient at
6 weeks. In the trial, the authors reported
re-infection in index patient at 1 and 3
months post treatment
Other bias Low risk Study authors planned to recruit 330 par-
ticipants in each arm but after 4 years were
only able to recruit about 50%. Early stop-
ping due to lower than expected recruit-
ment rate are not considered to be prone to
bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participant and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No blinding. The primary outcome was
repeat infection in index patient - an ob-
jective outcome measure (positive culture
or presence of motile trichomonads micro-
scopically)
Solomon 1988
Methods Setting: Eastern Clinic of the Baltimore City Health Department, MD, US
Enrolment: index patients were enrolled between May 1984 and January 1985
Follow up: index patients returned to clinic 14 days after treatment
Participants 902 index patients, with a positive Gram stain for gonorrhoea, were randomised
Inclusion criteria
• Male with positive Gram stain for gonococci
Exclusion criteria
• Not criteria specified
Interventions All index patients received a DIS contact tracing interview and treatment from a nurse.
At the time of test of cure examination an 18-item, oral test to assess the videotape’s
impact on knowledge and beliefs of the index patient was performed
Patient referral and videotape (n = 456)
Index patient was interviewed by DIS to get the contact details of their partners, and
was given contact cards and was invited to view a video-tape promoting PN
Simple patient referral (n = 446)
Index patient was interviewed by DIS to get the contact details of their partners, and
was given contact cards
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Outcomes • Number of index patients returning for a “test of cure” evaluation (clinic records)
• Number of partners presented for care (contact cards returned)
• Knowledge of the index patient (18-item, true-false, oral test)
• Time taken until partner presented at clinic (clinical records)
Notes Ethical approval details not given
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details were given except that the re-
search assistant assigned patients at random
to group 1 (watching the videotape) and
group 2 (not watching the videotape)
Allocation concealment (selection bias) Unclear risk No mention of allocation concealment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Outcome data available for all partners of
index patients
Selective reporting (reporting bias) Low risk Outcomes reported in methods section
were reported in results section. Trial reg-
istries not searched
Other bias Unclear risk Baseline comparability unclear
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participant and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk If a partner came to the clinic with a referral
card, a clerk noted the participant number
on registration. The clerk was blinded to
what experimental study the colour coding
belonged to. The research assistant, who
performed the oral test at the test of cure
evaluation, was blinded to whether partic-
ipant saw the video tape or not
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Tomnay 2006
Methods Setting: a publicly funded sexual health clinic in Melbourne, Vic, Australia
Enrolment: participants were enrolled between July 2003 and July 2004
Follow-up: 1 week after attending the clinic all index patients were contacted via tele-
phone and interviewed by an experienced “contact tracer”
Participants 105 index patients with chlamydia or NGU (76 men and 29 women) were randomised
Inclusion criteria
• Diagnosed with chlamydia or NGU
• 16 years or older
• Contactable partners who had not already been notified
• Spoke English
Exclusion criteria
• No criteria specified
Interventions Simple patient referral (n = 32)
Each index patient received a sealed envelope. In each envelope there were 5 standard
partner letters used for contact tracing. Each index patient was asked to pass a letter to
each partner
Patient referral with website (n = 73)
Each index patient received a sealed envelope. In each envelope there were 5 standard
letters used for contact tracing with addition of a uniform resource locator address to a
disease-specific website. Each index patient was asked to pass a letter to each partner. The
sites provided information for the partners about the infection to which they had been
exposed. A printable letter for the partner to take to their own doctor and an anonymous
questionnaire were available on the website. Contact details of the researchers and ethics
committee were available to report any complaints
Outcomes Primary outcome
• To determine the acceptability of the Internet for use in standard PN (follow-up
telephone interview with index patient)
Secondary outcome
• Partners elicited (follow-up telephone interview with index patient)
• Partners located (follow-up telephone interview with index patient)
• Index re-infection (clinic records)
• Harms - complaints and reaction (follow-up telephone interview with index
patient and opportunity for partner on website)
Notes Ethical approval by the Department of Human Services, Victoria and the University of
Melbourne
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Statistical package for Social Sciences
(SPSS Inc., Chicago, USA) to generate ran-
domnumbers between1 and27. Block ran-
domisation was used (blocks of 27), with
18 randomised to the website and 9 to the
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standard letter. This was performed so that
each clinic room had 1 randomised block
Allocation concealment (selection bias) Low risk The envelopes with the website or standard
pack were identical. Thickened opaque pa-
per andwere thoroughly sealed.No opened
ormissing envelopes were identified during
the study
Incomplete outcome data (attrition bias)
All outcomes
Low risk 97/105 (92%) index patients completed
study up to telephone interview. Only 48/
105 (46%) index patients returned to the
clinic to evaluate re-infection
Selective reporting (reporting bias) Low risk Same outcomes reported that is stated in
methods.No protocol available from 3 trial
registries
Other bias Low risk No other risk of bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding was not possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No blinding
Contact tracer: not clear if contact tracer
was blinded. Participants were contacted
via telephone 1 week after attending the
clinic and were interviewed by an experi-
enced contact tracer regarding the num-
ber of partners contacted, the method used
whether the letter had been passed on and
the reaction of the partner(s) to themethod
used. A questionnaire was used but no de-
tails given on whether this was a structured
questionnaire
Study personnel: to assess re-infection of
index patient, the study personnel looked at
medical files in the 2-12 week period post-
treatment
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Trent 2010
Methods Setting: 5 clinical sites in 2 institutions - a large academic medical centre (John Hopkins
School of Medicine) and a community hospital (Saint Agnes Hospital), Baltimore, MD,
US
The 5 sites of recruitment included the paediatrics and adult emergency department at
both centres and the combined general paediatrics and adolescent medicine clinic in the
large academic centre
Enrolment: trained research assistants screened patients with mild-to-moderate PID
regarding inclusion and exclusion criteria to determine eligibility - from 14 February
2006 to 25 July 2008
Follow-up: index patients returned for a 72-hour follow-up after treatment, and a 2-
week post-treatment, face-to-face interview with DIS
Participants 162 index patients with mild-to-moderate PID, were approached about recruitment,
131 were enrolled, data gathered from 126 participants were successfully transferred at
enrolment and could be randomised
Inclusion criteria
• Permanent residents of the metropolitan area under study
• Mild-to-moderate PID who had an outpatient-treatment disposition
• Aged 15 years and older
• Access to telephone for follow-up
• Willing to be randomised and contacted for follow-up
Exclusion criteria
• Severe disease - potential surgical emergencies, significant nausea, vomiting or
high fever; evidence of tubo-ovarian abscess; or other extenuating medical
circumstances
• Pregnant
• Concurrent diagnosis of sexual assault
• Unable to communicate
• Previously enrolled and re-diagnosed with PID
• Aged 14 years or younger
Interventions Care of patients in both arms included detailed discharge instructions, a full 14-day
course of medication and a written hand-out to facilitate self care
Patient referral with video (n = 61)
Index patient watched a 6-minute video that tells the story of PID as related by a universal
patient created by the voices and images of 7 different female adolescents. The video
portrays the patient’s interface with health provider and the male partner’s interface and
allows the universal girl to acknowledge the barriers and benefits of PID self care while
providing cues for action
Simple patient referral (n = 65)
Index patient received standardised discharge instructions based on the 2006 CDC STI
treatment guidelines
Outcomes Primary outcomes
• Index patient 72-hour follow-up (clinical records)
• Medication adherence (self report during 2-weeks postenrolment interview)
Secondary outcomes
• Partner treatment (self report during 2-weeks postenrolment interview)
• Temporary abstinence from sexual intercourse as evidence of self care (self report
during 2-weeks postenrolment interview)
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Notes The study was approved by the John Hopkins School of Medicine Institutional Review
Board and the Saint Agnes Hospital Institutional Review Board. Additional approval
was obtained from theMaryland State AttorneyGeneral for recruitment of children who
were wards of the state at the time of diagnosis
To reach 80% power to detect a statistically significant difference for the 72-hour follow-
up visit at the P value = 0.05 level an additional 240 study subjects would have been
needed. The authors were contacted for exact numbers of partners notified and treated
but these numbers were not available
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
Allocation concealment (selection bias) Unclear risk Envelopes containing the group assign-
ment and pertinent information materials
were opened by participants after informed
consent to participate had been obtained
from each of them
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 81/126 (62%) index patients had a 2-
week follow-up interview where informa-
tion on PN were collected
Selective reporting (reporting bias) Low risk Outcomes in method section same as in
results. No protocol available from 3 trial
registries
Other bias Low risk No other bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participant and personnel not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of DIS unclear. The DIS per-
formed the follow-up standardised inter-
view and completed a form. The DIS was
not involved with randomisation or initial
interaction with participant. Face-to-face
interview can introduce bias
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Wilson 2009
Methods Setting: 2 STI clinics in Brooklyn, NY, US. One was a non-Department of Health clinic
for STI and the other a Department of Health STI clinic
Enrolment: index patients enrolled between January 2002 and December 2004
Follow-up: index patient was interviewed at 1 and 6 months after baseline. Testing of
index patient for re-infection with Neisseria gonorrhoeae and Chlamydia trachomatis at 6
months after baseline
Participants 600 index patients (245 women and 355 men), with chlamydia or gonorrhoea, were
randomised
Inclusion criteria
• Microbiological confirmed diagnosis of C. trachomatis or N. gonorrhoeae within
the previous 2 weeks
• Aged 18 years or older
• Able to complete an interview in English or Spanish
• Sexually active in the 2 months prior to enrolment
• Residing in New York City area for the evaluation period
Exclusion criteria
• No criteria specified
Interventions Patient referral with 2 counselling sessions (4 weeks apart) (n = 304)
The first session was designed to occur in the clinic at the time of STI diagnosis. This
was a one-on-one counselling session with health educator discussing risk behaviour,
identification of eligible sexual partners, development of a notification plan, role-play
exercises and completion of a signed behavioural contract to notify partners. Index
patients received support material including written pamphlet on PN and referral slips
to give to partner with information on where to access free confidential STI testing and
treatment. The second session was designed to take place by telephone or in person, 4
weeks after initial session. Review of progress and any remaining barriers to notification
process were discussed
Simple patient referral (n = 296)
Index patient met with health educator at the time of STI diagnosis. The health educator
asked the index patient if there were any questions related to the clinic visit, diagnosis,
treatment or prevention. A brief discussion period followed. Index patient was given
referral slips to give to partner with information on where to access free confidential STI
testing and treatment
Outcomes Primary outcome
• PN (self report by index patient during interview 1 month after baseline)
• Harms - arguments or instances of physical violence (self report by index patient
during interview 1 month after baseline)
Secondary outcomes
• Re-infection of index patient at 6 months (urine test)
• Sexual behavioural changes over last 90 days - number of partners, type of
intercourse, condom use (self report by index patient during interview 6 months after
baseline)
Notes Ethical approval by institutional review board at participating sites and at the CDC
Author was contacted and they were unable to account for reasons for unequal distribu-
tion of STIs at baseline
Authors could not provide exact numbers of partners for outcomes.Distribution of harms
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between 2 groups and detail on protocol obtained from authors. The randomisation
process was implemented throughout recruitment as described in the study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Stratified block randomisation algorithm,
with stratifications by site of recruitment
and gender within site. Computerised ran-
dom number generator
Allocation concealment (selection bias) Unclear risk The principal investigator pre-assigned se-
quential study identification numbers ac-
cording to the random number generated
sequence. Participants were assigned study
identification numbers sequentially as they
enrolled in the study. There was no explicit
mention of safeguards to concealment such
as opaque sealed envelopes, or signing con-
sent before randomisation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 263/296 (88%) in simple patient referral
group completed 1 and 6month after base-
line interview and had a valid urine test re-
sult. In the patient referral group with 2
counselling sessions, 253/304(83%) com-
pleted 1 and 6 month after baseline and
had a valid urine test result
Selective reporting (reporting bias) High risk Protocol obtained from trial registries
Outcome in protocol:
Primary outcomes in protocol was PN and
re-infection of index patient at 6 months
Outcome in actual study:
Primary outcomes in actual study are PN
and harms
In the protocol, 3 intervention arms were
described, in the actual study only 2 arms
were reported
Other bias Low risk No other bias identified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding of participant or personnel
Blinding of outcome assessment (detection
bias)
Low risk Blinding of study interviewers was per-
formed. The study interviewers were not
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All outcomes employees of the study clinics neither did
they engage in any health education activi-
ties. Study interviewers were not informed
of participant group assignment. Labora-
tory personnel were blinded
CDC: Centers for Disease Control and Prevention; DIS: disease intervention specialist; DNA: deoxyribonucleic acid; EPT: expedited
partner therapy; FPC: family planning clinic; GUM: genitourinary medicine; HIV: human immunodeficiency virus; ITT: intention
to treat; NGU: non-gonococcal urethritis; PCR: polymerase chain reaction; PID: pelvic inflammatory disease; PN: partner notifi-
cation; RNA: ribonucleic acid; STI: sexually transmitted infection; WHO: World Health Organization.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Colvin 2006 PN was part of a package given to the index patient and the effect of PN alone cannot be evaluated
Garcia 2003 Study not on PN
Hogben 2005 Study was discontinued due to low recruitment
Marion 2009 Study not on PN
Okonofua 2003 No STI diagnosis was made
Richens 2010 Study not on PN
Shain 2004 Study not on PN
Sherman 2005 Study was discontinued due to low recruitment
Thurman 2008 Not an RCT
Wu 2009 STI diagnosis not made in all index patients
Young 2007 Not an RCT
PN: partner notification; RCT: randomised controlled trial; STI: sexually transmitted infections.
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Characteristics of studies awaiting assessment [ordered by study ID]
Levy 1998
Methods Setting: US, poor, high-crime urban area, neighbourhood-based service in converted store front
Enrolment: over the first 12 months of the study - 386 intravenous drug users were recruited by outreach team from
the streets
Follow-up: re-interview 3 months later
Participants 60 HIV-positive participants were randomised
Inclusion criteria
• Injecting drug users
• HIV positive and receiving results
• Have needle-sharing partners or sexual partners
Interventions All index patients receive referral to case management services, help in identifying and naming at-risk partners, reasons
to inform their partners and counselling in how to do so
Simple patient referral
Index patients receive help in identifying and naming partners and are counselled about notification
Choice patient referral or provider referral
Index patients receive help in identifying and naming partners and are counselled about notification. Outreach team
notify those partners the patient does not want to notify themselves, without revealing the identity of index patient
Outcomes Primary outcome
• Partners elicited
Secondary outcomes
• Partners tested
• Partners testing positive
• Domestic violence
• Suicide
Notes This study is still ongoing, and apart from limited data on patient preferences, there are no data on other outcomes
The only study conducted outside of the formal health services
Harms are being compared
HIV: human immunodeficiency virus.
Characteristics of ongoing studies [ordered by study ID]
Cassell 2010
Trial name or title Different Approaches to Partner Notification in Primary Care
Methods Cluster randomised trial
Participants Practices from the MRC General Practice Research Framework, South East Care Research Network or the
Primary Care Research Network Greater London, UK
Patients with curable STIs
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Interventions Patient referral, contract referral and provider referral
Outcomes Number of partners treated. Proportion of index patients testing negative for the relevant STI at 3 months
Starting date 1 May 2010
Contact information j.cassell@bsms.ac.uk
+044 (0) 1273 641924
Notes Trial registration number: ISRCTN24160819
Falk 2012
Trial name or title Home-Sampling in Partner Notification of Chlamydia
Methods Multicentre cluster-randomised controlled trial
Participants Sexual partners to chlamydia-infected index patients
Interventions Home sampling
Outcomes Difference in time, measured as days from the meeting between the index patient and the counsellor until
the date of testing of partners
Starting date November 2006
Contact information Not reported
Notes Trial registration number: NCT01596946
Farquhar 2012
Trial name or title Assisted-Partner Notification Services
Methods Randomised controlled trial
Participants Newly diagnosed HIV-infected patients
Interventions Assisted partner notification
Outcomes Rate of HIV testing of partners, newly identified HIV-infected partners, rate of linkage to HIV care, cost-
effectiveness
Starting date June 2012
Contact information cfarq@u.washington.edu
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Notes Trial registration number: NCT01616420
Golden 2012
Trial name or title Washington State Community Expedited Partner Treatment (EPT) Trial
Methods Cluster randomised trial
Participants Male or females given a diagnosis of chlamydia or gonorrhoea. Inclusion criteria Aged over 14 years, not men
who have sex with men
Setting: 23 Washington state local health jurisdictions
Enrolment: medical providers will refer selected persons for partner services
Follow-up: no follow-up scheduled but report through public health surveillance
Interventions Patient-delivered partner therapy packages including antibiotics, condom, written information
Outcomes Primary outcomes: test positivity for chlamydia in women at family planning clinics, incidence of gonorrhoea
among women
Secondary outcomes: re-infection of index patient, adverse drug reactions; use of patient-delivered partner
therapy by medical providers
Starting date July 2007
Contact information Matthew Golden, MD, University of Washington
Notes Trial registration number: NCT01665690
HIV: human immunodeficiency virus; MRC: Medical Research Council; STI: sexually transmitted infection.
90Strategies for partner notification for sexually transmitted infections, including HIV (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
D A T A A N D A N A L Y S E S
Comparison 1. Enhanced patient referral versus simple patient referral
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Re-infection in index patient 6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Home sampling vs. simple
patient referral
1 220 Risk Ratio (M-H, Random, 95% CI) 2.14 [0.91, 5.05]
1.2 Information booklet vs.
simple patient referral
2 942 Risk Ratio (M-H, Random, 95% CI) 0.55 [0.22, 1.33]
1.3 Patient referral
(DIS/health advisor) vs. patient
referral (nurse)
1 140 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.01, 8.51]
1.4 Disease-specific website
vs. simple referral
1 105 Risk Ratio (M-H, Random, 95% CI) 3.12 [0.17, 58.73]
1.5 Additional counselling vs.
simple patient referral
1 600 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.27, 0.89]
2 Number of partners elicited 11 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Home sampling vs.
patient referral
3 516 Mean Difference (IV, Random, 95% CI) -0.01 [-0.19, 0.18]
2.2 Additional counselling vs.
patient referral
3 4108 Mean Difference (IV, Random, 95% CI) 0.23 [0.03, 0.43]
2.3 Patient referral (DIS) vs.
patient referral (nurse)
2 597 Mean Difference (IV, Random, 95% CI) -0.40 [-0.57, -0.24]
2.4 Information booklet vs.
patient referral
1 633 Mean Difference (IV, Random, 95% CI) 0.0 [-0.22, 0.22]
2.5 Disease-specific website
vs. patient referral
2 140 Mean Difference (IV, Random, 95% CI) -0.15 [-0.72, 0.42]
3 Number of partners notified 5 1236 Mean Difference (IV, Random, 95% CI) 0.07 [-0.06, 0.20]
3.1 Home sampling vs.
patient referral
2 782 Mean Difference (IV, Random, 95% CI) 0.01 [-0.12, 0.14]
3.2 Additional counselling vs.
patient referral
1 272 Mean Difference (IV, Random, 95% CI) 0.21 [0.06, 0.36]
3.3 Disease-specific website
vs. patient referral
1 105 Mean Difference (IV, Random, 95% CI) -0.17 [-0.68, 0.34]
3.4 Videotape vs. patient
referral
1 77 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Number of partners presenting
for care
4 Mean Difference (IV, Random, 95% CI) Totals not selected
4.1 Home sampling vs.
patient referral
3 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4.2 Additional counselling vs.
patient referral
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Number of partners testing
positive
5 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Home sampling vs.
patient referral
3 878 Mean Difference (IV, Random, 95% CI) 0.11 [0.05, 0.17]
91Strategies for partner notification for sexually transmitted infections, including HIV (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5.2 Additional counselling vs.
patient referral
1 1266 Mean Difference (IV, Random, 95% CI) 0.01 [-0.05, 0.07]
5.3 Patient referral (DIS) vs.
patient referral (nurse)
1 457 Mean Difference (IV, Random, 95% CI) 0.0 [-0.03, 0.03]
6 Number of partners treated 6 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 2. Enhanced patient referral versus other enhanced patient referral
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Partners elicited 2 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Number of partners presenting
for care
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Number of partners treated 1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 3. Expedited partner therapy (EPT) versus simple patient referral
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Re-infection in index patients 6 6018 Risk Ratio (M-H, Random, 95% CI) 0.71 [0.56, 0.89]
1.1 Chlamydia 2 2007 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.60, 1.35]
1.2 Trichomonas 2 631 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.34, 1.28]
1.3 Chlamydia or gonorrhoea 2 3380 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.39, 0.94]
2 Number of partners elicited 6 4339 Mean Difference (IV, Random, 95% CI) -0.02 [-0.09, 0.04]
3 Number of partners notified 3 Mean Difference (IV, Random, 95% CI) Totals not selected
4 Number of partners presenting
for care
1 Mean Difference (IV, Random, 95% CI) Totals not selected
5 Number of partners treated 4 Mean Difference (IV, Random, 95% CI) Totals not selected
5.1 Chlamydia or gonorrhoea 2 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.2 Trichomonas 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5.3 Any STI syndrome 1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 Number of harmful events
reported
1 Mean Difference (IV, Random, 95% CI) Totals not selected
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Comparison 4. Expedited partner therapy (EPT) versus enhanced patient referral
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 EPT vs. enhanced patient referral 3 Risk Ratio (M-H, Random, 95% CI) Subtotals only
1.1 Re-infection in index
patients
3 1220 Risk Ratio (M-H, Random, 95% CI) 0.96 [0.60, 1.53]
2 EPT vs. enhanced patient referral 3 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Number of partners
elicited
3 945 Mean Difference (IV, Random, 95% CI) 0.07 [-0.18, 0.32]
2.2 Number of partners
notified
1 220 Mean Difference (IV, Random, 95% CI) 0.11 [-0.08, 0.30]
2.3 Number of partners
presenting for care
1 220 Mean Difference (IV, Random, 95% CI) 0.01 [-0.01, 0.03]
2.4 Number of partners
treated
1 692 Mean Difference (IV, Random, 95% CI) 0.22 [0.21, 0.23]
3 Enhanced patient referral plus
EPT vs. simple patient referral
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3.1 Number of partners
elicited
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 5. Contract referral versus simple patient referral
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of partners elicited 5 2006 Mean Difference (IV, Random, 95% CI) -0.22 [-0.37, -0.06]
2 Number of partners notified 1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Number of partners presenting
for care
3 1610 Mean Difference (IV, Random, 95% CI) 0.25 [0.18, 0.32]
4 Number of partners testing
positive
4 1684 Mean Difference (IV, Random, 95% CI) 0.13 [0.07, 0.18]
5 Number of partners treated 2 Mean Difference (IV, Random, 95% CI) Totals not selected
6 Number of harmful events
reported
1 Mean Difference (IV, Random, 95% CI) Totals not selected
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Comparison 6. Contract referral versus enhanced patient referral
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of partners elicited 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Partners presenting for care 1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Partners testing positive 1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 7. Contract referral versus expedited partner therapy (EPT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Re-infection in index patient 1 Risk Ratio (M-H, Random, 95% CI) Totals not selected
Comparison 8. Provider referral versus simple patient referral
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Provider referral vs. simple
patient referral
2 Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Number of partners
elicited
2 596 Mean Difference (IV, Random, 95% CI) -0.10 [-0.65, 0.46]
1.2 Number of partners
testing positive
2 596 Mean Difference (IV, Random, 95% CI) 0.06 [0.02, 0.11]
1.3 Number of partners
treated
1 438 Mean Difference (IV, Random, 95% CI) 0.5 [0.37, 0.63]
1.4 Number of harmful events
reported
1 158 Mean Difference (IV, Random, 95% CI) -0.01 [-0.04, 0.02]
2 Choice between provider or
simple patient referral vs.
simple patient referral
1 Mean Difference (IV, Random, 95% CI) Totals not selected
2.1 Number of partners
elicited
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Number of partners
notified
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2.3 Number of partners
presenting for care
1 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 9. Provider referral versus enhanced patient referral (disease intervention specialist)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of partners elicited 1 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Number of partners testing
positive
1 Mean Difference (IV, Random, 95% CI) Totals not selected
3 Number of partners treated 1 Mean Difference (IV, Random, 95% CI) Totals not selected
Comparison 10. Provider referral versus contract referral
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Number of partners elicited 2 Mean Difference (IV, Random, 95% CI) Totals not selected
2 Number of partners presenting
for care
1 163 Mean Difference (IV, Random, 95% CI) 0.03 [-0.19, 0.25]
3 Number of partners located 2 2129 Mean Difference (IV, Random, 95% CI) 0.10 [-0.00, 0.20]
4 Number of partners tested 1 Mean Difference (IV, Random, 95% CI) Totals not selected
5 Partners testing positive 2 2129 Mean Difference (IV, Random, 95% CI) 0.02 [-0.02, 0.06]
6 Number of partners treated 1 Mean Difference (IV, Random, 95% CI) Totals not selected
7 Number of harmful events
reported
1 Mean Difference (IV, Random, 95% CI) Totals not selected
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Analysis 1.1. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 1 Re-
infection in index patient.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 1 Enhanced patient referral versus simple patient referral
Outcome: 1 Re-infection in index patient
Study or subgroup Enhanced PR Simple PR Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Home sampling vs. simple patient referral
Cameron 2009 15/110 7/110 100.0 % 2.14 [ 0.91, 5.05 ]
Subtotal (95% CI) 110 110 100.0 % 2.14 [ 0.91, 5.05 ]
Total events: 15 (Enhanced PR), 7 (Simple PR)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.081)
2 Information booklet vs. simple patient referral
Kissinger 2005 30/348 67/285 57.0 % 0.37 [ 0.25, 0.55 ]
Kissinger 2006 11/154 12/155 43.0 % 0.92 [ 0.42, 2.03 ]
Subtotal (95% CI) 502 440 100.0 % 0.55 [ 0.22, 1.33 ]
Total events: 41 (Enhanced PR), 79 (Simple PR)
Heterogeneity: Tau2 = 0.32; Chi2 = 4.19, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 1.33 (P = 0.18)
3 Patient referral (DIS/health advisor) vs. patient referral (nurse)
Low 2006b 0/68 1/72 100.0 % 0.35 [ 0.01, 8.51 ]
Subtotal (95% CI) 68 72 100.0 % 0.35 [ 0.01, 8.51 ]
Total events: 0 (Enhanced PR), 1 (Simple PR)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
4 Disease-specific website vs. simple referral
Tomnay 2006 3/73 0/32 100.0 % 3.12 [ 0.17, 58.73 ]
Subtotal (95% CI) 73 32 100.0 % 3.12 [ 0.17, 58.73 ]
Total events: 3 (Enhanced PR), 0 (Simple PR)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
5 Additional counselling vs. simple patient referral
Wilson 2009 15/304 30/296 100.0 % 0.49 [ 0.27, 0.89 ]
Subtotal (95% CI) 304 296 100.0 % 0.49 [ 0.27, 0.89 ]
Total events: 15 (Enhanced PR), 30 (Simple PR)
Heterogeneity: not applicable
Test for overall effect: Z = 2.36 (P = 0.018)
Test for subgroup differences: Chi2 = 9.37, df = 4 (P = 0.05), I2 =57%
0.2 0.5 1 2 5
Enhanced PR Simple PR
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Analysis 1.2. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 2 Number of
partners elicited.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 1 Enhanced patient referral versus simple patient referral
Outcome: 2 Number of partners elicited
Study or subgroup Enhanced PR Simple PR
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home sampling vs. patient referral
Andersen 1998 45 1.44 (1.18) 51 1.33 (1.18) 15.8 % 0.11 [ -0.36, 0.58 ]
Apoola 2009 100 1.14 (1.08) 100 1.19 (1.08) 39.5 % -0.05 [ -0.35, 0.25 ]
Cameron 2009 110 1.13 (1.07) 110 1.14 (1.06) 44.7 % -0.01 [ -0.29, 0.27 ]
Subtotal (95% CI) 255 261 100.0 % -0.01 [ -0.19, 0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.31, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
2 Additional counselling vs. patient referral
Cleveland undated 634 3.3 (1.81) 632 3.3 (1.81) 18.8 % 0.0 [ -0.20, 0.20 ]
Ellison undated 423 1.16 (1.04) 433 1.03 (1.05) 20.8 % 0.13 [ -0.01, 0.27 ]
Ellison undated 431 1.28 (1.07) 433 1.03 (1.07) 20.7 % 0.25 [ 0.11, 0.39 ]
Ellison undated 417 1.64 (1.16) 433 1.03 (1.16) 20.3 % 0.61 [ 0.45, 0.77 ]
Moyo 2002 131 0.65 (0.77) 141 0.52 (0.76) 19.4 % 0.13 [ -0.05, 0.31 ]
Subtotal (95% CI) 2036 2072 100.0 % 0.23 [ 0.03, 0.43 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 30.96, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.22 (P = 0.026)
3 Patient referral (DIS) vs. patient referral (nurse)
Katz 1988 240 0.75 (0.98) 217 1.16 (0.98) 83.1 % -0.41 [ -0.59, -0.23 ]
Low 2006b 68 1.28 (1.2) 72 1.65 (1.21) 16.9 % -0.37 [ -0.77, 0.03 ]
Subtotal (95% CI) 308 289 100.0 % -0.40 [ -0.57, -0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 4.82 (P < 0.00001)
4 Information booklet vs. patient referral
Kissinger 2005 348 2.03 (1.42) 285 2.03 (1.42) 100.0 % 0.0 [ -0.22, 0.22 ]
Subtotal (95% CI) 348 285 100.0 % 0.0 [ -0.22, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
5 Disease-specific website vs. patient referral
-0.2 -0.1 0 0.1 0.2
Favours simple PR Favours enhanced PR
(Continued . . . )
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(. . . Continued)
Study or subgroup Enhanced PR Simple PR
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kerani 2011 17 1.76 (1.42) 18 2.33 (1.43) 32.4 % -0.57 [ -1.51, 0.37 ]
Tomnay 2006 73 2.2 (1.47) 32 2.15 (1.47) 67.6 % 0.05 [ -0.56, 0.66 ]
Subtotal (95% CI) 90 50 100.0 % -0.15 [ -0.72, 0.42 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.17, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 25.05, df = 4 (P = 0.00), I2 =84%
-0.2 -0.1 0 0.1 0.2
Favours simple PR Favours enhanced PR
Analysis 1.3. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 3 Number of
partners notified.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 1 Enhanced patient referral versus simple patient referral
Outcome: 3 Number of partners notified
Study or subgroup Enhanced PR Simple PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home sampling vs. patient referral
Cameron 2009 110 0.48 (0.69) 110 0.46 (0.69) 0.02 [ -0.16, 0.20 ]
Ostergaard 2003 304 1.3 (1.14) 258 1.3 (1.14) 0.0 [ -0.19, 0.19 ]
Subtotal (95% CI) 414 368 0.01 [ -0.12, 0.14 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Additional counselling vs. patient referral
Moyo 2002 131 0.53 (0.65) 141 0.32 (0.65) 0.21 [ 0.06, 0.36 ]
Subtotal (95% CI) 131 141 0.21 [ 0.06, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.66 (P = 0.0078)
3 Disease-specific website vs. patient referral
-1 -0.5 0 0.5 1
Favours simple PR Favours enhanced PR
(Continued . . . )
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(. . . Continued)
Study or subgroup Enhanced PR Simple PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Tomnay 2006 73 1.39 (1.23) 32 1.56 (1.23) -0.17 [ -0.68, 0.34 ]
Subtotal (95% CI) 73 32 -0.17 [ -0.68, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
4 Videotape vs. patient referral
Trent 2010 36 0.83 (0) 41 0.85 (0) 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 36 41 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 654 582 0.07 [ -0.06, 0.20 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.73, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi2 = 4.71, df = 2 (P = 0.09), I2 =58%
-1 -0.5 0 0.5 1
Favours simple PR Favours enhanced PR
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Analysis 1.4. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 4 Number of
partners presenting for care.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 1 Enhanced patient referral versus simple patient referral
Outcome: 4 Number of partners presenting for care
Study or subgroup Enhanced PR Simple PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home sampling vs. patient referral
Andersen 1998 45 0.98 (0.83) 51 0.37 (0.83) 0.61 [ 0.28, 0.94 ]
Apoola 2009 100 0.62 (0.8) 100 0.67 (0.8) -0.05 [ -0.27, 0.17 ]
Cameron 2009 110 0.46 (0.66) 110 0.42 (0.66) 0.04 [ -0.13, 0.21 ]
2 Additional counselling vs. patient referral
Cleveland undated 634 0.37 (0.6) 632 0.37 (0.6) 0.0 [ -0.07, 0.07 ]
-0.2 -0.1 0 0.1 0.2
Favours simple PR Favours enhanced PR
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Analysis 1.5. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 5 Number of
partners testing positive.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 1 Enhanced patient referral versus simple patient referral
Outcome: 5 Number of partners testing positive
Study or subgroup Enhanced PR Simple PR
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home sampling vs. patient referral
Andersen 1998 45 0.27 (0.45) 51 0.14 (0.45) 12.6 % 0.13 [ -0.05, 0.31 ]
Cameron 2009 110 0.28 (0.48) 110 0.18 (0.48) 25.4 % 0.10 [ -0.03, 0.23 ]
Ostergaard 2003 304 0.3 (0.49) 258 0.19 (0.49) 62.0 % 0.11 [ 0.03, 0.19 ]
Subtotal (95% CI) 459 419 100.0 % 0.11 [ 0.05, 0.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 3.37 (P = 0.00076)
2 Additional counselling vs. patient referral
Cleveland undated 634 0.25 (0.5) 632 0.24 (0.5) 100.0 % 0.01 [ -0.05, 0.07 ]
Subtotal (95% CI) 634 632 100.0 % 0.01 [ -0.05, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
3 Patient referral (DIS) vs. patient referral (nurse)
Katz 1988 240 0.03 (0.18) 217 0.03 (0.18) 100.0 % 0.0 [ -0.03, 0.03 ]
Subtotal (95% CI) 240 217 100.0 % 0.0 [ -0.03, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 9.13, df = 2 (P = 0.01), I2 =78%
-0.1 -0.05 0 0.05 0.1
Favours simple PR Favours enhanced PR
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Analysis 1.6. Comparison 1 Enhanced patient referral versus simple patient referral, Outcome 6 Number of
partners treated.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 1 Enhanced patient referral versus simple patient referral
Outcome: 6 Number of partners treated
Study or subgroup Enhanced PR Simple PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Apoola 2009 100 0.61 (0.79) 100 0.64 (0.79) -0.03 [ -0.25, 0.19 ]
Ellison undated (1) 417 0.25 (0.47) 433 0.18 (0.47) 0.07 [ 0.01, 0.13 ]
Ellison undated (2) 423 0.22 (0.45) 433 0.18 (0.45) 0.04 [ -0.02, 0.10 ]
Ellison undated (3) 431 0.2 (0.44) 433 0.18 (0.44) 0.02 [ -0.04, 0.08 ]
Katz 1988 240 0.18 (0.45) 217 0.22 (0.45) -0.04 [ -0.12, 0.04 ]
Kissinger 2005 348 0.93 (0.9) 285 0.71 (0.9) 0.22 [ 0.08, 0.36 ]
Low 2006b 68 0.57 (0.81) 72 0.74 (0.81) -0.17 [ -0.44, 0.10 ]
Trent 2010 77 0.57 (0) 41 0.49 (0) 0.0 [ 0.0, 0.0 ]
-1 -0.5 0 0.5 1
Favours simple PR Favours enhanced PR
(1) PR vs enhanced PR (health education message and counselling)
(2) PR vs enhanced PR (counselling)
(3) PR vs enhanced PR (health education message)
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Analysis 2.1. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 1
Partners elicited.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 2 Enhanced patient referral versus other enhanced patient referral
Outcome: 1 Partners elicited
Study or subgroup
Enhanced
PR
alternative Enhanced PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ellison undated 417 1.64 (1.18) 423 1.16 (1.18) 0.48 [ 0.32, 0.64 ]
Ellison undated 423 1.16 (1.11) 431 1.28 (1.11) -0.12 [ -0.27, 0.03 ]
Ellison undated 417 1.64 (1.21) 431 1.28 (1.21) 0.36 [ 0.20, 0.52 ]
Montesinos 1990 19 1.11 (1.07) 27 1.19 (1.07) -0.08 [ -0.71, 0.55 ]
Montesinos 1990 19 1.32 (1.12) 27 1.19 (1.12) 0.13 [ -0.53, 0.79 ]
Montesinos 1990 19 1.11 (1.1) 19 1.32 (1.1) -0.21 [ -0.91, 0.49 ]
-4 -2 0 2 4
Favours enhanced PR Favours enhanced PR (alt)
Analysis 2.2. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 2
Number of partners presenting for care.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 2 Enhanced patient referral versus other enhanced patient referral
Outcome: 2 Number of partners presenting for care
Study or subgroup
Enhanced
PR
alternative Enhanced PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Montesinos 1990 19 1 (0.96) 19 0.84 (0.96) 0.16 [ -0.45, 0.77 ]
Montesinos 1990 19 0.84 (0.88) 27 0.67 (0.88) 0.17 [ -0.35, 0.69 ]
Montesinos 1990 19 1 (0.93) 27 0.67 (0.93) 0.33 [ -0.22, 0.88 ]
-1 -0.5 0 0.5 1
Favours enhanced PR Favours enhanced PR (alt)
103Strategies for partner notification for sexually transmitted infections, including HIV (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.3. Comparison 2 Enhanced patient referral versus other enhanced patient referral, Outcome 3
Number of partners treated.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 2 Enhanced patient referral versus other enhanced patient referral
Outcome: 3 Number of partners treated
Study or subgroup Enhanced PR
Enhanced PR
(alternative)
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Ellison undated 417 0.25 (0.49) 423 0.22 (0.486981) 0.03 [ -0.04, 0.10 ]
Ellison undated 423 0.22 (0.46) 431 0.2 (0.459284) 0.02 [ -0.04, 0.08 ]
Ellison undated 417 0.25 (0.48) 431 0.2 (0.477973) 0.05 [ -0.02, 0.11 ]
-0.1 -0.05 0 0.05 0.1
Favours enhanced PR Favours enhanced PR (alt)
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Analysis 3.1. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 1 Re-
infection in index patients.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 3 Expedited partner therapy (EPT) versus simple patient referral
Outcome: 1 Re-infection in index patients
Study or subgroup EPT Simple PR Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Chlamydia
Cameron 2009 10/110 7/110 5.6 % 1.43 [ 0.56, 3.62 ]
Schillinger 2003 87/887 108/900 29.9 % 0.82 [ 0.63, 1.07 ]
Subtotal (95% CI) 997 1010 35.6 % 0.90 [ 0.60, 1.35 ]
Total events: 97 (EPT), 115 (Simple PR)
Heterogeneity: Tau2 = 0.03; Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Trichomonas
Kissinger 2006 8/154 12/155 6.4 % 0.67 [ 0.28, 1.60 ]
Schwebke 2010 6/162 9/160 4.9 % 0.66 [ 0.24, 1.81 ]
Subtotal (95% CI) 316 315 11.2 % 0.67 [ 0.34, 1.28 ]
Total events: 14 (EPT), 21 (Simple PR)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.21 (P = 0.23)
3 Chlamydia or gonorrhoea
Golden 2005 92/1375 124/1376 30.6 % 0.74 [ 0.57, 0.96 ]
Kissinger 2005 39/344 68/285 22.6 % 0.48 [ 0.33, 0.68 ]
Subtotal (95% CI) 1719 1661 53.2 % 0.61 [ 0.39, 0.94 ]
Total events: 131 (EPT), 192 (Simple PR)
Heterogeneity: Tau2 = 0.07; Chi2 = 3.88, df = 1 (P = 0.05); I2 =74%
Test for overall effect: Z = 2.26 (P = 0.024)
Total (95% CI) 3032 2986 100.0 % 0.71 [ 0.56, 0.89 ]
Total events: 242 (EPT), 328 (Simple PR)
Heterogeneity: Tau2 = 0.03; Chi2 = 8.15, df = 5 (P = 0.15); I2 =39%
Test for overall effect: Z = 2.89 (P = 0.0039)
Test for subgroup differences: Chi2 = 1.77, df = 2 (P = 0.41), I2 =0.0%
0.5 0.7 1 1.5 2
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Analysis 3.2. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 2
Number of partners elicited.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 3 Expedited partner therapy (EPT) versus simple patient referral
Outcome: 2 Number of partners elicited
Study or subgroup EPT Simple PR
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cameron 2009 110 1.14 (1.09) 110 1.22 (1.09) 4.8 % -0.08 [ -0.37, 0.21 ]
Golden 2005 1375 0.99 (1) 1376 1.02 (1) 71.3 % -0.03 [ -0.10, 0.04 ]
Kerani 2011 16 2.75 (1.6) 18 2.33 (1.6) 0.3 % 0.42 [ -0.66, 1.50 ]
Kissinger 2005 344 2.05 (1.43) 285 2.03 (1.43) 7.9 % 0.02 [ -0.20, 0.24 ]
Nuwaha 2001 192 1.23 (1.11) 191 1.23 (1.11) 8.1 % 0.0 [ -0.22, 0.22 ]
Schwebke 2010 162 1.1 (1.05) 160 1.12 (1.05) 7.6 % -0.02 [ -0.25, 0.21 ]
Total (95% CI) 2199 2140 100.0 % -0.02 [ -0.09, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 5 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 3
Number of partners notified.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 3 Expedited partner therapy (EPT) versus simple patient referral
Outcome: 3 Number of partners notified
Study or subgroup EPT Simple PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cameron 2009 110 0.59 (0.73) 110 0.46 (0.73) 0.13 [ -0.06, 0.32 ]
Golden 2005 1375 0.75 (0.88) 1376 0.8 (0.88) -0.05 [ -0.12, 0.02 ]
Kissinger 2005 344 1.44 (1.1) 285 1 (1.1) 0.44 [ 0.27, 0.61 ]
-0.5 -0.25 0 0.25 0.5
Favours simple PR Favours EPT
Analysis 3.4. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 4
Number of partners presenting for care.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 3 Expedited partner therapy (EPT) versus simple patient referral
Outcome: 4 Number of partners presenting for care
Study or subgroup EPT Simple PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cameron 2009 110 0.47 (0.66) 110 0.42 (0.67) 0.05 [ -0.13, 0.23 ]
-4 -2 0 2 4
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Analysis 3.5. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 5
Number of partners treated.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 3 Expedited partner therapy (EPT) versus simple patient referral
Outcome: 5 Number of partners treated
Study or subgroup EPT Simple PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Chlamydia or gonorrhoea
Golden 2005 1375 0.59 (0.75) 1376 0.53 (0.75) 0.06 [ 0.00, 0.12 ]
Kissinger 2005 344 1.14 (0.95) 285 0.71 (0.95) 0.43 [ 0.28, 0.58 ]
2 Trichomonas
Schwebke 2010 162 0.79 (0.73) 160 0.28 (0.73) 0.51 [ 0.35, 0.67 ]
3 Any STI syndrome
Nuwaha 2001 192 0.91 (0.81) 191 0.41 (0.81) 0.50 [ 0.34, 0.66 ]
-0.5 -0.25 0 0.25 0.5
Favours simple PR Favours EPT
Analysis 3.6. Comparison 3 Expedited partner therapy (EPT) versus simple patient referral, Outcome 6
Number of harmful events reported.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 3 Expedited partner therapy (EPT) versus simple patient referral
Outcome: 6 Number of harmful events reported
Study or subgroup EPT Simple PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Nuwaha 2001 192 0.12 (0.3) 191 0.06 (0.3) 0.06 [ 0.00, 0.12 ]
-4 -2 0 2 4
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Analysis 4.1. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 1
EPT vs. enhanced patient referral.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 4 Expedited partner therapy (EPT) versus enhanced patient referral
Outcome: 1 EPT vs. enhanced patient referral
Study or subgroup EPT Enhanced PR Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Re-infection in index patients
Cameron 2009 10/110 15/110 27.5 % 0.67 [ 0.31, 1.42 ]
Kissinger 2005 39/344 30/348 50.7 % 1.32 [ 0.84, 2.07 ]
Kissinger 2006 8/154 11/154 21.8 % 0.73 [ 0.30, 1.76 ]
Subtotal (95% CI) 608 612 100.0 % 0.96 [ 0.60, 1.53 ]
Total events: 57 (EPT), 56 (Enhanced PR)
Heterogeneity: Tau2 = 0.06; Chi2 = 2.99, df = 2 (P = 0.22); I2 =33%
Test for overall effect: Z = 0.18 (P = 0.86)
0.01 0.1 1 10 100
EPT Enhanced PR
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Analysis 4.2. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 2
EPT vs. enhanced patient referral.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 4 Expedited partner therapy (EPT) versus enhanced patient referral
Outcome: 2 EPT vs. enhanced patient referral
Study or subgroup EPT Enhanced PR
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Number of partners elicited
Cameron 2009 110 1.14 (1.06) 110 1.13 (1.06) 41.5 % 0.01 [ -0.27, 0.29 ]
Kerani 2011 16 2.75 (1.51) 17 1.76 (1.51) 5.6 % 0.99 [ -0.04, 2.02 ]
Kissinger 2005 344 2.05 (1.43) 348 2.03 (1.43) 52.8 % 0.02 [ -0.19, 0.23 ]
Subtotal (95% CI) 470 475 100.0 % 0.07 [ -0.18, 0.32 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.34, df = 2 (P = 0.19); I2 =40%
Test for overall effect: Z = 0.55 (P = 0.59)
2 Number of partners notified
Cameron 2009 110 0.59 (0.73) 110 0.48 (0.73) 100.0 % 0.11 [ -0.08, 0.30 ]
Subtotal (95% CI) 110 110 100.0 % 0.11 [ -0.08, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
3 Number of partners presenting for care
Cameron 2009 110 0.47 (0.09) 110 0.46 (0.09) 100.0 % 0.01 [ -0.01, 0.03 ]
Subtotal (95% CI) 110 110 100.0 % 0.01 [ -0.01, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
4 Number of partners treated
Kissinger 2005 344 1.142442 (0.07733) 348 0.93 (0.07733) 100.0 % 0.22 [ 0.21, 0.23 ]
Subtotal (95% CI) 344 348 100.0 % 0.22 [ 0.21, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 36.93 (P < 0.00001)
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Analysis 4.3. Comparison 4 Expedited partner therapy (EPT) versus enhanced patient referral, Outcome 3
Enhanced patient referral plus EPT vs. simple patient referral.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 4 Expedited partner therapy (EPT) versus enhanced patient referral
Outcome: 3 Enhanced patient referral plus EPT vs. simple patient referral
Study or subgroup PR+EPT Enhanced PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Number of partners elicited
Kerani 2011 2.9166667 (1.497447) 24 17 1.76 (1.497447) 1.15 [ 0.22, 2.08 ]
-100 -50 0 50 100
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Analysis 5.1. Comparison 5 Contract referral versus simple patient referral, Outcome 1 Number of
partners elicited.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 5 Contract referral versus simple patient referral
Outcome: 1 Number of partners elicited
Study or subgroup CR Simple PR
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2011 82 1.15 (1.09) 77 1.21 (1.09) 17.0 % -0.06 [ -0.40, 0.28 ]
Cleveland undated 632 2.9 (1.76) 632 3.3 (1.76) 37.2 % -0.40 [ -0.59, -0.21 ]
Landis 1992 39 4.03 (2.05) 35 4.37 (2.05) 2.7 % -0.34 [ -1.28, 0.60 ]
Potterat 1977 94 2.04 (1.44) 93 2.13 (1.44) 12.2 % -0.09 [ -0.50, 0.32 ]
Schwebke 2010 162 0.99 (1.03) 160 1.12 (1.03) 31.0 % -0.13 [ -0.36, 0.10 ]
Total (95% CI) 1009 997 100.0 % -0.22 [ -0.37, -0.06 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.16, df = 4 (P = 0.27); I2 =22%
Test for overall effect: Z = 2.77 (P = 0.0057)
Test for subgroup differences: Not applicable
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Analysis 5.2. Comparison 5 Contract referral versus simple patient referral, Outcome 2 Number of
partners notified.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 5 Contract referral versus simple patient referral
Outcome: 2 Number of partners notified
Study or subgroup CR Simple PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Landis 1992 39 2 (1.05) 35 0.28 (1.05) 1.72 [ 1.24, 2.20 ]
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Analysis 5.3. Comparison 5 Contract referral versus simple patient referral, Outcome 3 Number of
partners presenting for care.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 5 Contract referral versus simple patient referral
Outcome: 3 Number of partners presenting for care
Study or subgroup CR Simple PR
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2011 82 0.55 (0.63) 77 0.26 (0.63) 12.8 % 0.29 [ 0.09, 0.49 ]
Cleveland undated 632 0.62 (0.7) 632 0.37 (0.7) 82.3 % 0.25 [ 0.17, 0.33 ]
Potterat 1977 94 1.27 (1.1) 93 1.15 (1.1) 4.9 % 0.12 [ -0.20, 0.44 ]
Total (95% CI) 808 802 100.0 % 0.25 [ 0.18, 0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 6.96 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.4. Comparison 5 Contract referral versus simple patient referral, Outcome 4 Number of
partners testing positive.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 5 Contract referral versus simple patient referral
Outcome: 4 Number of partners testing positive
Study or subgroup CR Simple PR
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2011 82 0.26 (0.45) 77 0.16 (0.45) 13.5 % 0.10 [ -0.04, 0.24 ]
Cleveland undated 632 0.37 (0.55) 632 0.24 (0.55) 71.8 % 0.13 [ 0.07, 0.19 ]
Landis 1992 39 0.23 (0.35) 35 0.03 (0.35) 10.4 % 0.20 [ 0.04, 0.36 ]
Potterat 1977 94 0.71 (0.86) 93 0.75 (0.86) 4.3 % -0.04 [ -0.29, 0.21 ]
Total (95% CI) 847 837 100.0 % 0.13 [ 0.07, 0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.72, df = 3 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 4.80 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 5.5. Comparison 5 Contract referral versus simple patient referral, Outcome 5 Number of
partners treated.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 5 Contract referral versus simple patient referral
Outcome: 5 Number of partners treated
Study or subgroup CR Simple PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Potterat 1977 632 0.11 (0.33) 632 0.11 (0.33) 0.0 [ -0.04, 0.04 ]
Schwebke 2010 162 0.56 (0.65) 160 0.28 (0.65) 0.28 [ 0.14, 0.42 ]
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Analysis 5.6. Comparison 5 Contract referral versus simple patient referral, Outcome 6 Number of harmful
events reported.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 5 Contract referral versus simple patient referral
Outcome: 6 Number of harmful events reported
Study or subgroup CR Simple PR
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2011 82 0.012 (0.11) 77 0.01 (0.11) 0.00 [ -0.03, 0.04 ]
-100 -50 0 50 100
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Analysis 6.1. Comparison 6 Contract referral versus enhanced patient referral, Outcome 1 Number of
partners elicited.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 6 Contract referral versus enhanced patient referral
Outcome: 1 Number of partners elicited
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cleveland undated 632 2.9 (1.76) 634 3.3 (1.76) -0.40 [ -0.59, -0.21 ]
-100 -50 0 50 100
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Analysis 6.2. Comparison 6 Contract referral versus enhanced patient referral, Outcome 2 Partners
presenting for care.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 6 Contract referral versus enhanced patient referral
Outcome: 2 Partners presenting for care
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cleveland undated 632 0.62 (0.7) 634 0.37 (0.7) 0.25 [ 0.17, 0.33 ]
-100 -50 0 50 100
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Analysis 6.3. Comparison 6 Contract referral versus enhanced patient referral, Outcome 3 Partners testing
positive.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 6 Contract referral versus enhanced patient referral
Outcome: 3 Partners testing positive
Study or subgroup Experimental Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cleveland undated 632 0.371 (0.56) 634 0.25 (0.59) 0.12 [ 0.06, 0.18 ]
-100 -50 0 50 100
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Analysis 7.1. Comparison 7 Contract referral versus expedited partner therapy (EPT), Outcome 1 Re-
infection in index patient.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 7 Contract referral versus expedited partner therapy (EPT)
Outcome: 1 Re-infection in index patient
Study or subgroup CR EPT Risk Ratio Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Schwebke 2010 5/162 10/162 0.50 [ 0.17, 1.43 ]
Schwebke 2010 15/162 6/162 2.50 [ 0.99, 6.28 ]
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Analysis 8.1. Comparison 8 Provider referral versus simple patient referral, Outcome 1 Provider referral vs.
simple patient referral.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 8 Provider referral versus simple patient referral
Outcome: 1 Provider referral vs. simple patient referral
Study or subgroup Provider
Simple
patient
referral
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Number of partners elicited
Brown 2011 81 1.42 (1.15) 77 1.21 (1.15) 46.2 % 0.21 [ -0.15, 0.57 ]
Katz 1988 221 0.8 (0.99) 217 1.16 (0.99) 53.8 % -0.36 [ -0.55, -0.17 ]
Subtotal (95% CI) 302 294 100.0 % -0.10 [ -0.65, 0.46 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 7.65, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.34 (P = 0.73)
2 Number of partners testing positive
Brown 2011 81 0.26 (0.45) 77 0.16 (0.45) 10.0 % 0.10 [ -0.04, 0.24 ]
Katz 1988 221 0.09 (0.25) 217 0.03 (0.25) 90.0 % 0.06 [ 0.01, 0.11 ]
Subtotal (95% CI) 302 294 100.0 % 0.06 [ 0.02, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.82 (P = 0.0047)
3 Number of partners treated
Katz 1988 221 0.72 (0.684144) 217 0.22 (0.68) 100.0 % 0.50 [ 0.37, 0.63 ]
Subtotal (95% CI) 221 217 100.0 % 0.50 [ 0.37, 0.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.67 (P < 0.00001)
4 Number of harmful events reported
Brown 2011 81 0 (0.08) 77 0.01 (0.081596) 100.0 % -0.01 [ -0.04, 0.02 ]
Subtotal (95% CI) 81 77 100.0 % -0.01 [ -0.04, 0.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
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Analysis 8.2. Comparison 8 Provider referral versus simple patient referral, Outcome 2 Choice between
provider or simple patient referral vs. simple patient referral.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 8 Provider referral versus simple patient referral
Outcome: 2 Choice between provider or simple patient referral vs. simple patient referral
Study or subgroup Choice
Simple
patient
referral
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Number of partners elicited
Faxelid 1996 196 1.82 (1.35) 200 1.86 (1.36) -0.04 [ -0.31, 0.23 ]
2 Number of partners notified
Faxelid 1996 196 1.59 (1.18) 200 1.18 (1.18) 0.41 [ 0.18, 0.64 ]
3 Number of partners presenting for care
Faxelid 1996 196 1.49 (1.12) 200 1.03 (1.12) 0.46 [ 0.24, 0.68 ]
-2 -1 0 1 2
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Analysis 9.1. Comparison 9 Provider referral versus enhanced patient referral (disease intervention
specialist), Outcome 1 Number of partners elicited.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 9 Provider referral versus enhanced patient referral (disease intervention specialist)
Outcome: 1 Number of partners elicited
Study or subgroup Provider Enhanced PR (DIS)
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Katz 1988 221 0.75 (0.88) 240 0.8 (0.88) -0.05 [ -0.21, 0.11 ]
-100 -50 0 50 100
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Analysis 9.2. Comparison 9 Provider referral versus enhanced patient referral (disease intervention
specialist), Outcome 2 Number of partners testing positive.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 9 Provider referral versus enhanced patient referral (disease intervention specialist)
Outcome: 2 Number of partners testing positive
Study or subgroup Provider Enhanced PR (DIS)
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Katz 1988 240 0.029 (0.25) 221 0.09 (0.25) -0.06 [ -0.11, -0.02 ]
-100 -50 0 50 100
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Analysis 9.3. Comparison 9 Provider referral versus enhanced patient referral (disease intervention
specialist), Outcome 3 Number of partners treated.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 9 Provider referral versus enhanced patient referral (disease intervention specialist)
Outcome: 3 Number of partners treated
Study or subgroup Provider Enhanced PR (DIS)
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Katz 1988 240 0.18 (0.67) 221 0.72 (0.68) -0.54 [ -0.66, -0.42 ]
-100 -50 0 50 100
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Analysis 10.1. Comparison 10 Provider referral versus contract referral, Outcome 1 Number of partners
elicited.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 10 Provider referral versus contract referral
Outcome: 1 Number of partners elicited
Study or subgroup CR Provider
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2011 82 1.15 (1.13) 81 1.42 (1.13) -0.27 [ -0.62, 0.08 ]
Peterman 1997 586 6.4 (2.33) 1380 4.2 (2.47) 2.20 [ 1.97, 2.43 ]
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Analysis 10.2. Comparison 10 Provider referral versus contract referral, Outcome 2 Number of partners
presenting for care.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 10 Provider referral versus contract referral
Outcome: 2 Number of partners presenting for care
Study or subgroup CR Provider
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2011 82 0.55 (0.73) 81 0.52 (0.73) 100.0 % 0.03 [ -0.19, 0.25 ]
Total (95% CI) 82 81 100.0 % 0.03 [ -0.19, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Test for subgroup differences: Not applicable
-100 -50 0 50 100
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Analysis 10.3. Comparison 10 Provider referral versus contract referral, Outcome 3 Number of partners
located.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 10 Provider referral versus contract referral
Outcome: 3 Number of partners located
Study or subgroup CR Provider
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2011 82 1.07 (1.02) 81 1.01 (1.02) 10.0 % 0.06 [ -0.25, 0.37 ]
Peterman 1997 586 1.2 (1.08) 1380 1.1 (1.08) 90.0 % 0.10 [ 0.00, 0.20 ]
Total (95% CI) 668 1461 100.0 % 0.10 [ 0.00, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours provider Favours CR
Analysis 10.4. Comparison 10 Provider referral versus contract referral, Outcome 4 Number of partners
tested.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 10 Provider referral versus contract referral
Outcome: 4 Number of partners tested
Study or subgroup CR Provider
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Peterman 1997 586 0.92 (0.95) 1380 0.86 (0.95) 0.06 [ -0.03, 0.15 ]
-4 -2 0 2 4
Favours provider Favours CR
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Analysis 10.5. Comparison 10 Provider referral versus contract referral, Outcome 5 Partners testing
positive.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 10 Provider referral versus contract referral
Outcome: 5 Partners testing positive
Study or subgroup CR Provider
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2011 82 0.26 (0.51) 81 0.26 (0.51) 6.9 % 0.0 [ -0.16, 0.16 ]
Peterman 1997 586 0.2 (0.44) 1380 0.18 (0.44) 93.1 % 0.02 [ -0.02, 0.06 ]
Total (95% CI) 668 1461 100.0 % 0.02 [ -0.02, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
-0.5 -0.25 0 0.25 0.5
Favours provider Favours CR
Analysis 10.6. Comparison 10 Provider referral versus contract referral, Outcome 6 Number of partners
treated.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 10 Provider referral versus contract referral
Outcome: 6 Number of partners treated
Study or subgroup CR Provider
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Peterman 1997 586 0.67 (0.8) 1380 0.61 (0.8) 0.06 [ -0.02, 0.14 ]
-4 -2 0 2 4
Favours provider Favours CR
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Analysis 10.7. Comparison 10 Provider referral versus contract referral, Outcome 7 Number of harmful
events reported.
Review: Strategies for partner notification for sexually transmitted infections, including HIV
Comparison: 10 Provider referral versus contract referral
Outcome: 7 Number of harmful events reported
Study or subgroup CR Provider
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Brown 2011 82 0.01 (0.08) 81 0 (0.08) 0.01 [ -0.01, 0.03 ]
-4 -2 0 2 4
Favours provider Favours CR
A D D I T I O N A L T A B L E S
Table 1. Burden of disease
Disease DALYs
HIV 58.5 million
Chlamydia trachomatis 3.7 million
Gonorrhoea 3.5 million
Other 280,000
Source: WHO 2004.
DALY: disability adjusted life years.
Table 2. Summary of comparisons with data available and STI studied
Partner notifi-
cation strategy,
intervention
Partner notification comparator, comparison number (number of trials) STI included in
trials
Simple patient
referral
Enhanced
patient referral
Expedited part-
ner therapy
Contract refer-
ral
Other enhanced
patient referral
Enhanced
patient referral
1 (16) - - - 2 (2) Gonorrhoea,
chlamydia, non-
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Table 2. Summary of comparisons with data available and STI studied (Continued)
gonococcal ure-
thri-
tis, trichomonas,
pelvic inflamma-
tory disease, STI
syndromes
Expedited part-
ner therapy
3 (8) 4 (5)* - - Not applicable Gonorrhoea,
chlamydia, tri-
chomonas, STI
syndromes
Contract referral 5 (5) 6 (1) 7 (1) - Not applicable Gonorrhoea, tri-
chomonas, HIV
Provider referral 8 (3)† 9 (1) No trials 10 (2) Not applicable Non-gono-
coccal urethritis,
syphilis, HIV
* Comparison includes one trial comparing combinations of expedited partner therapy and patient referral.
† Comparison Includes one trial comparing a choice between provider or simple patient referral and simple patient referral.
- Indicates combinations of an intervention and comparison that are covered elsewhere in the table; HIV: human immunodeficiency
virus; STI: sexually transmitted infection.
Table 3. Summary of included studies and outcomes reported by authors, according to partner notification strategies and
comparisons
Partner notification
strategy
Comparison number,
comparison
N (studies) n
(participants)
Outcomes, as reported in any in-
cluded RCT
Study ID
ENHANCED PATIENT REFERRAL
1. Enhanced patient re-
ferral vs. simple patient
referral
16 7642 Index patient returning for a test
of cure
Knowledge of the index patient
Number of partners notified and
referral of partners for treatment
Proportion of index patients with
at least 1 partner tested
Proportion of index cases with at
least 1 sexual partner treated
Proportion of index patients with
at least 1 partner positive forC. tra-
chomatis
Number of partners treated per in-
Andersen 1998
Apoola 2009
Cleveland undated
Cameron 2009
Ellison undated
Kerani 2011
Katz 1988
Kissinger 2005
Kissinger 2006
Low 2005
Moyo 2002
Ostergaard 2003
Solomon 1988
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Table 3. Summary of included studies and outcomes reported by authors, according to partner notification strategies and
comparisons (Continued)
dex patient 6 weeks after randomi-
sation
Number of partners elicited
Proportion of index cases with a
positive chlamydia test result 6
weeks after randomisation
Proportion of index cases with all
sexual partners treated
Acceptability of Internet for use in
standard partner notification
Partners located
Index re-infection
Harms - adverse effects of medica-
tion
Index patient 72-hour follow-up
Medication adherence
Temporary abstinence from sexual
intercourse as evidence of self care
Behavioural change
Partners contacted
Partners tested
Partners testing positive
Time until testing of partners
Number of partners treated per in-
dex case
Number of partners identified per
index
Number of traceable partners
Number of partners treated within
28 days
Proportion of index patients with
at least 1 partner treated within 28
days per index case
Tomnay 2006
Trent 2010
Wilson 2009
2. Enhanced patient re-
ferral vs. other enhanced
patient referral method
2 1336 Partners presenting for care
Partners elicited
Partners treated
Montesinos 1990
Ellison undated
EXPEDITED PARTNER THERAPY
3. EPT vs. simple patient
referral
8 6537 Re-infection rate of index patient
Number of partners notified
Partner treatment
Sexual outcomes such as hav-
ing unprotected sex before partner
took medication, re-initiated sex
with partner, unprotected sex with
any partner
Partners elicited
Cameron 2009
Golden 2005
Kerani 2011
Kissinger 2005
Kissinger 2006
Nuwaha 2001
Schillinger 2002
Schwebke 2010
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Table 3. Summary of included studies and outcomes reported by authors, according to partner notification strategies and
comparisons (Continued)
Index patient 2-week post-treat-
ment return
Harms - fighting and refusal of in-
tercourse
Side effects of drugs
Partner testing
4.1 EPT vs. enhanced
patient referral
4 1253 Re-infection rate of index patient
Number of partners notified
Partner testing
Partner treatment
Sexual outcome (unprotected sex,
re-initiated sex with untreated
partner)
Cameron 2009
Kerani 2011
Kissinger 2005
Kissinger 2006
4.2 EPT and enhanced
patient referral vs. simple
patient referral
1 41 Number of partners notified
Number of partners treated
Method (telephone or in person)
of partner notification used
Partner tested for HIV/syphilis
Adverse events
Kerani 2011
CONTRACT REFERRAL
5 Contract referral vs.
simple patient referral
5 2006 Number of partners notified
Partners presenting to health ser-
vice
Partners testing positive
Brown 2011
Cleveland undated
Landis 1992
Potterat 1977
Schwebke 2010
6. Contract referral vs.
enhanced patient referral
1 1266 Partners presenting for care
Partners testing positive
Cleveland undated
7. Contract referral vs.
EPT
1 324 Re-infection index patient Schwebke 2010
8. PROVIDER REFERRAL
8.1 Provider referral vs.
simple patient referral
2 596 Partners located
Partners treated
Partner visit to the clinic during the
30 days after index enrolment
Harms
Partners testing positive
Brown 2011
Katz 1988
8.2 Choice be-
tween provider or simple
patient referral vs. simple
patient referral
1 396 Partners elicited
Number of partners notified
Partners treated
Harms
Faxelid 1996
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Table 3. Summary of included studies and outcomes reported by authors, according to partner notification strategies and
comparisons (Continued)
9. Provider referral vs.
enhanced patient referral
1 461 Partners elicited
Partners testing positive
Partners treated
Katz 1988
10. Provider referral vs.
contract referral
2 2206 Partners tested
Partners treated
Partner presenting for care
Harms
Partners testing positive
Brown 2011
Peterman 1997
The outcomes listed are those reported by the authors of the RCTs. Not all were named primary or secondary outcomes in the review.
EPT: expedited partner therapy; HIV: human immunodeficiency virus; RCT: randomised controlled trial.
Table 4. Enhanced patient referral versus simple patient referral, re-infection in the index patient, effect size
Comparison N
(studies)
n
(participants)
Study ID RR
(95% CI)
Test for heterogeneity
I2; Chi2, P value
Home sampling kit
vs. simple patient re-
ferral
1 220 Cameron 2009 2.14 (0.91 to 5.05) n/a
Information book-
let vs. simple patient
referral
2 942 Kissinger 2005;
Kissinger 2006
0.55 (0.22 to 1.33) 76%; 4.19, P value = 0.04
Patient refer-
ral (DIS/health ad-
viser) vs. patient re-
ferral (nurse)
1 140 Low 2005 0.35 (0.01 to 8.51) n/a
Disease-spe-
cific website vs. sim-
ple patient referral
1 105 Tomnay 2006 3.12 (0.17 to 58.73) n/a
Additional
counselling vs. sim-
ple patient referral
1 600 Wilson 2009 0.49 (0.27 to 0.89) n/a
Enhanced patient referral is taken as the experimental group. Risk ratio (RR) < 1 indicates a lower re-infection risk after enhanced
patient referral than simple patient referral. If RR = 1, the risk of re-infection is the same in both groups. If RR > 1, there is a higher
risk of re-infection in the enhanced patient referral group. In the trial by Low et al., the outcome was assessed in a minority of index
patients.
CI: confidence interval; DIS: disease intervention specialist; n/a: not applicable; RR: risk ratio.
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Table 5. Enhanced patient referral versus simple patient referral, number of partners elicited per index patient randomised,
effect size
Comparison N
(studies)
n
(participants)
Study ID MD
(95% CI)
Test for heterogeneity
I2; Chi2, P value
Home sampling kit
vs. simple patient re-
ferral
3 516 Cameron 2009; Ander-
sen 1998; Apoola 2009
0.00 (-0.19 to 0.19) 0%; 0.32, P value = 0.85
Additional
counselling vs. sim-
ple patient referral
3 2401 Cleveland undated; El-
lison undated; Moyo
2002
0.1 (0.00 to 0.19) 0%; 1.17, P value = 0.56
Patient refer-
ral (DIS) vs. patient
referral (nurse)
2 597 Katz 1988; Low 2005 -0.40 (-0.57 to -0.24) 0%; 0.03, P value = 0.87
Information book-
let vs. simple patient
referral
1 633 Kissinger 2005 0.0 (-0.22 to 0.22) n/a
Disease-spe-
cific website vs. sim-
ple patient referral
2 140 Kerani 2011; Tomnay
2006
-0.15 (-0.72 to 0.42) 13%; 1.15, P value = 0.
28
Enhanced patient referral is taken as the experimental group. Mean difference (MD) < 0 indicates that simple patient referral resulted
in more partners elicited; MD = 0 indicates no difference between groups; MD > 0 indicates more partners elicited in the enhanced
patient referral group.
CI: confidence interval; MD: mean difference; n/a indicates not applicable.
Table 6. Enhanced patient referral versus simple patient referral, number of partners notified per index patient randomised,
effect size
Comparison N
(studies)
n
(participants)
Study ID MD
(95% CI)
Test for heterogeneity
I2; Chi2, P value
Home sampling kit
vs. simple patient re-
ferral
2 782 Cameron 2009; Oster-
gaard 2003
0.01 (-0.12 to 0.14) 0%; 0.01, P value = 0.
93
Additional
counselling vs. sim-
ple patient referral
2 272 Moyo 2002;
Wilson 2009
0.21 (0.05 to 0.36)
data not available
n/a
Disease-spe-
cific website vs. sim-
ple patient referral
1 105 Tomnay 2006 -0.17 (-0.68 to 0.35) n/a
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Table 6. Enhanced patient referral versus simple patient referral, number of partners notified per index patient randomised,
effect size (Continued)
Videotape vs. sim-
ple patient referral
1 77 Trent 2010 data not available n/a
Enhanced patient referral group is taken as the experimental group. Mean difference (MD) < 0 indicates that simple patient referral
resulted in more partners notified; MD = 0 indicates no difference between groups; MD > 0 indicates more partners notified in the
enhanced patient referral group.
CI: confidence interval; MD: mean difference; n/a indicates not applicable.
Table 7. Enhanced patient referral versus simple patient referral, number of partners treated per index patient randomised,
effect size
Comparison N
(studies)
n
(participants)
Study ID MD
(95% CI)
Test for heterogeneity
I2; Chi2, P value
Home sampling kit
vs. simple patient re-
ferral
1 200 Apoola 2009 -0.03 (-0.25 to 0.19) n/a
Additional
counselling vs. sim-
ple patient referral
1 863 Ellison undated 0.04 (-0.02 to 0.1) n/a
Patient refer-
ral (DIS) vs. patient
referral (nurse)
2 597 Katz 1988; Low 2005 -0.05 (-0.13 to 0.03) 0%; 0.71, P value = 0.40
Information book-
let vs. simple patient
referral
1 633 Kissinger 2005 0.22 (0.08 to 0.36) n/a
Videotape vs. sim-
ple patient referral
1 12,677 Trent 2010 not reported n/a
Enhanced patient referral group is taken as the experimental group. Mean difference (MD) < 0 indicates that simple patient referral
resulted in more partners treated; MD = 0 indicates no difference between groups; MD > 0 indicates more partners treated in the
enhanced patient referral group.
CI: confidence interval; MD: mean difference; n/a indicates not applicable.
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Database: PubMed (2001-2012)
Date: 18 March 2011, 29 January 2012, and 31 August 2012
Search Most Recent Queries
#7 Search #3 AND #4 AND #5 Limits: Publication Date from 10 May 2001 to 18 March 2011
#6 Search #3 AND #4 AND #5
#5 Search partner notification[tiab] OR partner notifications[tiab] OR contact tracing[mh] OR contact tracing[tiab] OR
(expedited[tiab] ANDpartner[tiab])ORpatient delivered[tiab]OR referral[tiab]OR referrals[tiab]ORpartner tracing[tiab]
#4 Search (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug
therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])
#3 Search #1 OR #2
#2 Search HIV Infections[MeSH] OR HIV[MeSH] OR hiv[tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw]
OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficiency virus[tw] OR human immuno-
deficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR
acquired immunodeficiency syndrome[tw] OR acquired immunedeficiency syndrome[tw] OR acquired immuno-deficiency
syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw]))
#1 Search sexually transmitted infections[mh] OR sexually transmitted disease*[tiab] OR sexually transmissible disease*[tiab]
OR sexually transmitted infection*[tiab] OR sexually transmissible infection*[tiab] OR sexually transmitted infectious dis-
ease*[tiab] OR sexually transmissible infectious disease*[tiab] OR sexually transmitted disorder*[tiab] OR sexually trans-
missible disorder*[tiab] OR STI[tiab] OR STIs[tiab] OR STD[tiab] OR STIs[tiab] OR venereal disease*[tiab] OR venereal
infection*[tiab] OR venereal disorder*[tiab] OR genital herpes[tiab] OR herpes genitalis[mh] OR herpes genitalis[tiab]
OR genital infection*[tiab] OR genital disorder*[tiab] OR herpes simplex[tiab] OR herpes virus[tiab] OR HSV-1[tiab]
OR HSV-2[tiab] OR chancroid[mh] OR chancroid* [tiab] OR haemophilus ducreyi[tiab] OR chlamydia infection*[tiab]
OR chlamydia trachomatis[mh] OR chlamydia trachomatis[tiab] OR gonorrhea[mh] OR gonorrhoea*[tiab] OR gonor-
rhea*[tiab] OR syphilis[mh] OR syphilis[tiab] OR syphillis[tiab] OR condylomata lata[tiab] OR chancre*[tiab] OR lym-
phogranuloma venereum[mh] OR lymphogranuloma venereum[tiab] OR granuloma Inguinale[mh] OR granuloma in-
guinale[tiab] OR donovania[tiab] OR donovanosis[tiab] OR calymmatobacterium[mh] OR calymmatobacterium granulo-
matis[tiab] OR klebsiella granulomatis[tiab] OR klebsiella granulomatis[tiab] OR treponema pallidum[mh] OR treponema
pallidum[tiab] OR genital wart*[tiab] OR venereal wart*[tiab] OR condylomata acuminata[mh] OR human papillomavirus
6[mh] OR hpv-6[tiab] OR hpv-11[tiab] OR hpv6[tiab] OR human papillomavirus[tiab] OR hepatitis b[mh] OR hepatitis
b[tiab] OR trichomonas vaginitis[mh] OR trichomonas vaginitis[tiab] OR genital ulcer*[tiab] OR anogenital ulcer*[tiab]
OR anorectal ulcer*[tiab] OR anorectal ulcer*[tiab] OR penile ulcer*[tiab]
SEXUALLYTRANSMITTEDDISEASES[MH]ORHERPESGENITALIS[MH]ORGONORRHEA[MH]ORSYPHILIS[MH]
OR GRANULOMA INGUINALE[MH] OR CONDYLOMATA ACUMINATA[MH] OR LYMPHOGRANULOMA
VENEREUM[MH]
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Appendix 2. EMBASE search strategy
Database: EMBASE (2001-2012)
Date: 18 March 2011, 29 January 2012 and 31 August 2012
No. Query
#7 #3 AND #4 AND #5 AND [humans]/lim AND [EMBASE]/lim AND [1-5-2001]/sd NOT [18-3-2011]/sd
#6 #3 AND #4 AND #5
#5 ’contact examination’/syn OR ’contact detection’:ab,ti OR ’contact tracing’:ab,ti OR ’partner notification’:ab,ti OR ’partner
notifications’:ab,ti OR ’expedited partner’:ab,ti OR ’patient delivered’:ab,ti OR referral*:ab,ti OR ’partner tracing’:ab,ti
#4 #1 OR #2
#3 random*:ti OR random*:ab OR factorial*:ti OR factorial*:ab OR cross?over*:ti OR cross?over*:ab OR crossover*:ti OR
crossover*:ab OR placebo*:ti OR placebo*:ab OR (doubl*:ti AND blind*:ti) OR (doubl*:ab AND blind*:ab) OR (singl*:ti
AND blind*:ti) OR (singl*:ab AND blind*:ab) OR assign*:ti OR assign*:ab OR allocat*:ti OR allocat*:ab OR volunteer*:
ti OR volunteer*:ab OR ’crossover procedure’/exp OR ’crossover procedure’/de OR ’crossover procedure’ OR ’double-blind
procedure’/exp OR ’double-blind procedure’/de OR ’double-blind procedure’ OR ’single-blind procedure’/exp OR ’single-
blind procedure’/de OR ’single-blind procedure’ OR ’randomized controlled trial’/exp OR ’randomized controlled trial’/de
OR ’randomized controlled trial’
#2 ’human immunodeficiency virus infection’/exp OR ’human immunodeficiency virus infection’/de OR ’human immunode-
ficiency virus infection’ OR ’human immunodeficiency virus’/exp OR ’human immunodeficiency virus’/de OR ’human im-
munodeficiency virus’ OR hiv:ti OR hiv:ab OR ’hiv-1’:ti OR ’hiv-1’:ab OR ’hiv-2’:ti OR ’hiv-2’:ab OR ’human immun-
odeficiency virus’:ti OR ’human immunodeficiency virus’:ab OR ’human immuno-deficiency virus’:ti OR ’human immuno-
deficiency virus’:ab OR ’human immunedeficiency virus’:ti OR ’human immunedeficiency virus’:ab OR ’human immune-
deficiency virus’:ti OR ’human immune-deficiency virus’:ab OR ’acquired immune-deficiency syndrome’:ti OR ’acquired
immune-deficiency syndrome’:ab OR ’acquired immunedeficiency syndrome’:ti OR ’acquired immunedeficiency syndrome’:
ab OR ’acquired immunodeficiency syndrome’:ti OR ’acquired immunodeficiency syndrome’:ab OR ’acquired immuno-de-
ficiency syndrome’:ti OR ’acquired immuno-deficiency syndrome’:ab
#1 ’sexually transmitted infections’/exp OR ’sexually transmitted infections, bacterial’/exp OR ’sexually transmitted infections,
viral’/exp OR (sexually AND transmitted AND disease*:ti OR sexually AND transmitted AND disease*:ab) OR (sexually
AND transmissible AND disease*:ti OR sexually AND transmissible AND disease*:ab) OR (sexually AND transmitted AND
infection*:ti OR sexually AND transmitted AND infection*:ab) OR (sexually AND transmissible AND infection*:ti OR
sexually AND transmissible AND infection*:ab) OR (sexually AND transmitted AND infectious ANDdisease*:ti OR sexually
AND transmitted AND infectious AND disease*:ab) OR (sexually AND transmissible AND infectious AND disease*:ti OR
sexually AND transmissible AND infectious AND disease*:ab) OR (sexually AND transmitted AND disorder*:ti OR sexually
AND transmitted AND disorder*:ab) OR (sexually AND transmissible AND disorder*:ti OR sexually AND transmissible
AND disorder*:ab) OR sti:ti OR sti:ab OR std:ti OR std:ab OR (genital AND ulcer*:ti OR genital AND ulcer*:ab) OR
(genital AND ’ulcer’/exp AND disease*:ti OR genital AND ’ulcer’/exp AND disease*:ab) OR (ulcerative AND sexually
AND transmitted*:ti OR ulcerative AND sexually AND transmitted*:ab) OR (genital AND infection*:ti OR genital AND
infection*:ab) OR (genital AND disorder*:ti OR genital AND disorder*:ab) OR (venereal AND disease*:ti OR venereal AND
disease*:ab) OR (venereal AND infection*:ti OR venereal AND infection*:ab) OR (venereal AND disorder*:ti OR venereal
AND disorder*:ab) OR ’herpes simplex’/exp OR ’herpes genitalis’/exp OR (’herpes’/exp AND simplex:ti OR ’herpes’/exp
AND simplex:ab) OR (’herpes’/exp AND genitalis:ti OR ’herpes’/exp AND genitalis:ab) OR (genital AND herpes:ti OR
genital AND herpes:ab) OR (’herpes’/exp AND virus:ti OR ’herpes’/exp AND virus:ab) OR ’hsv 1’:ti OR ’hsv 1’:ab OR
’hsv 2’:ti OR ’hsv 2’:ab OR donovanosis:ti OR donovanosis:ab OR (’granuloma’/exp AND inguinale:ti OR ’granuloma’/exp
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(Continued)
AND inguinale:ab) OR (’calymmatobacterium’/exp AND granulomatis:ti OR ’calymmatobacterium’/exp AND granulomatis:
ab) OR donovania:ti OR donovania:ab OR (’klebsiella’/exp AND granulomatis:ti OR ’klebsiella’/exp AND granulomatis:ab)
OR ’syphilis’/exp OR syphilis:ti OR syphilis:ab OR syphillis:ab OR syphillis:ti OR (’treponema’/exp AND pallidum:ti OR
’treponema’/exp AND pallidum:ab) OR chancre:ti OR chancre:ab OR (’condylomata’/exp AND lata:ti OR ’condylomata’/
exp AND lata:ab) OR chancroid:ti OR chancroid:ab OR (’haemophilus’/exp AND ducreyi:ti) OR (soft AND chancre:ti
OR soft AND chancre:ab) OR ’chlamydia trachomatis’/exp OR ’lymphogranuloma venereum’/exp OR (lymphogranuloma
AND venereum:ti OR lymphogranuloma AND venereum:ab) OR (’chlamydia’/exp AND trachomatis:ti OR ’chlamydia’/
exp AND trachomatis:ab) OR (’chlamydia’/exp AND infections:ti OR ’chlamydia’/exp AND infections:ab) OR lgv:ti OR
lgv:ab OR (vaginal AND ulcer*:ti OR vaginal AND ulcer*:ab) OR (anogenital AND ulcer*:ti OR anogenital AND ulcer*:
ab) OR (anorectal AND ulcer*:ti OR anorectal AND ulcer*:ab) OR (penile AND ulcer*:ti OR penile AND ulcer*:ab) OR
(genital AND wart*:ti OR genital AND wart*:ab) OR (venereal AND wart*:ti OR venereal AND wart*:ab) OR ’condyloma
acuminatum’/exp OR ’human papillomavirus 6’/exp OR (’hpv 6’:ti OR ’hpv 6’:ab OR hpv6:ti OR hpv6:ab OR human
AND papillomavirus:ti OR human AND papillomavirus:ab) OR ’hepatitis b’/exp OR ’hepatitis b’:ti OR ’hepatitis b’:ab OR
’gonorrhea’/exp OR gonorrhea*:ti OR gonorrhea*:ab OR gonorrhoea*:ti OR gonorrhoea*:ab
Appendix 3. CENTRAL search strategy
Database: The Cochrane Library 2011, Issue 1 (2001-2012)
Date: 22 March 2011, 29 January 2012 and 31 August 2012
Number of clinical trials retrieved: 191 records
ID Search
#1 MeSH descriptor Sexually Transmitted Diseases explode all trees
#2 MeSH descriptor Herpes Genitalis, this term only
#3 MeSH descriptor Chancroid, this term only
#4 MeSH descriptor Chlamydia trachomatis, this term only
#5 MeSH descriptor Gonorrhea, this term only
#6 MeSH descriptor Syphilis, this term only
#7 MeSH descriptor Lymphogranuloma Venereum, this term only
#8 MeSH descriptor Granuloma Inguinale, this term only
#9 MeSH descriptor Calymmatobacterium, this term only
#10 MeSH descriptor Treponema pallidum, this term only
#11 MeSH descriptor Condylomata Acuminata, this term only
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(Continued)
#12 MeSH descriptor Human papillomavirus 6 explode all trees
#13 MeSH descriptor Hepatitis B explode all trees
#14 MeSH descriptor Trichomonas Vaginitis, this term only
#15 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14)
#16 sexually transmitted disease*:ti,ab,kw OR sexually transmissible disease*:ti,ab,kw OR sexually transmitted infection*:ti,ab,kw
OR sexually transmissible infection*:ti,ab,kw OR sexually transmitted infectious disease*:ti,ab,kw OR sexually transmissible
infectious disease*:ti,ab,kw OR sexually transmitted disorder*:ti,ab,kw OR sexually transmissible disorder*:ti,ab,kw OR STI:
ti,ab,kw OR STIs:ti,ab,kw OR STD:ti,ab,kw OR STIs:ti,ab,kw OR venereal disease*:ti,ab,kw OR venereal infection*:ti,ab,kw
OR venereal disorder*:ti,ab,kw OR genital herpes:ti,ab,kw OR herpes genitalis:ti,ab,kw OR genital infection*:ti,ab,kw OR
genital disorder*:ti,ab,kw
#17 herpes simplex:ti,ab,kw OR herpes virus:ti,ab,kw OR HSV-1:ti,ab,kw OR HSV-2:ti,ab,kw OR chancroid*:ti,ab,kw OR
haemophilus ducreyi:ti,ab,kw OR chlamydia infection*:ti,ab,kw OR chlamydia trachomatis:ti,ab,kw OR gonorrhoea*:ti,ab,
kw OR gonorrhea*:ti,ab,kw OR syphilis:ti,ab,kw OR syphillis:ti,ab,kw OR condylomata lata:ti,ab,kw OR chancre*:ti,ab,kw
OR lymphogranuloma venereum:ti,ab,kw OR granuloma inguinale:ti,ab,kw OR donovania:ti,ab,kw OR donovanosis:ti,ab,
kw OR calymmatobacterium granulomatis:ti,ab,kw OR klebsiella granulomatis:ti,ab,kw OR klebsiella granulomatis:ti,ab,kw
OR treponema pallidum:ti,ab,kw OR genital wart*:ti,ab,kw OR venereal wart*:ti,ab,kw OR hpv-6:ti,ab,kw OR hpv-11:ti,
ab,kw OR hpv6:ti,ab,kw OR human papillomavirus:ti,ab,kw OR hepatitis b:ti,ab,kw OR trichomonas vaginitis:ti,ab,kw OR
genital ulcer*:ti,ab,kw OR anogenital ulcer*:ti,ab,kw OR anorectal ulcer*:ti,ab,kw OR anorectal ulcer*:ti,ab,kw OR penile
ulcer*:ti,ab,kw
#18 (#15 OR #16 OR #17)
#19 MeSH descriptor HIV Infections explode all trees
#20 MeSH descriptor HIV explode all trees
#21 hiv OR hiv-1* OR hiv-2* OR hiv1 OR hiv2 OR HIV INFECT* OR HUMAN IMMUNODEFICIENCY VIRUS OR
HUMAN IMMUNEDEFICIENCY VIRUS OR HUMAN IMMUNE-DEFICIENCY VIRUS OR HUMAN IMMUNO-
DEFICIENCY VIRUSORHUMAN IMMUN* DEFICIENCY VIRUSORACQUIRED IMMUNODEFICIENCY SYN-
DROME OR ACQUIRED IMMUNEDEFICIENCY SYNDROME OR ACQUIRED IMMUNO-DEFICIENCY SYN-
DROME OR ACQUIRED IMMUNE-DEFICIENCY SYNDROME OR ACQUIRED IMMUN* DEFICIENCY SYN-
DROME
#22 MeSH descriptor Lymphoma, AIDS-Related, this term only
#23 (#19 OR #20 OR #21 OR #22)
#24 (#18 OR #23)
#25 MeSH descriptor Contact Tracing, this term only
#26 partner notification:ti,ab,kw OR partner notifications:ti,ab,kw OR contact tracing:ti,ab,kw OR expedited partner:ti,ab,kw
OR patient delivered:ti,ab,kw OR referral:ti,ab,kw OR referrals:ti,ab,kw OR partner tracing:ti,ab,kw
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(Continued)
#27 (#25 OR #26)
#28 (#24 AND #27)
#29 (#24 AND #27), from 2001 to 2011
WH A T ’ S N E W
Last assessed as up-to-date: 11 September 2012.
Date Event Description
30 September 2013 New citation required but conclusions have not
changed
The conclusions of the review are essentially un-
changed from the previously published version of the
review
11 September 2012 New search has been performed Major update completed which include a new search,
16 new studies, new review format and methodology
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